

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

)
IN RE:
INTEL CORP. MICROPROCESSOR) MDL Docket No. 05-1717 (JJF)
ANTITRUST LITIGATION)

)
PHIL PAUL, on behalf of himself and all)
others similarly situated,)
Plaintiffs,)
v.) C.A. No. 05-485 (JJF)

INTEL CORPORATION,) CONSOLIDATED
Defendant.)

)

**APPENDIX OF EXHIBITS TO LETTER TO
SPECIAL MASTER VINCENT J. POPPITI
FROM MARY B. GRAHAM**

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

Mary B. Graham (#2256)
Richard J. Bauer (#4828)
1201 N. Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
302.658.9200

Attorneys for Nonparty Fry's Electronics, Inc.

OF COUNSEL:

Robert W. Stone
Michael D. Powell
Quinn Emanuel Urquhart Oliver
& Hedges, LLP
555 Twin Dolphin Drive, Suite 560
Redwood Shores, CA 94065
650.801.5000

May 2, 2007

TABLE OF EXHIBITS

DESCRIPTION	EXHIBIT
Protective Order Governing Confidential Information, March 1, 2006 C.A. No.'s 03-120; 02-1512; 05-340; 05-360 (KAJ)	A
Impax Laboratories Inc. letter to Judge Jordan November 21, 2006, C.A. No. 03-120 (KAJ)	B
Abbott Laboratories letter to Judge Jordan November 24, 2006, C.A. No. 03-120 (KAJ)	C
Impax Laboratories Inc. reply letter to Judge Jordan November 30, 2006, C.A. No. 03-120 (KAJ)	D
Transcript, December 1, 2006, C.A. No. 03-120 (KAJ)	E
<i>Pitney Bowes Inc. v. Stamps.com Inc.</i> , C.A. No. 99-381 (JJF), slip op. at 2 (D. Del. Dec. 13, 2001)	F
Notice of Hearing re: D.I. 109, June 2, 2006	G
Letter to third parties re: hearing on protective order, June 9, 2006	H

817102.1

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on May 2, 2007, the foregoing was caused to be electronically filed with the Clerk of the Court using CM/ECF which will send electronic notification of such filing to all registered participants.

In addition, the undersigned hereby certifies that on May 2, 2007 true and correct copies of the foregoing were caused to be served upon the following parties in the manner indicated:

VIA HAND DELIVERY (in triplicate):

Vincent J. Poppiti
BLANK ROME LLP
1201 North Market Street, Suite 800
Wilmington, DE 19801-4226

VIA E-MAIL:

Vincent J. Poppiti
BLANK ROME LLP
poppiti@blankrome.com

VIA E-MAIL:

J. Clayton Athey
PRICKETT, JONES & ELLIOTT, P.A.
jcathey@prickett.com

WITH A COPY TO:

Dale R. Dube
BLANK ROME LLP
dube@blankrome.com

Mary Levan
BLANK ROME LLP
levan@blankrome.com

Carrie David
BLANK ROME LLP
david-c@blankrome.com

/s/ Mary B. Graham (#2256)

Mary B. Graham (#2256)

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Plaintiffs,)	
v.)	C.A. No. 02-1512 (KAJ)
TEVA PHARMACEUTICALS USA, INC., a Delaware corporation,)	CONSOLIDATED
Defendant,)	
<hr/>		
TEVA PHARMACEUTICALS USA, Inc., a Delaware corporation, and TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation,)	
Counterclaim Plaintiffs,)	
v.)	
ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Counterclaim Defendants,)	
<hr/>		
ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Plaintiffs,)	
v.)	C.A. No. 03-120 (KAJ)
IMPAX LABORATORIES, INC., a Delaware corporation,)	CONSOLIDATED
Defendant.)	

IN RE TRICOR DIRECT PURCHASER ANTITRUST LITIGATION)	
)	C.A. No. 05-340 (KAJ)
THIS DOCUMENT RELATES TO: ALL ACTIONS)	CONSOLIDATED
)	
IN RE TRICOR INDIRECT PURCHASER ANTITRUST LITIGATION)	
)	C.A. No. 05-360 (KAJ)
THIS DOCUMENT RELATES TO: ALL ACTIONS)	CONSOLIDATED
)	

PROTECTIVE ORDER GOVERNING CONFIDENTIAL INFORMATION

Pursuant to Fed. R. Civ. P. 26(c), by agreement of Abbott Laboratories, including its successors-in-interest, subsidiaries and predecessors (“Abbott”), Fournier Industrie et Santé and Laboratoires Fournier S.A., including their successors-in-interest, subsidiaries and predecessors (collectively, “Fournier”), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., including their successors-in-interest, subsidiaries and predecessors (collectively, “Teva”), Impax Laboratories, Inc., including its successors-in-interest, subsidiaries and predecessors (“Impax”), and all plaintiffs in the actions consolidated and/or coordinated in In re Tricor Direct Purchaser Antitrust Litig., No. 1:05-cv-00340-KAJ (D. Del) (collectively, “Direct Purchasers”) and In re Tricor Indirect Purchaser Antitrust Litig., No. 1:05-cv-00360-KAJ (D. Del.) (collectively, “Indirect Purchasers”) (all individually, a “party”, or collectively, “parties”), the Court finds that good cause exists for entry of this Protective Order to prevent unauthorized disclosure and use of the parties’ trade secrets and other confidential information during and after the course of the above-captioned litigations (collectively, the “Action”). Accordingly, IT IS HEREBY ORDERED THAT:

A. Definitions

For purposes of this Protective Order, the following definitions shall apply:

1. The term “Designated Material” shall include all information, documents and other materials revealed or disclosed during the proceedings of the above matter that are designated as “Confidential Material,” “Highly Confidential Material” and/or “Restricted Pricing Material” in the manner set forth in Section C of this Protective Order, including without limitation any records, exhibits, reports, samples, transcripts, oral testimony, video or audio recordings, affidavits, briefs, summaries, notes, abstracts, drawings, databases, communications, correspondence, letters, emails and attachments thereto, answers to interrogatories, responses to requests for admissions, or motions, including copies or computer-stored versions of any of the foregoing.
2. The term “Disclosing Party” shall mean any party or non-party who is requested to produce or produces Material through discovery in these actions.
3. The term “Confidential Material” shall mean material that is, in the normal course of business, maintained as confidential, and expressly includes material previously produced to Abbott and Fournier and designated as “Confidential Information” under the Confidentiality Agreement dated September 20, 2002, between Abbott, Fournier, and Teva as well as ANDA No. 76-433 (“Teva’s ANDA”).
4. The term “Highly Confidential Material” shall mean customer information, current (not more than three years old) financial and marketing information (including past information indicative of current practices), information relating to research, development, testing of, and plans for, a party’s existing fenofibrate products (including products referenced in any NDA or ANDA that have received tentative or final approval as of October 30, 2005), information relating to the processes, apparatus, or analytical techniques used by a party in its

present or proposed commercial production of such products, information relating to pending or abandoned patent applications which have not been made available to the public, personal medical or financial information, and any other information that the disclosing party believes in good faith could be used by a competitor to harm its business.

5. The term "Restricted Pricing Material" shall mean materials or information that contain contract terms or pricing, sales, or profit information concerning one or more individual customers or suppliers identified specifically by name or reference in the document.

6. The term "Competitive Fenofibrate Activities" means (i) competitive decision making activities (e.g., advising on decisions concerning marketing, pricing and design) relating to any fenofibrate product and (ii) any involvement in the prosecution of patent applications relating to fenofibrate. "Competitive decision making" activities also include competitive decision making related to the preparation of any (a) NDA or ANDA or "paper" NDA (21 U.S.C § 355(b)(2)) relating to fenofibrate or (b) Paragraph III or IV certification letters referencing any Abbott NDA relating to fenofibrate.

B. Applicability of this Protective Order

1. Except as specifically authorized by this Court, Designated Material shall not be disclosed or revealed to anyone not authorized by this Protective Order to receive such material. *Further, Designated Material shall be used only for the purpose of this Action and not for any other purpose or function, including without limitation any other litigation not part of this Action or any Competitive Fenofibrate Activity or business, patent prosecution, competitive or governmental purpose or function.* The terms of this Protective Order shall apply to all manner and means of discovery. All persons to whom Designated Material is disclosed shall be informed of and shown a copy of this Protective Order.

C. Designating Material

If, in the course of this Action, a Disclosing Party discloses material that the Disclosing Party contends is Confidential or Highly Confidential or Restricted Pricing, that Disclosing Party may so designate such material by applying to that material the appropriate confidentiality marking.

1. Designating “Confidential Material”: Any document produced by a party in this litigation may be designated as Confidential Material by marking it “CONFIDENTIAL: SUBJECT TO PROTECTIVE ORDER” or a similar label on the face of the document at or prior to the time of production.

2. Designating “Highly Confidential Material”: Any document produced by a party in this litigation may be designated as Highly Confidential Material by marking it “HIGHLY CONFIDENTIAL: SUBJECT TO PROTECTIVE ORDER” or a similar label on the face of the document at or prior to the time of production.

3. Designating “Restricted Pricing Material”: Any document produced by a party in this litigation may be designated as Restricted Pricing Material by marking it “RESTRICTED PRICING MATERIAL: SUBJECT TO PROTECTIVE ORDER” or a similar label on the face of the document at or prior to the time of production.

4. Designating Material that Cannot Easily Be Marked: If any Confidential or Highly Confidential or Restricted Pricing Material cannot easily be labeled with the appropriate Confidentiality marking, it shall be placed in a sealed envelope or other suitable container that is in turn marked with the appropriate Confidentiality marking, or otherwise designated in a manner agreed upon by the parties.

5. Designating Depositions: Any person giving deposition testimony in this litigation as a representative of a party may designate any or all of the testimony as Confidential

Material or Highly Confidential or Restricted Pricing Material. The person desiring to designate any portion of a deposition as Confidential Material or Highly Confidential or Restricted Pricing Material may do so on the record while the deposition is being taken, either personally or through counsel. Alternatively, the transcript of the deposition (or of any other testimony) may be designated as containing Confidential Material or Highly Confidential or Restricted Pricing Material by notifying the opposing party in writing, within ten (10) business days of receipt of the transcript that it contains Confidential Material or Highly Confidential or Restricted Pricing Material. Notwithstanding the foregoing, any deposition transcript shall be subject to a safe-harbor wherein the transcript will be treated as Highly Confidential Material for a period not to exceed ten (10) business days after the official transcript is received. Any portion of any deposition testimony that is not designated as Confidential Material or Highly Confidential or Restricted Pricing Material in accordance with Section C herein, within that ten (10) business day safe-harbor period, shall not be entitled to the protections afforded under this Protective Order.

6. Designating Deposition Exhibits: An exhibit to a deposition that has been produced (i.e., has a bates number) shall be treated in accordance with the confidentiality designation already given to it. If the exhibit has not been previously produced and has no preexisting designation ("New Exhibit"), then the exhibit shall be treated in accordance with the confidentiality designation given to it on the record at the time of the deposition and that confidentiality designation shall be noted on the first page of the exhibit. If no confidentiality designation is made for a New Exhibit at the deposition, it shall be treated as Highly Confidential Material for a period not to exceed ten (10) business days after the New Exhibit's initial disclosure. Any New Exhibit that is not designated as Confidential or Highly Confidential or

Restricted Pricing Material in accordance with Section C herein, within that ten (10) business day safe-harbor period, shall not be entitled to the protections afforded under this Protective Order.

7. Non-Party Designations: A non-party to this action that produces materials to any party in connection with this Action, whether pursuant to a subpoena or otherwise, may avail itself of the protections afforded by this Protective Order, by placing the appropriate Confidentiality marking on such materials.

8. Safe-Harbor for Inadvertent Failure to Designate: If a party or non-party inadvertently fails to designate material as Confidential or Highly Confidential or Restricted Pricing such failure shall not constitute a waiver of the Disclosing Party's right to so designate such material, provided the Disclosing Party so notifies, in writing, the parties known to have received the material in question and provide same with an appropriately marked substitute copy of the affected material. Upon receiving notification of an inadvertent failure to designate, all parties in receipt of the affected material must (i) destroy all copies of the incorrectly marked material, and (ii) retrieve all copies of the incorrectly marked material from all persons to whom that material was disclosed and destroy all such copies. In addition, the affected parties must inform the Disclosing Party, in writing, of the identity of any person not authorized under Section D to whom such affected material was disclosed and whether such party has returned that material. Such identifications shall not waive any attorney work product or attorney-client privileges.

D. Persons Authorized to Access Confidential or Highly Confidential or Restricted Pricing Material and the Authorized Use of Such Material

1. Persons Authorized to Access Confidential Material Shall Be Limited to:

(a) Outside counsel of record, who have been admitted in the United States District Court for the District of Delaware either directly or *pro hac vice* for this Action, for the respective parties to this litigation (“Outside Counsel”) and attorneys and regular employees **within the same law firm** of said Outside Counsel, who are assisting in the prosecution or defense of this litigation (“Outside Counsel Employees”). Outside Counsel shall have the duty of informing Outside Counsel Employees in the same law firm who receive Designated Material of the applicable provisions of this Protective Order and ensuring compliance with its terms. For the purpose of clarification, Designated Material may not be disclosed by the receiving party to any attorney or employee at a law firm, law office, professional corporation or similar entity that does not employ at least one attorney who has been admitted *pro hac vice* to this Action;

(b) Up to three in-house counsel or directors of legal affairs for Abbott, Fournier, Teva and Impax and up to one in-house counsel for each other named party provided that the identified counsel or directors of legal affairs are not engaged in Competitive Fenofibrate Activities, and support and clerical staff supporting said counsel. The in-house counsel or directors of legal affairs shall be identified in accordance with Section D.4 below. The parties may substitute an inside counsel for one identified in accordance with Section D.4 by notifying the other parties of the withdrawal and identifying the new inside counsel in accordance with Section D.4. The withdrawing inside counsel remains subject to all terms and conditions of this Protective Order;

(c) No more than two employees per Abbott, Fournier, Teva and Impax, who are not involved in Competitive Fenofibrate Activities and who are identified by the proposing party in the matter outlined below in Section D.5;

(d) Outside experts and consultants (and their employees or clerical assistants) who are employed, retained or otherwise consulted by outside counsel of record to assist in any way in the preparation and trial of this litigation. Outside experts and consultants may not be engaged in Competitive Fenofibrate Activities on behalf of any entity during the pendency of this litigation. For purposes of this Protective Order, the phrase "outside experts and consultants" shall not include any officer, director or employee of any party. Outside experts and consultants shall be identified in accordance with Section D.4 below;

(e) The Court, its staff, and other authorized Court personnel;

(f) Qualified persons taking testimony involving Confidential or Highly Confidential or Restricted Pricing Material and necessary stenographic, videographic, and clerical personnel thereof;

(g) Duplicating services, and auxiliary services of a like nature, routinely engaged by counsel;

(h) The Federal Trade Commission in connection with its investigation identified as Abbott Laboratories File 005-0124;

(i) Authors and recipients of the particular Material; and

(j) employees, officers or experts of a producing party.

2. Persons Authorized to Access Highly Confidential Material: shall be limited to the persons identified in (a)-(b) and (d)-(j) in Section D.1. above. Persons identified in (c) of Section D.1 above ARE NOT AUTHORIZED to access Highly Confidential Information.

3. Persons Authorized to Access Restricted Pricing Material: shall be limited to the persons identified in (a) and (d)-(j) in Section D.1 above, and the following additional persons: one in-house counsel at each of Abbott, Fournier, Teva, and Impax, who (i) has no role in marketing or formulating marketing strategies concerning any drug products, except that the in-house counsel may render Marketing Legal Advice (as defined below); (ii) has no role in pricing, or formulating pricing strategies, or drafting or negotiating contracts concerning any drug products, (iii) has no role in drafting, negotiating, or otherwise communicating with customers or suppliers concerning pricing or contracts for the sale of any drug products, except that the in-house counsel may render legal advice concerning breach or potential breach of contracts (for Abbott and Fournier, such advice is limited to non-generic products), and (iv) agrees to be bound by Order of this Court that s/he shall undertake no activities prohibited in subsections (i), (ii), and (iii) of this provision for a period of two (2) years after entry of a final judgment from which no appeal can be taken in this action. Such persons shall be identified in accordance with Section D.4 below. If any of Abbott, Fournier, Teva, or Impax does not have an in-house counsel who satisfies the requirements of this provision, that party (or those parties) shall be limited to disclosing Restricted Pricing Material to the persons identified in (a) and (d)-(j) in Section D.1 above. Persons identified in (b) and (c) of Section D.1 above ARE NOT AUTHORIZED to access Restricted Pricing Material, except that an in-house counsel for Abbott, Fournier, Teva, or Impax designated in (b) of Section D.1 may also be designated hereunder to access Restricted Pricing Material provided that the in-house counsel independently satisfies the requirements of both (b) and this provision. "Marketing Legal Advice" shall mean the provision of legal opinions, analysis or advice on marketing plans and strategies (for Abbott and Fournier, this advice is limited to non-generic products) on issues concerning regulatory and

statutory compliance, fraud, false advertising and litigations relating to the marketing plans and strategies.

4. Certain Authorized Persons Must First Agree to Be Bound to the Terms of This Protective Order Before Gaining Access to Confidential or Highly Confidential or Restricted Pricing Materials: Confidential or Highly Confidential Material shall not be disclosed to any authorized person identified in (b) or (d) in Section D.1. above and Restricted Pricing Materials shall not be disclosed to any authorized person identified in (d) in Section D.1 or in Section D.3 above, unless and until such person has agreed in writing to be bound by the terms of this Protective Order. The requirement of obtaining such written agreement shall be satisfied by obtaining the signature of each such person on the Confidentiality Agreement attached hereto as Exhibit A. In addition to the foregoing, before disclosing Confidential or Highly Confidential Material to any authorized person identified in (b) in Section D.1. above or Restricted Pricing Material to any authorized person identified in Section D.3, the party seeking to make such disclosure shall first give five (5) business days prior written notice to counsel for the producing party of the name, job title and job description of the in-house attorney or director of legal affairs to whom disclosure is to be made and an executed copy of the Confidentiality Agreement attached as Exhibit A. Before disclosing Confidential or Highly Confidential or Restricted Pricing Material to any authorized person identified in (d) in Section D.1. above, the party seeking to make such disclosure shall first give five (5) business days prior written notice to counsel for the producing party of the name and address of the person to whom disclosure is to be made, including a current resume disclosing such person's prior or present relationship, if any, with the parties and any involvement that the person has had in Competitive Fenofibrate Activities and an executed copy of the Confidentiality Agreement attached as Exhibit A. If the

producing party reasonably believes it would be harmed by the disclosure of any Highly Confidential or Restricted Pricing Material any person proposed above, it may object in writing to such disclosure within five (5) business days after receipt of the notice. In the event of an objection, the parties shall promptly confer to attempt to resolve the concerns giving rise to the objection. If the parties are unable to reach agreement regarding such disclosure, the party objecting to disclosure may, prior to the time of the intended disclosure, request this Court to issue an order prohibiting the disclosure. No disclosure shall be made pending the ruling of the Court. The Court may impose additional restrictions on such disclosure as a condition of issuing such order. The parties hereby agree that any expert who submitted an expert report in connection with C.A. No. 02-1512 (KAJ) or 03-120 (KAJ) cannot be objected to and need only execute the Confidentiality Agreement in Exhibit A.

5. Employee Access To Confidential Information Is Limited to Two Persons

Identified by the Proposing Party:

Confidential Material shall not be disclosed to any authorized person identified in (c) in Section D.1. above, unless and until such person has agreed in writing to be bound by the terms of this Protective Order. The requirement of obtaining such written agreement shall be satisfied by obtaining the signature of each such person on the Confidentiality Agreement attached hereto as Exhibit A. In addition to the foregoing, before disclosing Confidential Material to any authorized person identified in (c) in Section D.1. above, the party seeking to make such disclosure to any person not previously identified to the parties shall first give five (5) business days prior written notice to counsel for the producing party of the name and address of the person to whom disclosure is to be made, including a current resume disclosing such person's prior or present relationship, if any, with the parties and an executed copy of the Confidentiality

Agreement attached as Exhibit A. If the producing party reasonably believes it would be harmed by the disclosure of any Confidential Material to the proposed person, it may object in writing to such disclosure within five (5) business days after receipt of the notice. In the event of an objection, the parties shall promptly confer to attempt to resolve the concerns giving rise to the objection. If the parties are unable to reach agreement regarding such disclosure, the party objecting to disclosure may, prior to the time of the intended disclosure, request this Court to issue an order prohibiting the disclosure. No disclosure shall be made pending the ruling of the Court. The Court may impose additional restrictions on such disclosure as a condition of issuing such order.

6. Persons Accessing Confidential or Highly Confidential Information Pursuant to Section D.1. (b) and (c) above Shall Not Engage in Competitive Fenofibrate Activities for a period of Two (2) Years After Termination of this Action.

7. Use Limited to this Action: Designated Material may only be used in the course of any hearings or trial of this Action. Counsel will address in the Pretrial Order how they propose to handle the use and disclosure at trial of Designated Material.

E. Filing Under Seal

1. Procedure: Designated Material may be used or submitted to the Court in connection with any filing or proceeding in this Action, but the party using such material shall cause an original and one copy to be filed separately under seal with the Clerk of the Court. All papers that contain Confidential Material which are submitted to or filed with the Court shall be submitted or filed in a sealed envelope bearing the following legend clearly written on the face of the envelope under the relevant case caption for this Action:

**CONFIDENTIAL – FILED UNDER SEAL
PURSUANT TO COURT ORDER**

All papers that contain Highly Confidential Material which are submitted to or filed with the Court shall be submitted or filed in a sealed envelope bearing the following legend clearly written on the face of the envelope under the relevant case caption for this Action:

**HIGHLY CONFIDENTIAL – FILED UNDER SEAL
PURSUANT TO COURT ORDER**

All papers that contain Restricted Pricing Material which are submitted to or filed with the Court shall be submitted or filed in a sealed envelope bearing the following legend clearly written on the face of the envelope under the relevant case caption for this Action:

**RESTRICTED PRICING MATERIAL/HIGHLY
CONFIDENTIAL – FILED UNDER SEAL
PURSUANT TO COURT ORDER**

2. Public Versions of Documents Filed Under Seal: A party submitting or filing papers under seal with the Court shall also submit or file a public version of such papers. Such public version shall redact any Designated Material. Prior to submitting or filing a public version of documents filed under seal, the party making such filing shall give the Disclosing Party an opportunity to review the proposed public version to ensure that all Designated Material has been properly redacted.

3. No Summaries: Designated materials shall not be disclosed or summarized, either in writing or orally, to anyone other than persons permitted to have access to such

information under this Protective Order. Notwithstanding the foregoing, nothing in this Protective Order prohibits outside counsel for any party from advising their respective clients of the presence or absence of evidence supporting or refuting the claims or defenses in this Action.

F. Challenging Designations

1. Designation Not Conclusive: Nothing in this Protective Order shall be construed as a finding that any Designated Material actually constitutes or contains proprietary or confidential information or trade secrets. For purposes of this order, proprietary or confidential information or trade secrets shall not include information or material that:

- (a) was, is or becomes public knowledge in a manner other than by violation of this Order;
- (b) is acquired by the non-designating party from a third-party, except if the non-designating party knows that the third-party does not have a right to disclose such information or material;
- (c) was possessed by the non-designating party prior to the entry of this Order by the Court, except if the non-designating party knows that it possessed the information or material unlawfully. For the purpose of clarification, any materials produced by Abbott, Fournier, Teva or Impax pursuant to earlier protective orders in C.A. Nos. 02-1512 (KAJ) or 03-120 (KAJ) shall be entitled to continued protection under both the prior applicable protective order and this Protective Order; or
- (d) was developed by the non-designating party independent of the information produced under the protective order.

2. Challenge Need Not Be Contemporaneous With Designation: There shall be no obligation to challenge a Confidential or Highly Confidential or Restricted Pricing designation when made and failure to do so shall not preclude a subsequent challenge. If a party

objects to the designation of any material as Confidential or Highly Confidential Material or Restricted Pricing, it may apply to this Court for a ruling that the information or material shall not be so designated. The burden shall be on the party arguing that the information should be treated as Confidential or Highly Confidential or Restricted Material to establish, based upon a showing of good cause, that the material constitutes or contains proprietary or confidential information or trade secrets. Until the Court rules upon the designation, the affected material shall continue to be treated in the manner the pre-challenge designation would ordinarily require.

G. Non-Party or Governmental Requests on Non-Disclosing Parties to Produce Material Designated as Confidential or Highly Confidential

In the event any of the parties is (i) subpoenaed in another action, or (ii) served with a demand in another action to which it is a party, or (iii) served with any other legal process and is requested to produce or otherwise disclose information that was designated as Designated Material by the producing party in this action, the party subpoenaed or otherwise served as referred to in this paragraph shall object to production of the material and shall give prompt written notice to the producing party to this litigation with sufficient time to afford the producing party to this litigation an opportunity to intervene. The notice shall include a copy of any such subpoena, demand, or other process. Should the person seeking access to the Designated Material take action against the party covered by this Protective Order to enforce such a subpoena, demand or other legal process, it shall respond by setting forth the existence of this Protective Order. Notwithstanding the foregoing, any document produced in this Litigation is subject to review by the Federal Trade Commission in connection with its investigation identified as Abbott Laboratories File 005-0124.

H. Confidentiality Interests of Third-Parties

1. Limitations on the Right to Refuse Production of Third-Party Materials: A party may temporarily withhold production of otherwise discoverable information (whether by subpoena, deposition question, or discovery request), if the party is under an obligation to a third-party not to disclose such information. In such an event, such party shall:

- (a) Promptly provide to the third-party whose confidentiality interests are implicated (i) notice of the party's obligation to disclose the information in question, and (ii) a copy of this Protective Order; and
- (b) Within thirty (30) business days, produce the requested information in question in compliance with this Order, unless that third-party, within that time, moves for or obtains from this Court a protective order precluding such disclosure.

I. Limitations of this Protective Order

1. Advice of Counsel: Nothing in this Protective Order shall bar or otherwise restrict any attorney for the parties from rendering advice to his or her client with respect to this litigation. In the course of doing so, said attorney may generally refer to or rely upon his or her examination of Designated Material, but shall not disclose the specific contents of Designated Material to persons not authorized to receive such Designated Material pursuant to this Protective Order.

2. No Waiver of Rights: Nothing in this Order shall be deemed a waiver of any right any party otherwise might have under the Federal Rules or the doctrines of attorney-client, attorney work product, or any other applicable privileges, including without limitation (i) the right of a party or non-party to object to any discovery request on any ground; (ii) the right of a party to seek an order compelling discovery with respect to any discovery request; (iii) the right of a party to object to the admission of evidence on any ground; (iv) the right of a party or non-

party to use its own materials within its own discretion; (v) the right of a party or non-party to seek additional protection for certain materials or information. With respect to a request for additional protection, the entity seeking such protection shall first confer with the parties to reach agreement with respect to such additional protection. If the parties are unable to reach agreement, the entity seeking such additional protection may, within 10 business days of receipt of a request for such information, file a motion with this Court for an additional protective order.

J. Inadvertent Disclosure of Designated Materials

Should any material designated as Confidential or Highly Confidential or Restricted Pricing be disclosed, through inadvertence or otherwise, in violation of this order, then the party responsible for such disclosure shall use its best efforts to retrieve from such persons all copies of the affected material and bind those receiving the disclosure to the terms of this Protective Order, by (i) promptly informing such persons of the provisions of this Protective Order and (ii) requesting that such persons sign the Confidentiality Agreement attached as Exhibit A. In addition, the affected parties must inform the Disclosing Party, in writing, of (i) the identity of any person not authorized under Section D to whom such affected material was disclosed, (ii) the identity of the material disclosed to that person, and (iii) whether such party has returned that material. Such identifications shall not waive any attorney work product or attorney-client privileges.

K. Inadvertent Disclosure of Privileged Documents

1. **No Waiver:** The production or disclosure of any discovery material made in connection with this Action which a producing party claims was inadvertent and should not have been produced or disclosed because of a privilege will not be deemed to be a waiver of any privilege to which the producing party would have been entitled had the affected material not

inadvertently been disclosed. In the event of such claimed inadvertent disclosure, the following procedures shall be followed:

- (a) The producing party may request, in writing, the return of any such discovery material by specifically identifying the affected material; and
- (b) If a producing party requests the return, pursuant to this paragraph, of any such discovery material from another party, the party to whom the request is made shall return immediately to the producing party all copies of the affected material within its possession, custody, or control—including all copies in the possession of experts, consultants, or others to whom the affected material was provided. Notwithstanding the foregoing, if a receiving party wishes to challenge the recall of a document on the grounds that it does not contain or reflect privileged material, it may keep one copy of the challenged document for a period not exceeding ten (10) business days after receiving a return request pursuant to Section K(1)(a), to submit to the Court for *in camera* review. If the challenged document is not submitted to the Court prior to the end of the ten (10) business day period, then the document must immediately be returned to the disclosing party. In the event that only portions of the discovery material contain privileged subject matter, the producing party shall substitute a redacted version of the discovery material at the time of making the request for the return of the requested discovery material. Until such materials are returned, such materials and the information contained therein shall be treated as Highly Confidential Material.

L. Other Proceedings

By entering this order and limiting the disclosure of information in this case, the Court does not intend to preclude another court from finding that information may be relevant and subject to disclosure in another case. Any person or party subject to this order who becomes subject to a motion to disclose another party's information designated "Confidential Material,"

"Highly Confidential Material," or "Restricted Pricing Material" pursuant to this order shall promptly notify that party of the motion so that the party may have an opportunity to appear and be heard on whether that information should be disclosed.

M. Destruction or Return of Designated Materials at Conclusion of Action

1. Destruction or Return by Parties and Other Authorized Persons: Upon the final conclusion of this Action, all persons to whom Designated Material has been disclosed shall, without demand, either (a) destroy, or (b) return to the party that originally produced it, all Designated Material (and all copies of such material) and all other documents containing information taken from the Designated Material, except that each party's outside counsel may retain one copy of (i) materials created during the course of the Action; (ii) work product of non-testifying consultants/experts; (iii) materials made part of the Court record; (iv) all deposition and Court transcripts, including exhibits; and (v) deposition summaries. Such file copy must be maintained subject to the terms of this Protective Order. All recipients of Designated Material shall certify in writing within sixty (60) days of the entry of settlement or final judgment that they have complied with the provisions of this paragraph.

2. Return by the Court: Upon the final conclusion of this litigation:

- (a) any Designated Material produced hereunder that has been submitted for identification or in evidence at any hearing or trial in this Action may be withdrawn by counsel for the person who so offered or originally produced such Designated Material; and
- (b) the courtroom clerk and other Court staff are authorized to deliver said Designated Material to said counsel.

N. Modification, Relief, and Post-Termination Effect of This Protective Order

This Protective Order shall survive the final termination of this Action (whether by settlement or by final judgment) and continue in full force and effect, unless modified by an

order of the Court or by written stipulation by the parties filed with the Court. The parties reserve all rights to apply to the Court at any time, before or after termination of this Action, for an order (i) modifying this Protective Order, or (ii) seeking further protection against discovery of use of Designated Material or other information. Without limiting the foregoing, this Court shall retain jurisdiction to enforce the terms of this Protective Order after the final termination of this Action.

SO ORDERED this 1st day of March, 2006.


U.S.D.J.

507151

EXHIBIT A

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Plaintiffs,)	
v.)	C.A. No. 02-1512 (KAJ)
TEVA PHARMACEUTICALS USA, INC., a Delaware corporation,)	CONSOLIDATED
Defendant,)	
<hr/>		
TEVA PHARMACEUTICALS USA, Inc., a Delaware corporation, and TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation,)	
Counterclaim Plaintiffs,)	
v.)	
ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Counterclaim Defendants,)	
<hr/>		
ABBOTT LABORATORIES, an Illinois corporation, FOURNIER INDUSTRIE ET SANTÉ, a French corporation, and LABORATOIRES FOURNIER S.A., a French corporation,)	
Plaintiffs,)	
v.)	C.A. No. 03-120 (KAJ)
IMPAX LABORATORIES, INC., a Delaware corporation,)	CONSOLIDATED
Defendant.)	

IN RE TRICOR DIRECT PURCHASER ANTITRUST LITIGATION)	
)	C.A. No. 05-340 (KAJ)
THIS DOCUMENT RELATES TO: ALL ACTIONS)	CONSOLIDATED
)	
IN RE TRICOR INDIRECT PURCHASER ANTITRUST LITIGATION)	
)	C.A. No. 05-360 (KAJ)
THIS DOCUMENT RELATES TO: ALL ACTIONS)	CONSOLIDATED
)	

CONFIDENTIALITY AGREEMENT

The undersigned hereby acknowledges that (s)he has read the Protective Order entered on _____, in the above-captioned action, and understands the terms thereof, and agrees, upon threat of penalty of contempt, to be bound by such terms of each paragraph of the Protective Order. **In particular, the undersigned understands that the terms of said Protective Order obligate him/her to use Confidential or Highly Confidential or Restricted Pricing Material solely for the purposes of this Litigation and to not disclose any such Confidential or Highly Confidential or Restricted Pricing Material to any other person, firm or entity,** except that there will be no restriction on documents that are used as exhibits in Court, unless such exhibits were filed under seal, and there will be no restriction on information disclosed in open Court, unless the Courtroom is sealed at the time of such disclosure. Further, for the purpose of enforcing this Confidentiality Agreement the undersigned hereby subjects himself/herself to the jurisdiction of this Court.

Date

Signature

EXHIBIT B

MORRIS, JAMES, HITCHENS & WILLIAMS LLP

222 Delaware Avenue, 10th Floor
 Wilmington, Delaware 19801-1621
 (302) 888-6800
 Facsimile (302) 571-1750
www.morrisjames.com

Mary B. Matterer
 (302) 888-6960
mmatterer@morrisjames.com

Mailing Address
 P.O. Box 2306
 Wilmington, DE 19899-2306

November 21, 2006

VIA EFILING & HAND DELIVERY

The Honorable Kent A. Jordan
 USDC for the District of Delaware
 844 King Street
 Wilmington, DE 19801

Re: Abbott Labs., et al. v. Impax Labs., Inc., C. A. No. 03-120 KAJ (consolidated)

Your Honor:

Pursuant to the Court's order, Impax has negotiated in good faith regarding an outside counsel only tier to the protective order that would provide adequate protection for its sensitive business information that the Court ordered produced at the hearing on November 14, including Impax's company-wide manufacturing and sales models and strategic plans that go well beyond fenofibrate.¹ After several meet and confer sessions,² the parties have narrowed the issues on which they disagree to one point: whether to require that counsel receiving the outside counsel only information be admitted *pro hac vice* to this Court and limit dissemination of the information to a reasonable number of non-lawyers in outside counsel firms. A proposed order, agreed to in all respects except Impax's proposed requirements for outside counsel and staff who receive outside counsel only information, is attached as Exhibit A.

Impax's proposal would require that to receive outside counsel only information, counsel must appear on the record in this case, either as a member of the District of Delaware bar or as counsel *pro hac vice*. Impax's proposal further requires any such counsel to limit dissemination of outside counsel only information to a reasonable number of non-lawyer staff in his/her law firm who sign the undertaking in the protective order. Neither the undertakings of staff nor the identity of staff who sign them need be disclosed.

¹ In a follow up meet and confer, counsel for Fournier has requested that Impax produce 57,000 pages of material in unredacted form, plus all company wide monthly status reports, all monthly manufacturing reports, all monthly sales and marketing reports, and all strategic plans. This information goes to the heart of Impax's business, its product line, and its business model.

² Abbott's counsel did not participate in the meet and confer on this issue; thus, this letter refers to Fournier's positions. Fournier was presumably representing Abbott's interests here.

The Honorable Kent A. Jordan
 November 21, 2006
 Page 2

MORRIS, JAMES, HITCHENS & WILLIAMS LLP

Abbott and Fournier have articulated the dangers of unlimited dissemination of highly sensitive information, even within outside counsel firms. In a motion for protective order that the Court granted, they noted: “the risk of inadvertent disclosure is particularly high given the number of outside counsel. . . . Here, approximately twenty-five law firms represent plaintiffs as outside counsel,” plus, of course, the five law firms representing Abbott and Fournier. Ex. B, Letter from Mary Graham, Esq. to Hon. Kent Jordan, Nov. 14, 2005, at 3; *see also* Ex. C, Hearing Transcript, Nov. 15, 2005, at 17:19-18:18. Thus, Abbott and Fournier even objected to providing information about future products to counsel of record—something Impax does not seek to limit, in light of the Court’s order. They went on to add that if not limited to counsel of record, outside counsel would include:

hundreds of individuals, many of whom would never be disclosed to Abbott or Fournier, be given access to Abbott’s and Fournier’s most valuable information. When dealing with such a large group of people, the likelihood of even an inadvertent disclosure is substantial. Moreover, after the information is disclosed, there is no way to ‘put the genie back in the bottle.’

Ex. B, at 3, n.2. In view of these dangers that Abbott and Fournier articulated, Impax’s proposed requirements for counsel’s accessing only the most highly sensitive outside counsel only information is not unreasonable.

There’s no dispute that the information Impax would provide is precisely the type of sensitive information Abbott and Fournier were concerned about disclosing. Abbott’s counsel noted that a pharmaceutical company’s product pipeline is the “key[] to the kingdom.” Ex. C, at 18:7-9. The information that Fournier has asked for in light of the Court’s order includes strategic plans that would discuss Impax’s product plans, monthly company reports that would discuss the company’s products across the board, and unredacted forecast spreadsheets that would cover all the company’s products, including pipeline products that were not yet launched but included in the forecasts. These documents are the keys to the kingdom for Impax, and the restrictions Impax suggests are reasonable in light of the information’s sensitivity.

Fournier’s response in meet and confer was that these restrictions would create practical problems because, for example, contract attorneys receiving this information would not be admitted *pro hac vice* and requiring staff members to sign an undertaking would be burdensome because law firm staff changes.³ Those burdens do not outweigh the risk of inadvertent disclosure of Impax’s most sensitive information, which, if inadvertently disclosed, comes “out of the bottle” forever. If anything, the transience of contract attorneys and staff is precisely why

³ Impax’s proposal provides that five staff members may receive outside counsel only information. In meet and confer, Impax offered to increase that number by a reasonable amount if Fournier’s counsel did not feel that five was enough. Fournier was unwilling to offer a counter-proposal regarding the number of staff it would want to be able to receive this information. Impax is not wedded to a particular number of staff people, but rather seeks a reasonable limit and that staff be required to sign the protective order undertaking.

The Honorable Kent A. Jordan
November 21, 2006
Page 3

MORRIS, JAMES, HITCHENS & WILLIAMS LLP

the restrictions Impax proposes are necessary—so that this information does not end up in the hands of the hundreds of unidentified individuals that Abbott's counsel referred to when seeking protection of her own client's sensitive information. The risk of inadvertent disclosure with such wide dissemination is too high.

Furthermore, the fact that the existing protective order does not include the requirements that Impax proposes is of no moment here. The existing order was negotiated as to a much narrower category of information, not the highly sensitive non-fenofibrate information that Abbott and Fournier now seek. Moreover, the Court ordered the parties to negotiate this new category precisely because the old ones were inadequate to protect the information at issue.

Respectfully,



Mary B. Matterer

cc: All counsel (via e-mail)

A

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

TEVA PHARMACEUTICALS USA, INC.,)	
TEVA PHARMACEUTICAL INDUSTRIES LTD.,)	
and NOVOPHARM, LTD.,)	
)	
Counterclaim Plaintiffs,)	
)	
v.)	C.A. No. 02-1512 (KAJ)
)	
ABBOTT LABORATORIES,)	CONSOLIDATED
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
)	
Counterclaim Defendants.)	
)	
<hr/>		
IMPAX LABORATORIES, INC.,)	
)	
Counterclaim Plaintiff,)	
v.)	
)	
ABBOTT LABORATORIES,)	C.A. No. 03-120 (KAJ)
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
)	
Counterclaim Defendants.)	
)	
<hr/>		
IN RE TRICOR DIRECT PURCHASER)	
ANTITRUST LITIGATION)	
)	
<hr/>		
THIS DOCUMENT RELATES TO:)	CONSOLIDATED
ALL ACTIONS)	
)	
<hr/>		
IN RE TRICOR INDIRECT PURCHASER)	
ANTITRUST LITIGATION)	
)	
<hr/>		
THIS DOCUMENT RELATES TO:)	C.A. No. 05-360 (KAJ)
ALL ACTIONS)	
)	

**AMENDMENT TO THE STIPULATED MARCH 1, 2006 PROTECTIVE ORDER
GOVERNING CONFIDENTIAL INFORMATION**

Pursuant to Fed. R. Civ. P. 26(c), by agreement of Abbott Laboratories, including its successors-in-interest, subsidiaries and predecessors (“Abbott”), Fournier Industrie et Santé and Laboratoires Fournier S.A, including their successors-in-interest, subsidiaries and predecessors (collectively, “Fournier”), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., including their successors-in-interest, subsidiaries and predecessors (collectively, “Teva”), Impax Laboratories, Inc., including its successors-in-interest, subsidiaries and predecessors (“Impax”), and all plaintiffs in the actions consolidated and/or coordinated in In re Tricor Direct Purchaser Antitrust Litig., No. 1:05-cv-00340-KAJ (D. Del) (collectively, “Direct Purchasers”) and In re Tricor Indirect Purchaser Antitrust Litig., No. 1:05-cv-00360-KAJ (D. Del.) (collectively, “Indirect Purchasers”) (all individually, a “party”, or collectively, “parties”), the Court, finding good cause existed therefor, entered a Protective Order on March 1, 2006 to prevent unauthorized disclosure and use of the parties’ trade secrets and other confidential information during and after the course of the above-captioned litigations (collectively, the “Action”). IT IS HEREBY ORDERED THAT said Protective Order be amended as follows.

This Amendment adds an “Outside Counsel Only” designation to cover materials or information that ordinarily would be designated as “Highly Confidential” or “Restricted Pricing Material” but that is so competitively sensitive that the “Highly Confidential” and “Restricted Pricing Material” designations as defined in the Protective Order are inadequate to protect against the possibility of competitive harm.

Persons authorized to access "Outside Counsel Only" designated materials shall be limited to:

1. Outside counsel of record, who have been admitted in the United States District Court for the District of Delaware either directly or pro hac vice for this Action, for the respective parties to this litigation ("Outside Counsel"), and no more than five (5) staff members within the same law firm of said Outside Counsel. Staff members are required to sign the undertaking in Exhibit A and the law firm must maintain these undertakings, but neither the undertakings nor the staff members' identities need be disclosed;
2. Persons identified in items (d)-(j) of Section D, Subsection 1 of the Protective Order.

Further, counsel shall provide Outside Counsel Only materials and information to an authorized person identified in paragraph (d) of Section D, Subsection 1 of the Protective Order, (1) only to the extent counsel reasonably believes such information may be necessary to that person's analysis; and (2) only after that person has signed the undertaking attached to this Amendment that specifically references Outside Counsel Only material and that undertaking has been disclosed to counsel for all parties.

SO ORDERED this ____ day of November 2006.

U.S.D.J.

EXHIBIT A [revised as per Amendment]

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

TEVA PHARMACEUTICALS USA, INC.,)	
TEVA PHARMACEUTICAL INDUSTRIES LTD.,)	
and NOVOPHARM, LTD.,)	
)	
Counterclaim Plaintiffs,)	
)	
v.)	C.A. No. 02-1512 (KAJ)
)	
ABBOTT LABORATORIES,)	CONSOLIDATED
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
)	
Counterclaim Defendants.)	
)	
<hr/>		
IMPAX LABORATORIES, INC.,)	
)	
Counterclaim Plaintiff,)	
v.)	
)	
ABBOTT LABORATORIES,)	C.A. No. 03-120 (KAJ)
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
)	
Counterclaim Defendants.)	
)	
<hr/>		
IN RE TRICOR DIRECT PURCHASER)	
ANTITRUST LITIGATION)	
)	
<hr/>		
THIS DOCUMENT RELATES TO:)	C.A. No. 05-340 (KAJ)
ALL ACTIONS)	
)	

IN RE TRICOR INDIRECT PURCHASER ANTITRUST LITIGATION)
<hr/>)
THIS DOCUMENT RELATES TO: ALL ACTIONS)
<hr/>)
	C.A. No. 05-360 (KAJ)
)
	CONSOLIDATED
)

CONFIDENTIALITY AGREEMENT

The undersigned hereby acknowledges that (s)he has read the Protective Order entered on March 1, 2006, and the November 2006 amendment thereto, in the above-captioned action, and understands the terms thereof, and agrees, upon threat of penalty of contempt, to be bound by such terms of each paragraph of the Protective Order. In particular, the undersigned understands that the terms of said Protective Order obligate him/her to use Confidential or Highly Confidential or Restricted Pricing Material or Outside Counsel Only material solely for the purposes of this Litigation and to not disclose any such Confidential or Highly Confidential or Restricted Pricing Material or Outside Counsel Only to any other person, firm or entity, except that there will be no restriction on documents that are used as exhibits in Court, unless such exhibits were filed under seal, and there will be no restriction on information disclosed in open Court, unless the Courtroom is sealed at the time of such disclosure. Further, for the purpose of enforcing this Confidentiality Agreement the undersigned hereby subjects himself/herself to the jurisdiction of this Court.

Date

Signature

B

MORRIS, NICHOLS, ARSHT & TUNNELL

1201 NORTH MARKET STREET
P.O. Box 1347
WILMINGTON, DELAWARE 19899-1347

302 658 9200
302 658 3989 FAX

MARY B. GRAHAM
(302) 575-7287
mgraham@mnat.com

November 14, 2005

The Honorable Kent A. Jordan
United States District Court
For the District of Delaware
844 King Street
Wilmington, DE 19801

BY EFILING & HAND DELIVERY

Re: In re TriCor® Antitrust Litigations: C.A. Nos. 02-1512, 03-120,
05-340 and 05-360 (KAJ)

Dear Judge Jordan:

I write on behalf of Abbott Laboratories, Fournier Industrie et Santé, and Laboratoires Fournier S.A. in opposition to plaintiffs' demands for access to information concerning the specific details of Abbott's or Fournier's confidential future business plans regarding TriCor®.

Plaintiffs' request should be considered in context. Plaintiffs, which number almost twenty, include Teva and Impax, whose business model is to make identical copies of branded drugs as quickly as possible. The competitive sensitivity of specific information about Abbott's or Fournier's on-going research into next generation products is even greater than is ordinarily the case between competitors.¹ This is not a case where redactions mask a "smoking gun" about past conduct that is the true subject of plaintiffs' claims. As plaintiffs themselves acknowledge, that Abbott or Fournier are developing new products is known. It is the highly confidential details of the R&D, regulatory and commercial strategies of future products or "pipeline" products still in development (none of which have been approved by the FDA) that Abbott and Fournier have redacted.

Plaintiffs' conclusory assertions that future plans are relevant either to their claims of an overall scheme or their request for injunctive relief do not withstand scrutiny. Plaintiffs allege that Abbott's and Fournier's past conduct was anticompetitive. Future conduct, especially future development plans so nebulous that FDA approval has not been obtained and has no guarantee of being obtained, has no legitimate place in this litigation. The documents plaintiffs cite serve only to underscore that it is the general fact of the existence of these future plans that is arguably relevant to their "overall scheme" claim, and that general fact has been set out in documents produced to plaintiffs. The fact that Abbott and Fournier are continuing to study the development of new products does not provide insight into plaintiffs' claims about the manner of past product introductions. In addition, discovery as to the scope of an injunction is extraordinarily premature. Plaintiffs fail to describe any circumstances that could conceivably warrant barring Abbott or

¹ Abbott's and Fournier's redactions are not a knee-jerk unwillingness to allow discovery, but are instead limited in number and calibrated to the numbers and identities of the recipients. These concerns did not exist when Abbott and Fournier produced unredacted documents to the Federal Trade Commission under strict assurances of confidentiality.

The Honorable Kent A. Jordan
 Page 2
 November 14, 2005

Fournier from continuing to research new products and indications or prosecuting New Drug Applications with the FDA. Any potentially adverse impact on plaintiffs as a result of these research efforts could occur only in the future if new products are ever launched and depending on the manner of new product introduction or as a result of what plaintiffs falsely characterize as "market destruction" conduct, both of which are premature and speculative at this time.

The scope of permissible discovery under Rule 26(b), while broad, is not unbounded. Discovery should be denied where, as here, (a) the discovery sought is highly confidential, (b) disclosure would harm the producing party and (c) the discovery is irrelevant and unnecessary to the requesting party's case. *See American Standard v. Pfizer*, 828 F.2d 734, 740-44 (Fed. Cir. 1987).

A. Abbott's and Fournier's Future Plans are Highly Confidential

The details of on-going development by Abbott or Fournier are highly proprietary. Courts have routinely viewed this kind of information, which includes such sensitive information as product formulas, marketing plans and market entry decisions, as confidential. *See American Standard*, 828 F.2d at 740 (collecting cases); *Serono Laboratories, Inc. v. Shalala*, 35 F. Supp. 2d 1, 2 (D.D.C. 1999) ("In a field as competitive and technical as the pharmaceutical industry, success or failure will turn in large measure on innovation and the members of the industry justifiably hoard their trade secrets as jealously as a miser hoards his gold.").

New product innovation (and the ability to keep such information confidential) is critical to the success of any pharmaceutical company. *See Ex. A*, Declaration of Michael A. Jones, ¶¶ 5-6; *Ex. B.*, Declaration of Pierre Diebolt, ¶¶ 5-7. While general information concerning the type of products that the companies are researching is disclosed for the benefit of shareholders, the companies limit the detailed information that the plaintiffs are seeking to high-level executives and staff working on the TriCor® brand who have a need to know. *See Jones Decl.*, ¶¶ 8-11; *Diebolt Decl.*, ¶ 4.

To further demonstrate the sensitivity and irrelevance of the business and product plans sought by plaintiffs, under separate letter, Abbott and Fournier are submitting a few examples of the documents at issue for *in camera* review.

B. Disclosure of Abbott's and Fournier's Future Plans Would Cause Them Significant Harm

As Messrs. Jones and Diebolt describe in their declarations, even inadvertent disclosure of confidential future business plans would cause significant harm to Abbott and Fournier. *See Jones Decl.*, ¶ 9; *Diebolt Decl.*, ¶ 7. Moreover, unique circumstances in this case significantly increase the risk of such disclosure, even under a protective order limiting disclosure to outside counsel only.

First, as noted previously, two of the plaintiffs are direct competitors of Abbott. Each has obtained FDA approval to make generic versions of the prior two generations of TriCor® products, and Teva is asking this Court to grant it a compulsory license to Abbott's and Fournier's patents covering its current generation TriCor® products. Not only are Teva and Impax competitors of Abbott, they routinely engage in strategic alliances to market generic drugs. It is well established that "disclosure to a competitor is more harmful than disclosure to a noncompetitor," *id.* at 741, and that "[c]ompetitive disadvantage is a type of harm cognizable under Rule 26." *Zenith Radio Corp. v. Matsushita Elec. Indus. Co.*, 529 F. Supp. 866, 890 (E.D. Pa. 1981); *Neill Corp. v. John Paul Mitchell Sys.*, Civ. A. No. 92-2157, 1995 WL 217480, at *5 (E.D. La. Apr. 12, 1995) (citation omitted) ("the denial of a discovery request for confidential information is particularly appropriate" when the disclosure is to a competitor). In this case, the potential harm is even greater as the generics' business model is simply to copy defendants' products.

The Honorable Kent A. Jordan
 Page 3
 November 14, 2005

Second, the risk of inadvertent disclosure is particularly high given the number of outside counsel.² In a case such as this, “[t]he critical inquiry is whether the attorney[s] in question [are] in a position that creates a high risk of inadvertent disclosure of highly confidential information.” *Commissariat A L’Energie v. Dell Computer Corp.*, No. Civ. A. 03-484-KAJ, 2004 WL 1196965, at *2 (D. Del. May 25, 2004) (internal quotation omitted). Here, approximately twenty-five law firms represent plaintiffs as outside counsel, with at least three representing Teva on an ongoing basis.

C. Abbott’s and Fournier’s Future Plans Are Irrelevant and Unnecessary to Plaintiffs’ Actions

Because plaintiffs seek the disclosure of highly sensitive and confidential information, they must demonstrate that Abbott’s and Fournier’s future plans are “relevant and necessary to the action.” *Coca-Cola Bottling Co. of Shreveport v. Coca-Cola Co.*, 107 F.R.D. 288, 292-93 (D. Del. 1985) (citation omitted). In this case, plaintiffs can show neither.

Information concerning Abbott’s and Fournier’s future plans is irrelevant to plaintiffs’ claims. Here, the plaintiffs are asserting various antitrust and unfair competition claims based on allegations of misconduct by Abbott and Fournier surrounding introductions of new fenofibrate products in 2001 and 2004 and concurrent “market destruction” activities. There is no count in any of the Amended Complaints that concerns, either directly or indirectly, Abbott’s and Fournier’s future actions. Abbott’s and Fournier’s *future plans*, including drug pipeline development, have no bearing on the *past wrongs* alleged in these actions. In addition, because past conduct is the only conduct implicated by the claims in this case, plaintiffs cannot contend that this information is necessary for them to “to prepare [their] case[s] for trial.” *Id.* at 293.

Plaintiffs’ argument that revealing planning and deliberations on new product efforts is relevant to their allegations of “motive, knowledge and intent in executing past conversions,” “the anticompetitive effects” and a “continuous and ongoing pattern of anticompetitive conduct” does not stand up to analysis. Proprietary information on future product development is not relevant to supposed past motives or to the anticompetitive effects of precisely how existing products were commercially launched. One has nothing to do with the other. Attempting to link possible future products with existing products under the banner of “ongoing conduct” similarly fails. No harm can come to a competitor or to competition from research or planning on possible new products. Even under plaintiffs’ expansive theory, the alleged harm only occurs when a new product is actually approved by the FDA and is introduced into the market.

Respectfully,

/s/ Mary B. Graham (#2256)

Mary B. Graham

cc: Clerk of Court (by hand) (with enclosures)
 (all record counsel)

² In the protective order plaintiffs propose, “Outside Attorneys’ Eyes Only” includes (i) approximately 70 counsel of record, (ii) employees of those firms (a group of countless unidentified individuals), and (iii) experts or consultants and their staff. Thus, the “attorneys’ eyes only” designation is a misnomer. In fact, plaintiffs propose that hundreds of individuals, many of whom would never be disclosed to Abbott or Fournier, be given access to Abbott’s and Fournier’s most valuable information. When dealing with such a large group of people, the likelihood of even an inadvertent disclosure is substantial. Moreover, after the information is disclosed, there is no way to “put the genie back in the bottle.”

C

1 IN THE UNITED STATES DISTRICT COURT
2
3 IN AND FOR THE DISTRICT OF DELAWARE
4
5 - - -
6

7 IN RE: TRICOR DIRECT PURCHASER : CIVIL ACTION
8 ANTITRUST LITIGATION :
9 : NO. 05-340 (KAJ)
10
11

12 THIS DOCUMENT RELATES TO: : (Consolidated)
13 ALL ACTIONS :
14
15

16 -and-

17 IN RE: TRICOR INDIRECT PURCHASER :
18 ANTITRUST LITIGATION :
19 : NO. 05-360 (KAJ)
20

21 THIS DOCUMENT RELATES TO: : (Consolidated)
22 ALL ACTIONS :
23
24

25 - - -

26 Wilmington, Delaware
27 Tuesday, November 15, 2005 at 10:00 o'clock, a.m.
28 TELEPHONE CONFERENCE
29
30

31 BEFORE: HONORABLE KENT A. JORDAN, U.S.D.C.J.
32
33

34 APPEARANCES: (Listed on page two)
35
36

37 Brian P. Gaffigan
38 Registered Merit Reporter
39

1 of Abbott and Fournier. But that is the point that I want
2 to stress. What we're discussing here and what we proposed
3 here is not disclosure to a competitor. The protective
4 order that we have submitted to Abbott and Fournier, we're
5 talking about disclosure on an outside counsel basis. That
6 is the point. And as this Court knows from the antecedent
7 patent litigation, there was a protective order in place
8 covering sensitive information and that worked just fine.
9 These are outside counsel who know how to protect this
10 information.

11 We do not see any risk of competitive harm on
12 an outside counsel only basis. And, similarly, Abbott and
13 Fournier have not cited a case which holds that a court was
14 going to refuse to disclose relevant information to outside
15 counsel only on the basis of competitive harm. So to the
16 extent that there is a concern about the number of outside
17 counsel, then I would suggest that the more appropriate
18 approach would be for the parties to engage in a discussion
19 that deals with that issue rather than simply saying that
20 relevant information can be withheld entirely.

21 THE COURT: All right. Mr. Cavanaugh.

22 MR. CAVANAUGH: Thank you, Your Honor. Your
23 Honor, counsel for plaintiffs say "Abbott and Fournier are
24 controlling the market and poisoning the market." Those
25 are actual steps taken in the marketplace: ongoing research

1 and development, technical assessments of possible new
2 indications for treatments, analyses of where the market is
3 going and where Abbott and Fournier might be able to best
4 serve patient needs with developments of new innovative
5 products has nothing to do with actual market effects.
6 Actual market effects, even under the plaintiff's expansive
7 theory about controlling the market and poisoning the
8 market, only occurs when the Food and Drug Administration
9 actually approves the product and you begin selling it and
10 then you look at what are the market effects of this new
11 product that has been introduced into the market.

12 That is not what we're talking about here.
13 Their case is based upon product introduction that have
14 occurred that have had an impact on the market, and we're
15 going to, both sides will argue about what the effects
16 have been. We think they have been pro-competitive. We
17 think we've introduced innovative new products that the
18 marketplace was looking for. They allege it was part of a
19 scheme. That is fine.

20 But we're talking about what has actually been
21 taking place in the marketplace. That is what is relevant
22 in this case. And to take us down the road of having to
23 produce highly proprietary information on new products that
24 may never see the light of day ... for the FDA may approve
25 them, they may not approve them. They may approve them with

1 certain indications. Our hopes and aspirations as to what
2 those indications may be, what the success of those products
3 may be, when the FDA may approve them, strikes us as, you
4 know, fairly speculative but certainly of no relevance to
5 this case. I have no problem with full discovery as to
6 our existing products. We think that is what this case is
7 about.

8 Your Honor raised the point or counsel raised
9 the point about injunctive relief. The issue of the scope
10 of an injunction is, from our perspective, certainly
11 premature, but I think more importantly, Your Honor, I
12 think it's inconceivable there could be an injunction that
13 would say "you can't introduce new products. You have to
14 stop your research and development." One, that is not what
15 this case is about and, two, it's frankly we think legally
16 inconceivable that there could be an injunction along those
17 lines, if we ever reach the stage of having a discussion
18 with the Court about an injunction.

19 So turning to the question of harm. I think
20 Your Honor hit the nail on the head when you said, is
21 there a greater harm when 70 people have access? Well,
22 Your Honor, it's not just 70 people. Those are only the
23 attorneys who have filed pro hacs. So far, it's 25
24 different law firms. It's the paralegals, the other
25 associates. It's the experts. It's the consultants working

1 with all of these different law firms.

2 This is a group that includes competitors. It
3 includes purchasers. It includes third-party payors. It
4 includes people who made no sense of the value of this
5 information. And as we've set forth in the declarations,
6 this is, you know, your product pipeline is for any pharma-
7 ceutical company. It's the keys to the kingdom. This is
8 what is among the most valuable trade secrets out of the
9 company.

10 Now, the plaintiff cites the Coca-Cola case.
11 And the Coca-Cola case, the trade secret was an essential
12 element of that case. That was a contract dispute as
13 to whether the product was within the scope of the trade
14 secret. Here, the information they're seeking really has
15 no relevance here. And I think the best that they can
16 come up with is some marginal or possible future relevance.

17 I don't think those arguments favor producing
18 what we think is highly proprietary information for which
19 given the nature of this case, the harm of disclosure would
20 be significant and the number of parties involved, the risk
21 of disclosure we think is enhanced. Plaintiffs will take
22 extensive discovery of our existing products which is what
23 this case is about. At this point, we think that should be
24 the appropriate scope of discovery in the case, Your Honor.

25 THE COURT: All right. Mr. Steinfeld or

EXHIBIT C

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

1201 NORTH MARKET STREET
P.O. Box 1347
WILMINGTON, DELAWARE 19899-1347

302 658 9200
302 658 3989 FAX

MARY B. GRAHAM
302.351.9199
mgraham@mnat.com

November 24, 2006

The Honorable Kent A. Jordan
United States District Court
844 King Street
Wilmington, DE 19801

VIA ELECTRONIC FILING

Re: *Abbott Laboratories, et al v. Impax Laboratories*
C.A. No. 03-120 (KAJ)

Dear Judge Jordan:

We are counsel for Abbott Laboratories and are writing in connection with the November 21, 2006 letters of Richards, Layton & Finger and of Morris, James, Hitchens & Williams LLP concerning revisions to the March 1, 2006 "Protection Order Governing Confidential Information" (the "Order"). Abbott respectfully submits that the Order's existing definition of "Restricted Pricing Material" should be expanded to cover the information to be produced by Impax in response to the Court's order on November 14.

Contrary to the November 21 joint submission of Abbott and Fournier, upon further reflection, Abbott believes there is no need to create a fourth category under the Order for "Outside Counsel Only." (Fournier does not join in this letter and does not oppose an "Outside Counsel Only" category.) If Impax's information is given the protections of the existing "Restricted Pricing Material" designation, that information cannot be disclosed to any non-legal employees of Abbott and can be disclosed to only one in-house counsel (who cannot be involved in the business activities itemized in paragraph D.3 of the Order). In essence, that in-house counsel is an "outside" litigation counsel. Such a limited revision of the Order protects Impax while allowing one in-house counsel to participate fully in the preparation of Abbott's defense.

Abbott's in-house counsel develop and execute litigation strategy with Abbott's outside counsel, and Abbott consistently opposes exclusion of its in-house counsel from access to information produced in discovery. The counsel for Abbott who participated in the November 14 telephone conference should have raised this point during the November 14 conference call and in a separate letter on November 21, and we apologize for raising it now. The issue, however, is a very important one. The documents to be produced by Impax are relevant to the billions of dollars of damages claimed by Impax, by the proposed Direct Purchaser and End-Payor classes and by the individual plaintiffs. The information will have a significant role in building Abbott's defense to the various plaintiffs' damages claims. We submit that an Abbott

in-house litigation counsel should not be excluded from the preparation of Abbott's defense to the damages claim.

An Abbott in-house litigation counsel can be allowed access to the information to be produced by Impax without harming Impax. The Order currently provides three tiers of protection for confidential information ("Confidential Material," "Highly Confidential Material" and "Restricted Pricing Material"). The "Restricted Pricing Material" category is the most restrictive category. The existing three-tier approach appropriately balances disclosure of a party's sensitive business information and an opposing party's participation in formulating the party's legal strategy.

The "Restricted Pricing Material" category anticipates the type of information to be disclosed by Impax. As Impax explains in its November 21 letter, Impax will disclose information about drug products that are not fenofibrates. Accordingly, that information should not be disclosed to in-house counsel if that counsel is involved in certain business decisions involving any type of drug product. If in-house counsel is not involved in such decisions, there should not be a prohibition on disclosure to that counsel.

As set forth in the Order, "Restricted Pricing Material" information cannot be seen by in-house counsel unless (with certain defined exceptions) that counsel has (1) no role in marketing or formulating marketing strategies "concerning any drug products;" (2) no role in pricing or formulating pricing strategies "concerning any drug products;" and (3) no role in communicating with customers or suppliers concerning pricing or contracts for "any drug product." Thus, to the extent Impax will be producing documents that concern drug products other than fenofibrates, the "Restricted Price Material" category already ensures that the in-house counsel who has access to such information has no involvement in marketing and pricing any drug product.

The Order was drafted by the parties to allow access to information by specific types of in-house counsel who could not inadvertently use that information for competitive purposes. Although the plaintiffs initially proposed an "Outside Counsel Only" category, they agreed to eliminate that category when the parties negotiated, for example, the definition of "Competitive Fenofibrate Activities." *See* Order at paragraph A.6. Abbott respectfully submits that the information now to be disclosed by Impax does not require a fourth tier that was not required as of March 2006 – especially in view of the strict limitations on the in-house counsel who has access to "Restricted Pricing Material."

The case law vigorously supports the conclusion that in-house counsel are not second-class lawyers who cannot be trusted with sensitive information. *See, e.g., Brown Bag v. Symantec Corp.*, 960 F.2d 1465, 1470 (9th Cir. 1992); *U.S. Steel Corp. v. United States*, 730 F.2d 1465, 1468 (Fed. Cir. 1984). *See also Matsushita Elec. Industrial Co., Ltd. v. United States*, 929 F.2d 1577, 1579 (Fed. Cir. 1991). When restrictions must be placed on in-house attorneys, the restrictions are based on a counsel's duties – not the counsel's status as in-house counsel. *Sullivan Mktg., Inc. v. Valassis Communications, Inc.*, No. 93 Civ. 6350, 1994 WL 177795, at *2 (S.D.N.Y. May 5, 1994). The Delaware court routinely allows under the highest tier of a protective order at least one in-house counsel, where there are assurances that counsel's duties do not put the information at risk from "competitive decision making" or the like. *See, e.g., Affymetrix, Inc. v. Illumina, Inc.*, C.A. No. 04-901-JJF, 2005 U.S. Dist. LEXIS 15482 (7/28/05) (Citing *U.S. Steel*, Court allowed access by four lawyers of plaintiff's in-house "Litigation Unit"

to “highly confidential” information because there were “numerous safeguards” to protect the information and the lawyers did not assume a role in management or “competitive decision-making activities of the company.”); *Mobius v. Acartus*, C.A. No. 05-346-SLR (letter from Court to counsel, 3/14/06) (“I allow in every case one in-house representative to view the most confidential of documents.”) (Exhibit A); *BTG Int'l., Inc. v. Amazon.com*, C.A. No. 04-1264-SLR (Order 1/25/05) (While taking into account the nature of the employee’s duties, “I always allow at least one employee of a party to have access to all information, including the most confidential information.”) (Exhibit B).

The Order’s existing provisions follow the bright line drawn by the cases between in-house counsel who are engaged in competitive decision making and in-house counsel who are not. The types of activities that are not allowed for an in-house counsel given access to “Restricted Pricing Materials” are the types of activities itemized by the courts. *See, e.g., U.S. Steel*, 730 F.2d at 1468, n.3 (which focuses on counsel’s involvement in decisions relating to “pricing, product design, etc.”).

Where in-house counsel are not involved in competitive decision making, courts have regularly refused to bar in-house counsel access to confidential discovery materials. *See, e.g., In re Plastics Additives Antitrust Litig.*, 2005 U.S. Dist. LEXIS 23771, at *11-12 (E.D. Pa. Aug 24, 2005) (granting in-house counsel access where no involvement in “competitive decision making”); *Caterpillar Inc. v. Detroit Diesel Corp.*, 1996 U.S. Dist. LEXIS 20575, at *8-*9 (N.D. Ill. Jan. 5, 1996) (same); *Amgen, Inc. v. Elanex Pharm. Inc.*, 160 F.R.D. 134, 139 (E.D. Wash. 1994) (denying motion for protective order excluding confidential materials from in-house counsel where counsel was not involved in competitive decision making); *Fluke Corp. v. Fine Instruments, Corp.*, 32 U.S.P.Q. 2d 1789, 1793 (W.D. Wash. 1994) (permitting access and noting that designated counsel “is not involved in competitive decision making”); *Safe Flight Instrument Corp. v. Sunstrand Data Control, Inc.*, 682 F.Supp. 20 (D. Del. 1988) (noting that a blanket ban on in-house counsel’s access to confidential information is inappropriate). Abbott has successfully opposed attempts to preclude access by its in-house counsel in two recent cases, *The Rockefeller University and Chiron Corp. v. Centocor, Inc. and Abbott Laboratories*, C.A. No. 2-04CV-168 (JTW) (W.D. Pa.) and *Therasense, Inc. and Abbott Laboratories v. Becton, Dickinson & Co.*, C.A. No. C04-2123 (MJJ) (N.D. Cal.).

The “Restricted Pricing Material” category already strikes the appropriate balance between protecting the information to be produced by Impax and avoiding impairment of Abbott’s full participation in its own defense. Abbott therefore respectfully submits that the Order should be revised to include in the “Restricted Pricing Material” category the documents that will be produced by Impax pursuant to the Court’s November 14 order.

Respectfully,

/s/ Mary B. Graham

Mary B. Graham (#2256)

MBG/dam

cc: Clerk of the Court (via hand delivery and electronic filing)
All Counsel of Record (via e-mail)

546822

A

UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

CHAMBERS OF
SUE L. ROBINSON
CHIEF JUDGE

LOCKBOX 31
844 KING STREET
U.S.COURTHOUSE
WILMINGTON, DELAWARE 19801

March 14, 2006

Kurt Michael Heyman, Esq.
Proctor Heyman LLP
1116 West Street
Wilmington, DE 19801

Mary B. Graham, Esq.
Morris, Nichols, Arsht & Tunnell
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899


**Re: Mobius Management Systems, Inc. v. Acartus, Inc.,
Civ. No. 05-346-SLR**

Dear Counsel:

I am in receipt of the February 7, 2006 letter sent by plaintiff concerning the protective order. I allow in every case one in-house representative to view the most confidential of documents. If the parties to this case cannot agree on the individuals to have such access, I will schedule a hearing to have the proposed individuals come to court and answer inquiries, under oath, about their ability and intent to abide by the protective order.

The appropriate response to this letter, if the parties are unable to resolve their dispute, is an email to my civil account requesting a hearing.

Cordially,


Sue L. Robinson

cc: Clerk of Court

B

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

BTG INTERNATIONAL, INC.,)
Plaintiff,)
v.) Civ. No. 04-1264-SLR
AMAZON.COM, et al.,)
Defendants.)

O R D E R

At Wilmington this 25th day of January, 2005, having reviewed the proposed protective order and the parties' submissions relating to it (attached hereto as exhibits);

IT IS ORDERED that:

1. Access to confidential information by employees. I always allow at least one employee of a party to have access to all information, including the most confidential information. I am not comfortable, however, with the employees identified by plaintiff, at least without a hearing and more information. Therefore, unless the parties can agree on one BTG employee (usually an employee who does not prosecute patents and who is not a business or technical employee), I will conduct an evidentiary hearing on Tuesday, February 1, 2005 at 3:00 p.m. in courtroom 6B of the Federal Building, to hear from the designated

employees in order to determine their suitability to have the access requested. Each party shall have forty-five minutes to conduct their respective examinations.

2. **Access to source code.** Absent agreement among the parties, the following procedures shall apply to ensure secure access to source code:

a. A single electronic copy of source code or executable code shall be made available for inspection on a stand-alone computer.

b. The stand-alone computer shall be password protected and supplied by the source code provider.

c. The stand-alone computer shall be located with an independent escrow agent, with the costs of such to be shared by the parties. If the parties cannot agree on such an agent, each party shall submit to the court the name and qualifications of their proposed agents for the court to choose.

d. Access to the stand-alone computer shall be permitted, after notice to the provider and an opportunity to object, to two (2) outside counsel representing the requesting party and two (2) experts retained by the requesting party, all of whom have been approved under the protective order in place. No one from the provider shall have further access to the computer during the remainder of discovery.

e. Source code may not be printed or copied

without the agreement of the producing party or further order of the court.

Sue L. Robinson
United States District Judge

EXHIBIT D

Morris James LLP

Mary B. Matterer
302.888.6960
mmatterer@morrisjames.com

November 30, 2006

VIA E-FILING & HAND DELIVERY

The Honorable Kent A. Jordan
USDC for the District of Delaware
844 King Street
Wilmington, DE 19801

Re: Abbott Labs., et al. v. Impax Labs., Inc., C. A. No. 03-120 KAJ (consolidated)

Your Honor:

We are writing on behalf of Impax Laboratories in response to the belated submission by Abbott Laboratories on November 24, 2006 relating to revisions to the protective order ordered by the Court on November 14 regarding protecting Impax's highly competitively sensitive information.

A. Abbott has twice foregone the chances to challenge an Outside Counsel Only Category and cannot object to it now.

When the Court ordered the creation of a true outside counsel only category at the November 14 hearing, Abbott's counsel were present by phone and had the opportunity to object to that category. They did not, nor had they ever addressed this issue previously. The existence of an outside counsel only category is an issue the Court has already decided. Abbott is seeking reconsideration on an issue where it raised no prior objection.

Moreover, after the hearing, counsel for Impax and Fournier had extensive meet and confers and worked in good faith to resolve several areas of disagreement, leaving just one issue for the Court to address. Abbott chose not to participate in those meet and confers, leaving the impression that Fournier had the proxy to act for Abbott on this issue.

That impression was confirmed when Abbott joined the letter sent in by Fournier's counsel on Tuesday, Nov. 21 regarding the dispute on the scope of the outside counsel only category. Nothing in this letter suggested that Abbott objected to a true outside counsel only category. To the contrary, by joining that letter, which addresses the scope of an outside counsel category without disputing the need for the category, Abbott again gave up—for a second time—the right to challenge an outside counsel only category. Abbott first raised its concern about having a true outside counsel only category in a Nov. 24 letter—the Friday after Thanksgiving—10 days after the Court's original ruling on this issue.

B. The Restricted Pricing Materials category does not adequately protect the type of Impax confidential information the Court ordered produced at the Nov. 14 hearing.

The nature of the information to be produced is described in Impax's Nov. 21 letter; it includes sensitive data about present and future products other than fenofibrate, strategic plans, and the company's business model generally. This is the type of information that Abbott's counsel has referred to as the "keys to the kingdom."

The restrictive pricing materials category was never intended to cover information that sensitive. Rather, it is a limited category intended to protect price (and related marketing) information. In-house counsel could qualify to receive material covered by the restricted pricing information category *while still being involved in strategic decisions*—e.g. whether to make a product, how much to make, or to replace it—about products that compete with the ones discussed in the documents Impax will produce. Indeed, part of what Impax will produce involves 1-year and 5-year manufacturing plans across all products and has nothing to do with pricing or marketing. The restrictive pricing materials category was not intended to and will not adequately protect that information.¹

Indeed, the order from Judge Robinson that Abbott cites itself provides for a true outside counsel only category, contrary to Abbott's suggestion. In the order attached as Exhibit B to Abbott's letter, Judge Robinson ordered that source code could be disclosed only to outside counsel or retained experts of the requesting party. The information regarding Impax's present and planned products that Abbott and Fournier seek is as sensitive to a pharmaceutical company as source code is for an internet company. In another order, Judge McKelvie ordered an outside counsel only category for source code as well. Ex. A, at 7. Furthermore, Judge McKelvie's order also provides for an outside counsel category for other materials, where the producing party makes a showing that such protection is necessary. Ex. A, at 6. Here, the Court has already determined that outside counsel only protection is appropriate for the narrow category of materials that will provide information about Impax products other than fenofibrate.

For all these reasons, Impax respectfully requests that the Court not modify its November 14 ruling requiring an outside counsel only category, if Impax is—as the Court has ordered—required to produce information about non-fenofibrate products.

Respectfully,



Mary B. Matterer

cc: All counsel (via e-mail)

¹ The cases cited by Abbott that dealt with in-house counsel not involved in competitive decision making are inapposite. As explained above, the restricted pricing materials category does allow counsel involved in competitive decision making to receive the information, just not counsel involved in marketing, pricing, or communicating with customers regarding pricing or contracts.

A

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

NCR CORPORATION,)
)
Plaintiff,)
)
v.) Civil Action No. 01-0169-RRM
)
PALM, INC. and HANDSPRING, INC.,)
)
Defendants.)

RECEIVED
JAN 14 2002
B.R.C.M. U.S.

PROTECTIVE ORDER

Whereas, the parties in the above-captioned action believe that discovery may involve the disclosure of confidential, trade secret, proprietary, technical, scientific, business, or financial information of a party or of a non-party;

Whereas, the parties desire to establish a mechanism to protect the disclosure of such information in this section;

Pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, IT IS HEREBY ORDERED THAT:

1. **Definitions:** For purposes of this Protective Order, the following definitions shall apply:

(a) The term "DOCUMENT" shall include without limitation any records, exhibits, reports, samples, transcripts, video or audio recordings, affidavits, briefs, summaries, notes, abstracts, drawings, company records and reports, answers to Interrogatories, responses to requests for admissions, or motions, including copies or computer-stored versions of any of the foregoing.

(b) The term "DISCLOSING PARTY" is defined herein as any party or non-party who is requested to produce or produces documents or testimony containing confidential information.

(c) The term "CONFIDENTIAL INFORMATION" is defined herein as information that the disclosing party in good faith believes is information not publicly known that would be valuable to the disclosing party's actual and potential competitors and that the

disclosing party would not normally reveal to third parties without an agreement to maintain it in confidence.

(d) The term "HIGHLY CONFIDENTIAL INFORMATION" is defined herein as information the disclosure of which the disclosing party in good faith believes would cause harm to the competitive position of the disclosing party.

(e) "CONFIDENTIALITY LEGEND" is defined herein as a label placed upon material that contains either confidential or highly confidential information and clearly designates the information as such, pursuant to the provisions of this Order.

(f) "COURT" is defined herein as encompassing the trial court that issued this Order and any appellate court that hears this action on appeal.

(g) "OUTSIDE COUNSEL" is defined herein as being limited to outside counsel who have been retained by a party to this Order as counsel of record in this litigation, including attorneys employed by their law firms, and who are not in-house employees of any party to this Order.

(h) "SUPPORT STAFF" is defined herein as permanent employees of counsel for the parties, including paralegals, clerical personnel and secretarial personnel.

(i) "LITIGATION SUPPORT SERVICES" is defined herein as encompassing without limitation copy services, document production services, exhibit-making services, translation services, coding services, scanning services, animation services, jury consultants and mock jurors.

(j) "IN-HOUSE COUNSEL" is defined herein as including any attorneys, paralegals or other legal professionals that are in-house employees of a party, whether on a salary, hourly, contract or other basis.

2. **Designating Information:** If, in the course of this litigation, a party to this Order undertakes to disclose or is caused to disclose what the disclosing party in good faith contends is confidential or highly confidential information, that party may designate such information as such by applying to the material that contains the information the appropriate confidentiality legend. Any information so designated shall thereafter be treated pursuant to the appropriate terms of this Order.

(a) **Designating Confidential Information.** If the disclosing party contends in good faith that the information to be disclosed is confidential information, then the following confidentiality legend shall be affixed:

CONFIDENTIAL

(b) **Designating Highly Confidential Information:** If the disclosing party contends in good faith that the information to be disclosed is highly confidential information, then the following confidentiality legend shall be affixed:

HIGHLY CONFIDENTIAL

(c) If any confidential or highly confidential information cannot be labeled with the appropriate confidentiality legend, it shall be placed in a sealed envelope or other container that is in turn marked with the appropriate confidentiality legend, or else designated as "confidential information" or "highly confidential information" in a manner agreed upon by the disclosing and requesting parties.

(d) **Initial Inspections of Materials:** In the event materials are to be subject to an initial inspection, e.g., in order for the requesting party to decide whether to copy all or only parts of a production, the materials shall be treated as containing "highly confidential information" for purposes of the initial inspection, thereby limiting those who may conduct such an initial inspection to those permitted by Paragraph 4 to view highly confidential information. After the initial inspection, the disclosing party may designate the inspected materials as "confidential information" or "highly confidential information," with the appropriate confidentiality legend.

(e) **Inspections of Property, etc.:** If a disclosing party believes in good faith that the inspection, measuring, testing, sampling, or photographing of its processes, products, equipment, premises, or other property, pursuant to Federal Rule of Civil Procedure 34, will reveal or disclose confidential or highly confidential information, then the disclosing party shall advise the requesting party that the inspection, measuring, testing, sampling, or photographing will be permitted only on a confidential or highly confidential basis, as appropriate. In such an event, the inspection, measuring, testing, sampling, or photographing may only be performed by those permitted to have access to confidential or highly confidential information, as appropriate, under this Order, and information derived from such activities shall be treated as confidential or highly confidential information, as appropriate.

(f) **Depositions:** All deposition testimony will be considered as being initially designated as "CONFIDENTIAL" unless, during the deposition, counsel for the deponent or for the party designates a portion of the deposition "HIGHLY CONFIDENTIAL." Accordingly, other than the deponent, only those persons authorized to have access to "CONFIDENTIAL" information under this Protective Order shall be permitted to be in attendance at any deposition and only those authorized to have access to "HIGHLY CONFIDENTIAL" information shall be permitted to attend the portions of the deposition designated as "HIGHLY CONFIDENTIAL." Subsequent to the expiration of thirty (30) calendar days following receipt by counsel of record for each party of the transcript of any deposition, said transcript shall be automatically reclassified and re-designated as being "CONFIDENTIAL" (but not "HIGHLY CONFIDENTIAL"), except as to such sections of the deposition transcript that the deponent, counsel for the deponent or counsel for a party designates in writing to all counsel of record within said thirty (30) day period as being "HIGHLY CONFIDENTIAL" or de-designates from being "CONFIDENTIAL." A party so designating a portion of the testimony may also request that the affected portions be bound separately from the rest of the transcript.

(g) **Deposition Exhibits:** An exhibit to a deposition shall be treated in accordance with the confidentiality designation already given to it or, if the exhibit has not been previously produced, given to it on the record at the time of the deposition. An exhibit to a deposition shall not lose its confidentiality designation upon the expiration of the thirty (30) day period from the receipt of the deposition transcript, except as otherwise provided by this Order. Notwithstanding the foregoing, nothing prevents a party to this Order or the deponent within thirty (30) days from the receipt of the deposition transcript from designating an exhibit as "confidential" or "highly confidential," in accordance with the terms of this Order.

(h) **Inadvertent Failure to Designate:** If a party to this Order inadvertently fails to designate information as "confidential" or "highly confidential" such failure shall not constitute a waiver of the disclosing party's right to so designate such information. In the event that such an inadvertent failure occurs, the disclosing party shall upon discovery of the inadvertent failure promptly notify in writing to all parties known to have received the information in question, and provide them with appropriately marked substitute copies of the affected information. Until a receiving party receives such notification, any disclosure made by that party of the information to those not permitted by this Order to have access to the

information shall not constitute a violation of this Order. However, upon receiving such notification, the receiving party shall request all parties to whom the information was disclosed by the receiving party but who are not permitted to have access to such information under the terms of this Order to return the information to the producing party, and/or request that such parties sign a Declaration and Acknowledgement with this Order (attached hereto as Exhibit A), depending upon the designation. The receiving party shall also destroy all copies of the incorrectly labeled information and replace them with the substitute copies provided by the disclosing party.

3. Persons Permitted to Access Confidential Information: Access to information that has been designated as "confidential information" shall be limited to the following persons:

- (1) The Court and its support staff and other authorized Court personnel;
- (2) Outside counsel representing a party to this Order and their support staff;
- (3) No more than four (4) in-house attorneys of a party to this Order who have primary litigation management responsibility for this case, and their support staff, such in-house attorneys of a party shall be identified to the other parties in this litigation prior to their access to Confidential Information;
- (4) Stenographers and videographers who take, record or transcribe testimony in this litigation, either at deposition or at a hearing or trial, to the extent necessary to carry out their services, provided that they first sign the Certificate of Confidentiality (attached hereto as Exhibit B);
- (5) Litigation support services, as defined in paragraph 1, to the extent necessary to carry out their services, provided that they first sign the Certificate of Confidentiality (attached hereto as Exhibit B);
- (6) Witnesses, either at trial or at deposition, provided that they first sign the Declaration attached hereto as Exhibit A;
- (7) Independent experts or consultants retained by outside counsel for assistance in connection with this litigation who qualify under the requirements of paragraph 9 below, and their support staff.

4. Persons Permitted to Access Highly Confidential Information: Access to information that has been designated as "highly confidential information" shall be limited to those referenced in paragraph 3 above, except that such "highly confidential information" will be restricted to no more than two (2) in-house attorneys of a party to this Order, who have primary

litigation management responsibility for this case. Such in-house attorneys of a party shall be identified to other parties in this litigation prior to their access to Highly Confidential Information.

5. In addition, any individual may be shown a given document that contains confidential or highly confidential information, provided:

(1) The document indicates that the individual is either an author or unauthorized recipient of the document;

(2) The individual is a current officer, director, employee of the same disclosing party that designated the document as confidential or highly confidential;

(3) The individual has been designated as a witness, pursuant to Federal Rule of Civil Procedure 30(b)(6), by the same party that designated the document as confidential or highly confidential; or

(4) The individual is a former officer, director or employee of the same party that designated the document as confidential or highly confidential, and it appears from the face of the document or from other proof that the individual had access either to the document or to the information it contains, at the time of his or her employment.

6. **Highly Confidential and Restricted Information**

In the event the disclosing party contends in good faith that a document (excluding Restricted Electronic Media as defined in paragraph 7 below), is of such a highly confidential nature that it cannot be disclosed to in-house attorneys for a party to this Order ("Highly Confidential and Restricted Information"), the disclosing party shall produce the document containing the allegedly Highly Confidential and Restricted Information; however, access to the document shall be limited to those individuals identified in paragraph 3(1), (2), (4), (5), (6) and (7). Unless the disclosing party moves the Court for a protective Order seeking to maintain the information as "Highly Confidential and Restricted" within five (5) days of its production, the document allegedly containing the Highly Confidential and Restricted Information shall become "Highly Confidential Information," with its access governed by paragraphs 4 and 5, above. The burden of proof shall be on the disclosing party to show that the Highly Confidential and Restricted Information designation is appropriate. Until the matter is resolved by the parties or the Court, the information in question shall continue to be treated as Highly Confidential and Restricted Information.

7. **Source code:** A party or non-party may specially designate source code and other similar highly sensitive source-code materials (whether in electronic or hardcopy form) as "Highly Confidential Restricted Electronic Media" ("Restricted Electronic Media"). Such materials shall be treated as being "Highly Confidential" information and shall also be subject to the following additional restrictions on access, copying, and use:

- (a) Access to Restricted Electronic Media shall be limited to those individuals identified in Paragraph 3(1), (2), (4), (5), (6), and (7) ("Authorized Individuals");
- (b) The Authorized Individuals for the requesting party may use a total of no more than two copies of each Restricted Electronic Media produced to the requesting party;
- (c) The Authorized Individuals for the requesting party shall not make any additional copies of any Restricted Electronic Media produced to the requesting party;
- (d) The Authorized Individuals for the requesting party may use each Restricted Electronic Media produced to the requesting party on no more than two stand alone, non-networked, locked PCs at any one time;
- (e) All copies of the Restricted Electronic Media shall be kept in a locked room or file cabinet when not in use;
- (f) Use of the software provided on the Restricted Electronic Media shall be password protected;
- (g) The Authorized Individuals for the requesting party shall inform any of its employees having access to the Restricted Electronic Media of its limitations, duties, and obligations regarding nondisclosure and limiting copying thereof and shall obtain or have obtained such employees' written agreement to comply with such limitations, duties, and obligations;
- (h) The requesting party shall notify the disclosing party in writing of the identities of any authorized individual who has accessed the Restricted Electronic Media, and shall maintain a log of which of the two copies of the Restricted Electronic Media such authorized individual has accessed, together with copies of each such authorized individual's written agreement to comply with the terms;
- (i) Upon reasonable notice, the disclosing party may request such records;
- (j) The source code will be used only for purposes of this particular litigation and not for any other purpose;

- (k) The independent experts or consultants who access the source code shall execute an undertaking of Exhibit C;
- (l) The requesting party may not produce the source code received from one producing party to the other party;
- (m) Any hard copy made of the source code shall be marked "Highly Confidential – Restricted Electronic Media; and
- (n) No portion of the source code may be copied onto a removable electronic media.

8. Handling of Documents Produced Prior to Entry of This Order:

(a) Documents Previously Designated As Confidential:

All documents designated prior to the date of entry of this Order as "Confidential" shall become "Confidential Information," and access to such information shall be governed by paragraph 3, above.

(b) Documents Previously Designated As Highly Confidential:

All documents designated prior to the date of entry of this Order in accordance with Local Rule 26.2 of the District Court for the District of Delaware or otherwise restricted to Outside Counsel only shall become "Highly Confidential Information," and access to such information shall be governed by paragraph 4, above, unless the disclosing party moves the Court for a protective order seeking to designate the information as "Highly Confidential and Restricted" within five (5) days of the date of entry of this Order. Pursuant to paragraph 6, above, the burden of proof shall be on the disclosing party to show that the Highly Confidential and Restricted Information designation is appropriate. Until the matter is resolved by the parties or the Court, the information in question shall continue to be treated as Highly Confidential and Restricted Information.

9. Procedure for Qualifying Independent Experts and Consultants: In order for an independent expert or consultant to be permitted access to confidential or highly confidential information, the counsel of the party employing the expert or consultant must notify by facsimile the disclosing party or parties, at least ten (10) days before allowing such access.

(a) Contents of the Written Notification: Such written notice shall include the following:

- (1) The name of the expert or consultant;
- (2) The present employer and title of the expert or consultant;
- (3) A copy of a declaration (attached hereto as Exhibit A) signed by the expert or consultant that states that the expert or consultant has read and understood the terms of this Order and agrees to be bound by its terms;
- (4) For technical experts and consultants, a current curriculum vitae that lists all employers and clients to whom the expert or consultant has provided services in the past five (5) years.

(b) **Objections by Disclosing Parties:** Before the ten (10) day period from the receipt of the written notification has expired, a disclosing party may object by facsimile to the disclosure of confidential or highly confidential information to the expert or Consultant in question. Should a disclosing party so object, no confidential or highly confidential information shall be disclosed to the expert or consultant in question until the objection has been resolved by the parties or by the Court.

10. Storage and Custody:

(a) **Storage and Custody of Confidential and Highly Confidential Information:** Counsel for each party to this Protective Order shall take reasonable precautions to prevent the unauthorized or inadvertent disclosure of any information designated as "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL" under this Protective Order.

11. Copying Designated Information: Copies of confidential and highly confidential information may be made only to the extent reasonably necessary to prepare work product or conduct proceedings in this litigation. This includes, but is not limited to, such things as making photocopies, and storing digital images of the documents in a reasonably secure manner and the coding and retrieval of the same.

12. Information in the Public Domain: A disclosing party shall use reasonable care to avoid designating any information as "confidential" or "highly confidential" that is generally available to the public, for example:

- (1) Information in the public domain at the time of disclosure;
- (2) Information that becomes part of the public domain through no fault of the receiving party;
- (3) Information that was lawfully in the possession of the receiving party at the time of the disclosure;

(4) Information that is at any time lawfully disclosed to the receiving party by a third party having the right to make such disclosure under no obligation of secrecy; or

(5) Information that is at any time independently developed by the receiving party without use of or reliance upon any information designated as either confidential or highly confidential.

13. Disclosure of Designated Information at Hearings and Trials: Nothing in the Protective Order shall prevent a party from using any document or information designated "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL" during a hearing. However, such use of such document or information shall be made in camera and the document, information and transcript of that portion of the proceeding during which such use is made shall be maintained by the Clerk under seal with access thereto limited to persons entitled to access by this Protective Order. Counsel will address in the Pretrial Order how they propose to handle the use and disclosure at trial of information designated "CONFIDENTIAL" and "HIGHLY CONFIDENTIAL."

14. Filing Under Seal: Any information designated as "confidential information" or "highly confidential information" that is included with, or its contents are in any way disclosed in, any pleading, motion, deposition transcript, or other papers filed with the Clerk of the Court shall be filed in sealed envelopes, or other appropriately sealed containers, prominently marked with the following notations:

- (1) The style of the action and case number (Civil Action No. 01-169-RRM);
- (2) The name of the filing party;
- (3) An indication of the filing's contents, such as the title of the filing; and
- (4) A statement substantially similar to the following:

[HIGHLY] CONFIDENTIAL INFORMATION

SUBJECT TO COURT ORDER

THIS ENVELOPE IS NOT TO BE OPENED NOR THE CONTENTS DISPLAYED, COPIED
OR REVEALED EXCEPT BY COURT ORDER OR BY THE WRITTEN AGREEMENT OF
THE PARTIES

15. No Summaries: Designated information shall not be disclosed or summarized, either in writing or orally, to anyone other than persons permitted to have access to such information under this Order.

16. **Challenging a Designation:** At any time, a party to this Order may challenge the designation of information as "confidential" or "highly confidential" by notifying the disclosing party in writing of the designation that the challenging party in good faith believes should not have been given the information in question. The parties shall then confer within five (5) business days to try to resolve the matter, and if unable to resolve the matter, may thereafter seek the Court's assistance. The burden of proof shall be on the disclosing party to show that the designation is appropriate under this Order. Until the matter is resolved by the parties or the Court, the information in question shall continue to be treated according to its designation under the terms of this Order. By failing to object to the designation of information upon its production, a party does not waive its right to object at a future time to that designation.

17. **Designation by Non-Parties:** A non-party to this litigation that produces information to any party to this litigation in connection with this litigation, whether or not pursuant to a subpoena, may avail itself of the protections afforded by this Order, provided that the non-party signs a Declaration and Acknowledgement (attached thereto as Exhibit A) stating that the non-party has read and understood this Order and agrees to be bound by its terms.

18. **Confidentiality Interests of Third Parties:** A party may refuse to produce otherwise discoverable information pursuant to a subpoena, deposition question, or discovery request, if the party is under an obligation to a third party not to disclose such information. In such an event, the objecting party shall:

(1) Promptly identify to the requesting party the name and address of each person or entity whose confidentiality interests are implicated by the discovery request;

(2) Promptly provide to the person or entity whose confidentiality interests are implicated (i) notice of its intention to disclose the information in question and (ii) a copy of this Order; and

(3) Within fourteen (14) days, produce the requested information in question in compliance with this Order, unless the person or entity whose confidentiality interests are implicated moves for or obtains a protective order in this Court within that time.

19. **No Waiver of Rights:** This Order shall not be deemed (a) a waiver of any party's or producing entity's right to object to any discovery requests on any ground; (b) a waiver of any party's right to seek an order compelling discovery with respect to any discovery requests; (c) a waiver of any party's right to object to the admission of evidence on any ground; (d) a waiver of any party's or producing entity's right to use its own documents, testimony, transcripts, and/or

other materials or things within its own discretion; or (e) any waiver of the attorney-client privilege or protection of the work product doctrine.

20. Disclosure Beyond the Terms of this Order: Nothing shall prevent disclosure beyond the terms of this Protective Order if the party designating the information as confidential consents to such disclosure in writing or on the record, or if the Court, after notice to all affected parties, orders such disclosure.

21. Restriction on Use of Documents in Prosecution of Patent Applications: From the date of entry of this Order or the production of confidential documents or confidential information in this litigation, whichever occurs first, until the conclusion of this litigation, no individual attorney, paralegal, expert, consultant, or patent counsel retained on behalf of a Party shall use "confidential information" or "highly confidential information" disclosed by the other Party to prosecute patent applications related to handheld computers, personal digital assistants, or smart cards. As used herein, an individual attorney or patent counsel "prosecute[s] patent applications" when that individual attorney or patent counsel drafts, amends, or revises patents or patent applications, or assists or advises in the drafting, amending, or revising of patent claims.

22. Inadvertent Disclosure: Should any designated information be disclosed, through inadvertence or otherwise, to any person or party in violation of this Order, then the party responsible for the inadvertent disclosure shall use its best efforts to bind such person to the terms of this Order, and shall (a) promptly inform such person of all the provisions of this Order, (b) request such person to sign the agreement in the form attached hereto as Exhibit A; and (c) identify such person immediately to the disclosing party that designated the document as confidential. The executed agreement shall promptly be served upon the disclosing party.

23. No Effect upon State and Federal Confidentiality Laws: The purpose of this order is to facilitate discovery in this litigation, and in no manner shall it affect the application of any state or federal law regarding confidentiality of information.

24. Disclosure of a Party's Own Information: The terms of this Order shall in no way affect a disclosing party's right (a) to withhold information on grounds of immunity from discovery such as, for example, the attorney/client privilege or the work product doctrine, or (b) to reveal or disclose to anyone any documents or information designated by that party as "confidential information" or "highly confidential information."

25. **Final Disposition:**

(a) **Designated Information:** Unless counsel agree otherwise in writing, within sixty (60) days of the final disposition of this action, the attorneys for the parties shall return promptly to the disclosing party or witness from whom they were obtained, all documents, other than attorney work-product, that have been designated "confidential information" or "highly confidential information," or destroy same; and return or destroy all copies made thereof, including all documents or copies provided by a receiving party to any other person. Notwithstanding the foregoing, counsel for the parties shall be permitted to retain one file copy of (1) materials created during the course of the litigation, including attorney annotations and other work product; (2) work product of non-testifying consultants/experts; (3) materials made part of the Court record, or which have been filed under seal with the Clerk of the Court; (4) all depositions and Court transcripts, including exhibits; and (5) summaries of depositions. Such file copies must be maintained subject to the terms of this Order. A party that destroys rather than returns the documents to the producing party, shall certify in writing that the documents have been destroyed in compliance with the Order.

(b) **Filings under Seal:** Papers filed with the Court under seal pursuant to this Order shall remain under seal with the Court for sixty (60) days after the final disposition of this action, during which period the disclosing party whose information is disclosed in the papers may retrieve the papers. After this sixty (60) day period expires, the sealed papers shall become publicly accessible.

26. **Other Proceedings:** By entering this Order and limiting the disclosure of information in this case, the Court does not intend to preclude another court from finding that information may be relevant and subject to disclosure in another case. Any person or party subject to this Order that may be subject to a motion to disclose another party's information designated confidential pursuant to this Order, shall promptly notify that party of the motion so that it may have an opportunity to appear and to be heard on whether that information should be disclosed.

27. **Retention of Jurisdiction:** This Order will remain in full force and effect unless modified by an order of the Court or by the written stipulation of the parties hereto filed with the Court. The disclosing parties reserve all rights to apply to the Court at any time, before or after termination of this action, for an order: (i) modifying this Protective Order, (ii) seeking further

protection against discovery or use of designated information, or other documents or information, or (iii) seeking further production, discovery, disclosure, or use of claimed designated information or other documents or information. Without limiting the foregoing, this Order survive and remain in full force and effect, and this Court shall retain jurisdiction to enforce all provisions of this Order, after termination of this litigation.

28. Inadvertent Disclosure of Privileged Information: If a disclosing party inadvertently discloses information that is privileged or otherwise immune from discovery, the disclosing party shall promptly upon discovery of the disclosure so advise the receiving party in writing and request that the item or items of information be returned, and if that request is made, no party to this action shall thereafter assert that the disclosure waived any privilege or immunity. It is further agreed that the receiving party will return or destroy the inadvertently produced item or items of information, and all copies and derivations, within five (5) days of the receiving party's receipt of a written request for the return of the information. The party having returned the inadvertently produced item or items of information may thereafter seek production of the information in accordance with the Federal Rules of Civil Procedure.

29. No Liability for Innocent Disclosures: It is understood that no person or party shall incur liability with respect to any disclosure by the receiving party of confidential or highly confidential information that was inadvertently disclosed without proper designation by the disclosing party, provided the disclosure by the receiving party occurred prior to the receipt by the receiving party of a notice of the inadvertent disclosure without proper designation.

30. No Admissions Intended: Unless the parties stipulate otherwise, evidence of the existence or nonexistence of a designation under this Protective Order shall not be admissible for any purpose, nor shall the designation or acceptance of any information designated pursuant to this Protective Order constitute an admission or acknowledgment that the material so designated is in fact proprietary, confidential or a trade secret.

31. This Protective Order is being entered without prejudice to the right of any party or other person to move the Court for modification of or relief from any of its terms.

32. Nothing in this Order precludes any party or producing entity from seeking a further Protective Order for any particularly sensitive information as to which such party or producing entity believes this Protective Order insufficiently protects. Nothing in this Protective Order precludes any party or producing entity from seeking relief as to this Protective Order or

portions thereof for good cause shown. All parties are subject to the continuing jurisdiction of this Court to modify and interpret this Order.

33. **No Waiver of Claim or Defense:** Neither the taking of any action in accordance with the provisions of this Order nor the failure to object to such action shall be construed as a waiver of any claim or defense in this action.

34. **Retroactive Effect:** All materials produced pursuant to Delaware Local Rule 26.2 prior to entry of this Order shall be redesignated in a manner consistent with this Order within 10 (ten) court days of receipt hereto, unless such materials have already been designated in a manner consistent with this Order.

SO ORDERED this 11 day of January, 2002.

J. L. McDonald
United States District Judge

499920

EXHIBIT E

1 IN THE UNITED STATES DISTRICT COURT
2 IN AND FOR THE DISTRICT OF DELAWARE

3 - - -

4 ABBOTT LABORATORIES, an Illinois : CIVIL ACTION
5 corporation, FOURNIER INDUSTRIE :
6 ET SANTE, a French corporation, :
7 and LABORATOIRES FOURNIER S.A., :
8 a French corporation, :
9 Plaintiffs, :
10 : :
11 v. : :
12 : :
13 IMPAKX LABORATORIES, INC., a :
14 Delaware corporation, :
15 : :
16 Defendant. : NO. 03-120 (KAJ)
17 : :
18 : (Consolidated)

19 - - -

20 Wilmington, Delaware
21 Friday, December 1, 2006 at 3:06 o'clock, p.m.
22 TELEPHONE CONFERENCE

23 - - -

24 BEFORE: HONORABLE KENT A. JORDAN, U.S.D.C.J.

25 - - -

1 APPEARANCES:

2 MORRIS, NICHOLS, ARSHT & TUNNELL

3 BY: MARY B. GRAHAM, ESQ.

4 -and-

5 PATTERSON, BELKNAP, WEBB & TYLER, LLP

6 BY: THOMAS W. PIPPERT, ESQ.

7 (New York, New York)

8 Counsel for Abbott Laboratories

9 Brian P. Gaffigan

10 Registered Merit Reporter

	Page 2		Page 4
1 APPEARANCES: (Continued)		1 THE COURT: Hi, this is Judge Jordan. Who do I	
2 RICHARDS LAYTON & FINGER		2 have on the line?	
3 BY: ANNE SHEA GAZA, ESQ.		3 MS. GAZA: Good afternoon, Your Honor. This	
4 -and-		4 is Anne Gaza on behalf of Fournier from Richards Layton &	
5 CADWALADER, WICKERSHAM & TAFT, LLP		5 Finger. With me are I believe Steve Sunshine and Matt	
6 BY: STEVEN C. SUNSHINE, ESQ., and		6 Hendrickson.	
7 MATTHEW HENDRICKSON, ESQ.		7 THE COURT: Okay.	
8 (Washington, District of Columbia)		8 MS. GRAHAM: Good afternoon, Your Honor. This	
9 Counsel for Fournier Industrie et		9 is Mary Graham on behalf of Abbott. And with me on the line	
10 Sante, and Laboratories Fournier S.A.		10 this afternoon is Tom Pippert from Patterson Belknap in New	
11 YOUNG CONAWAY STARGATT & TAYLOR		11 York.	
12 BY: JOSY W. INGERSOLL, ESQ.		12 MS. INGERSOLL: Good afternoon, Your Honor.	
13 -and-		13 It's Josy Ingersoll on behalf of Teva; and on the line is	
14 GOODWIN PROCTOR LLP		14 Chris Holding from Goodwin Procter. He is out in Chicago in	
15 BY: CHRISTOPHER HOLDING, ESQ.		15 the blizzard.	
16 (Boston, Massachusetts)		16 MS. MATTERER: Good afternoon, Your Honor. This	
17 Counsel for Teva Pharmaceuticals		17 is Mary Matterer on behalf of Impax; and on the line with	
18 USA, Inc.		18 me is Asim Bhansali from the Keker and Van Nest firm in San	
19 MORRIS JAMES HITCHENS & WILLIAMS, LLP		19 Francisco.	
20 BY: MARY MATTERER, ESQ.		20 MS. McGEEVER: Your Honor, this is Betsy	
21 -and-		21 McGeever for certain direct purchasers. With me is Joseph	
22 KEKER & VAN NEST, LLP		22 Lukens who represents Rite-Aid and CVS.	
23 BY: ASIM BHANSALI, ESQ.		23 MR. GODDESS: Your Honor, Jeff Goddess for the	
24 (San Francisco, California)		24 direct purchaser class. With me is Stewart Des Roche.	
25 Counsel for Impax Laboratories		25 MR. NAYLOR: Your Honor, good morning. Zack	

	Page 3		Page 5
1 APPEARANCES: (Continued)		1 Naylor for the indirect purchaser plaintiff. And I'm joined	
2 CHIMICLES & TIKELLIS		2 by Pat Cafferty of Miller Faucher & Cafferty.	
3 BY: A. ZACHARY NAYLOR, ESQ.		3 MR. PARSHALL: Good afternoon, Your Honor.	
4 -and-		4 Jonathan Parshall from Murphy Spadaro & Landon for	
5 MILLER FAUCHER & CAFFERTY		5 PacifiCare.	
6 BY: PATRICK E. CAFFERTY, ESQ.		6 THE COURT: Is there anybody else?	
7 (Ann Arbor, Michigan)		7 (Pause.)	
8 Counsel for indirect purchaser		8 THE COURT: Okay. Well, here we are again.	
9 plaintiffs, Painters District,		9 This time we're trying to deal with the disputes about this	
10 Council No. 30, Health and Welfare		10 protective order. And the last letter I got was the one	
11 Fund and Richard Wild		11 that came in yesterday from Ms. Matterer. And I guess I	
12 ROSENTHAL MONHAIT & GODDESS, P.A.		12 should ask in the first instance whether counsel for Abbott	
13 BY: JEFFREY S. GODDESS, ESQ.		13 has anything they want to say in response to that letter.	
14 -and-		14 And I'm turning to Abbott first. You guys straighten me	
15 ODOM & DES ROCHEs, LLP		15 out if I'm wrong but I understand that we've got a slightly	
16 BY: STUART DES ROCHEs, ESQ.		16 different position from Abbott and Fournier going into	
17 (New Orleans, Louisiana)		17 this dispute and so I'll give Ms. Graham or Mr. Pippert	
18 Counsel for direct purchaser class		18 the chance to take a crack at the last submission that	
19 PRICKETT JONES & ELLIOTT		19 came in and tell me why you think your position is right.	
20 BY: ELIZABETH M. McGEEVER, ESQ.		20 MR. PIPPERT: Your Honor, this is Tom Pippert	
21 -and-		21 speaking. Thank you for allowing us to go forward.	
22 HANGLEY ARONCHICK		22 I would like to start with an apology. It	
23 BY: JOSEPH T. LUKENS, ESQ.		23 was my personal mistake this issue was not raised when we	
24 (Philadelphia, Pennsylvania)		24 were last together or in the first round of letters to	
25 Counsel on behalf of CVS - Rite Aid		25 Your Honor. It is my oversight not to have known Abbott's	
- oOo -			
PROCEEDINGS			
(REPORTER'S NOTE: The following telephone conference was held in chambers, beginning at 3:06 p.m.)			

<p>1 policies are about the involvement of their in-house 2 attorneys essentially function as outside counsel. 3 We do oppose the outside-counsel-only tier 4 because a party should be able to see all the documents and 5 we respectfully submit that an in-house counsel who acts 6 like an outside litigation counsel is the right person to be 7 that representative of the party. The case law that we have 8 cited in our November 24th letter to Your Honor establishes 9 that the in-house counsel who essentially functions like 10 outside litigation counsel are entitled to the same types 11 of documents that outside litigation counsel see and none of 12 the other parties have submitted case law to the contrary. 13 Speaking specifically about Abbott's situation, 14 Abbott, I have learned now, relied very heavily on the 15 advice of its in-house counsel for its litigation strategy. 16 The documents that Impax is going to be producing are very 17 relevant to the damages claims not just of Impax, also the 18 direct purchasers damages, the end payers damages and the 19 damages of some of the individual plaintiffs like CVS. And 20 Abbott needed to have one of its in-house counsel to be able 21 to understand the documents and participate in litigation 22 strategy concerning damages. 23 THE COURT: Stop there, Mr. Pippert, because 24 that's the point you need to address for me. 25 MR. PIPPERT: All right.</p>	<p>Page 6</p> <p>1 THE COURT: Okay. Mr. Bhansali; I hope I'm 2 saying your name right, sir; you tell me what is it that 3 your opponents have asked for, this category of documents, 4 that is so sensitive that it should be reserved to outside 5 counsel? What is this slice of the world we're talking 6 about? Tell me that with precision and why it is so 7 sensitive. 8 MR. BHANSALI: Sure. Your Honor, this refers 9 back to our conversation obviously that we had a few weeks 10 ago. It is a set of documents that includes all of our 11 manufacturing production and production plans across all 12 of the company's products, not just fenofibrate. So, for 13 instance, it would -- I mean some of the documents that 14 we're right now preparing to produce in response to the 15 Court's order of the 14th are manufacturing plans, one year 16 and five year manufacturing plans that cover all of our 17 products and ones that Teva or Abbott or Fournier may be 18 competing with. And it's not just current products. It 19 would also include anticipated future products. And as 20 a result of that, the information is among the most 21 competitively sensitive information that my client has. 22 THE COURT: All right. Now, Mr. Pippert, 23 you have before you I hope the November 30 letter that 24 Ms. Matterer sent to me? 25 MR. PIPPERT: I do, Your Honor.</p>
<p>1 THE COURT: What is it that makes this 2 information -- and, in fact, why don't you tell me what it 3 is that you think this category or this type of information 4 is that we're talking about? 5 MR. PIPPERT: When we were last with Your Honor, 6 it was explained that it was expected that this information 7 is going to have a significant relevance to the damage case 8 that is being asserted against Abbott because when Impax 9 produces these documents, they're going to learn whether 10 it could have supplied the market, and if it could, at what 11 level it could have supplied the market with fenofibrate. 12 That is going to have a cascading effect on the damage 13 claims of all of the plaintiffs. It obviously affects 14 the Impax damages if it couldn't have supplied the market. 15 It wouldn't have had sales volume. 16 THE COURT: All right. Let me stop you again. 17 I just want to make sure we're all on the same page. 18 Counsel for Impax, who is speaking for Impax on 19 this call? 20 MR. BHANSALI: Asim Bhansali, Your Honor. 21 THE COURT: One more time, please. 22 MR. BHANSALI: Asim Bhansali. 23 THE COURT: Spell that for me. 24 MR. BHANSALI: Yes, sir. First name, A-S-I-M. 25 Last name, B-H-A-N-S-A-L-I.</p>	<p>Page 7</p> <p>1 THE COURT: And the second page of that talks 2 about why the restricted pricing material category does not 3 adequately protect the type of confidential information 4 that is anticipated being produced. And you have heard 5 what Mr. Bhansali described here. You need to talk to me 6 about two things. One, why you think they're wrong in what 7 they're telling me about with the previous category for 8 restricted pricing materials was meant to cover and not 9 cover and, two, what it is that makes you say that without 10 somebody inside Abbott knowing this stuff, they just can't 11 defend this case. 12 MR. PIPPERT: All right. Your Honor, Impax is 13 wrong because if there is anything that needs to be tinkered 14 with the existing protective order, it would be putting more 15 restrictions on in-house counsel, not completely eliminating 16 in-house counsel. But I would submit that that tinkering 17 is not even needed because the restricted pricing material 18 category lays out what the in-house attorney can do and not 19 do and they cannot do affecting all of the sorts of interest 20 that Mr. Bhansali was just speaking about. As you walk 21 through page 10 of the existing protective order, you see 22 that in-house counsel cannot be involved, for any drug, 23 marketing or formulating marketing strategies, cannot be 24 involved in pricing or formulating pricing strategies 25 for any drug, cannot communicate with any customers or</p>

<p style="text-align: right;">Page 10</p> <p>1 suppliers -- cases or sales -- of any drug. What they 2 can do is to give legal advice in order to give advice on 3 regulatory violations --</p> <p>4 THE COURT: Hold on, Mr. Pippert. Do you have 5 me on speaker?</p> <p>6 MR. PIPPERT: Yes, I do, sir.</p> <p>7 THE COURT: You are going to have to speak up 8 for two reasons. One, it makes it difficult to interrupt 9 if I need to, but more to the point, your speakerphone is 10 cutting out occasionally and it's making it difficult for 11 the court reporter to pick you up, so please pick up the 12 handset.</p> <p>13 MR. PIPPERT: I picked it up already. I 14 apologize. Would you like me to start again?</p> <p>15 THE COURT: Well, why don't you go back to the 16 start of the last point you were making.</p> <p>17 MR. PIPPERT: Okay. I was itemizing from page 18 10 of the existing protective order, what is the list of 19 things that the in-house attorney cannot do who will see 20 restricted price material, and that in-house attorney 21 cannot, for any drug product, not just fenofibrates but any 22 drug product, cannot be involved in marketing or formulating 23 marketing strategies, cannot be involved in pricing or 24 formulating pricing strategies and cannot be involved in 25 communicating with customers or suppliers with regards to</p>	<p style="text-align: right;">Page 12</p> <p>1 have the benefit of seeing it. That if there is information 2 in that that is genuinely relevant or important to the 3 defense of the case, that it can be somehow dealt with on a 4 basis that doesn't involve showing that raw data from inside 5 Impax to anybody inside Abbott. What is wrong with that 6 thinking? What is the logical flaw?</p> <p>7 MR. PIPPERT: The logical flaw is it goes 8 against the grain of all the cases we've cited that somehow 9 you can treat in-house attorneys as if they were second 10 class citizens and were less reliable than I or Ms. Graham 11 are. Because whatever concern you would have that that 12 information could be used inappropriately by business people 13 is just as applicable to me as it is the Abbott in-house 14 attorney. The case law says we should not create second 15 class citizens of in-house attorneys.</p> <p>16 THE COURT: What about the assertion --</p> <p>17 MR. PIPPERT: That, Your Honor, I would submit 18 is the flaw.</p> <p>19 THE COURT: How about this as a distinction with 20 a meaningful difference? That you and Ms. Graham, while you 21 get fees from Abbott, are not dependent on your livelihood 22 for Abbott. That you don't have an office next to a 23 businessperson at Abbott. That you don't run into them 24 daily at Abbott. That they don't walk by your desk at 25 Abbott? And that, accordingly, it's not a question of</p>
<p style="text-align: right;">Page 11</p> <p>1 prices or sales contracts.</p> <p>2 What they can do is spelled out in the existing 3 protective order at pages 10 to 11. They can give legal 4 advice in order to advise their client on regulatory 5 violations that might arise in the marketing context; 6 statutory violations in the marketing context; fraud, false 7 advertising in the marketing context. Between what the 8 existing order says that in-house attorney cannot do and 9 what they can do, these limited things they can do. The 10 interests that Impax is talking about are fully protected.</p> <p>11 In the letter that Your Honor referred me to, 12 the functions that are described are things that 13 attorneys don't do. Impax says they are concerned that an 14 attorney might be involved in how much product to actually 15 manufacture. We already eliminated with the existing 16 protective order the business people who make those sorts 17 of decisions. They're never going to see restricted pricing 18 material information.</p> <p>19 THE COURT: Well, here is what I take their 20 concern to be. I take their concern to be no matter how 21 good your people are, this is information which is of such 22 an extraordinarily sensitive nature, their business plans 23 across all their product lines over a five-year time 24 horizon, that just nobody inside the company ought to have 25 the benefit of seeing it. Nobody from your shop ought to</p>	<p style="text-align: right;">Page 13</p> <p>1 first class and second class citizens. It's a question of 2 human beings in entirely different settings and that those 3 settings and the distinction between the settings are 4 such that when you come talking about the most sensitive 5 information a company has got, the setting can't be ignored.</p> <p>6 Now, I'm speaking in the way I understand the 7 letter from Impax to be couched in terms of this is the "key 8 to the kingdom" and I'll give them a chance to speak for 9 themselves, but given the time and the limitations that I 10 have on my time, I'm trying to shorten this up a little bit. 11 Do you have something for me that addresses that line of 12 argument and thinking which is what I understand their tact 13 to be?</p> <p>14 MR. PIPPERT: Well, Your Honor, I have all of 15 the cases that are cited in our November 24th letter. The 16 cases obviously don't indicate every argument that was made 17 by the parties seeking outside-counsel's-eyes only, but I 18 think the factual distinctions Your Honor has just drawn 19 would exist in all environments and where the courts have 20 come out is that as Officers of the Court, as people who 21 have their ethical obligations, are members of the bar and 22 who signed whatever orders are required by the Court in 23 which litigation is pending, the concern that Your Honor 24 raised about passing people in the hallway are overcome 25 by the respect held for attorneys who take their ethical</p>

<p>1 obligations seriously and sign the Court's protective 2 orders.</p> <p>3 THE COURT: And, of course, they cite things 4 back to you from language that you put to me about -- and 5 now I'm looking at the November 21 letter, not the 6 November 30 letter, from Ms. Matterer about the dangers to 7 Abbott and Fournier. So go ahead and tell me why. Do you 8 see what I'm talking about?</p> <p>9 MR. PIPPERT: I do, Your Honor. And the issue 10 is now that we've established this is relevant information, 11 that was what was established in our last telephone call, I 12 think this cuts to Your Honor's next question, why doesn't 13 and does an Abbott person have to see this relevant 14 information? And I may have been on the speakerphone before 15 when I was speaking about the cascade effect of this 16 information.</p> <p>17 This will, depending on what the information 18 shows, it could cripple Impax's damages claim. The models 19 of the other plaintiffs in this case, based on what their 20 experts have said in class certification discovery, depends 21 very much on there being two or more generic products in 22 the marketplace to affect the overall price structure. If 23 Impax could not have been the second generic product in 24 the marketplace, this will have an impact on the direct 25 purchasers damage claims, on the end payers damage claims,</p>	<p>Page 14</p> <p>1 impact the damages model. To put all those pieces 2 together is, in all likelihood, going to require analysis 3 by counsel as well as by experts who -- and, in fact, I 4 think Ms. Reinhart is on the phone today, made the very 5 point that their experts need this information to make a 6 determination about, to offer an opinion about Impax's 7 ability to manufacture the fenofibrate. Counsel can 8 certainly advise their client about the opinions that 9 experts form or the conclusions of counsel without 10 identifying the specific products that are described in 11 these documents. And, again, I'm not trying to suggest how 12 Abbott's outside counsel should advise the in-house lawyers, 13 but simply that there is a way to provide the advice that 14 we're talking about as it relates to the relevance of these 15 documents without disclosing the actual documents themselves 16 to in-house counsel.</p> <p>17 Furthermore, Your Honor, in terms of the prior 18 statements by Abbott, with all due respect, I don't think 19 those have been addressed. I mean when Abbott and Fournier 20 sought the relief not to have certain information produced 21 at all in this case, they very strongly emphasized the point 22 of the risk of disclosure even when the documents only went 23 to outside counsel. And it's very similar information. I 24 mean it's information about future products and pipelines 25 and so forth. And so, again, I think that their own</p>
<p>1 as well as the CVS and Rite-Aid damage claims.</p> <p>2 THE COURT: And the point you are making is that 3 unless somebody from inside Abbott sees this and can comment 4 on it, you folks won't be able to address that evidence?</p> <p>5 MR. PIPPERT: Well, Your Honor, we won't be 6 able to describe the nature of that evidence in any detail. 7 We're the only people who can see it and can only give 8 Abbott -- no person in Abbott can know why we're giving the 9 advice we're giving. We are seeking to have one in-house 10 attorney to be able to understand why we would be giving 11 the advice we're giving on a damage strategy.</p> <p>12 THE COURT: All right. Go ahead, Mr. Bhansali, 13 if you would, and you take the other side.</p> <p>14 MR. BHANSALI: Okay, Your Honor. I think it 15 probably makes sense to start with the last point. Then I 16 can address the other points and would ask the Court to, if 17 it has further questions, I'd be happy to answer.</p> <p>18 With respect to the last point, I think that 19 it's just not the case that the client can't be advised. I 20 think it's important to remember the argument that was made 21 for the relevance of this information, which is to say that 22 the argument was, well, we need this information about the 23 other products to understand Impax's manufacturing capacity 24 and whether the existence of these other products would 25 eliminate its ability to manufacture fenofibrate and not</p>	<p>Page 15</p> <p>1 position, when they were on the other side of the stick, 2 as it were, should inform the decision here.</p> <p>3 THE COURT: All right. Let me hear from folks 4 for Fournier, and then I'll hear from others on the call. 5 Do you have anything you want to say in this regard?</p> <p>6 MR. HENDRICKSON: Yes, Your Honor. This is Matt 7 Hendrickson from Cadwalader for Fournier, Your Honor.</p> <p>8 Our position is regardless how you come out on 9 this dispute, we don't think you need any more protection 10 than is provided by outside-counsel-only designation. I 11 think the additional burdens that Impax has suggested are 12 appropriate, are unnecessary and will add difficulty for the 13 defense of our case without really providing any more 14 meaningful protection for them.</p> <p>15 THE COURT: Well, what additional burdens do you 16 see them asking for? They're asking for outside counsel 17 review, and I hear Fournier saying you could live with that. 18 What are you worried about besides that?</p> <p>19 MR. HENDRICKSON: Well, they're also suggesting 20 that we need to limit the number of staff inside our law 21 firm who can have any access to the document. That could 22 include secretary, night secretary, word processing people, 23 who they proposed only five people.</p> <p>24 THE COURT: Oh, I'm with you. Okay. I 25 understand. Thanks.</p>

<p style="text-align: right;">Page 18</p> <p>1 MR. HENDRICKSON: We also proposed every lawyer 2 has to be admitted pro hac and counsel of record. 3 THE COURT: Right. I understand. 4 All right. Ms. Ingersoll or whoever else is 5 speaking for Teva? 6 MR. HOLDING: Your Honor, this is Chris Holding 7 on behalf of Teva. With respect to the argument of what 8 the layer of confidentiality should be, I'm happy to rest 9 it with what Mr. Bhansali has said. After you've decided 10 that, there is a very quick and discrete follow-on issue 11 that flows from that decision that has arisen between 12 Mr. Peterman and me in the last two days, but I would like 13 to come to that only quickly and briefly after you finished 14 with this. 15 MR. PIPPERT: Your Honor, this is Tom Pippert. 16 I think we might bring up Mr. Holding's issue now, I would 17 respectfully submit, because it may affect Your Honor's 18 decision. 19 THE COURT: Go ahead. 20 MR. HOLDING: Tom, I can do that, if you would 21 like. 22 MR. PIPPERT: Okay. 23 MR. HOLDING: Your Honor, this is Chris Holding. 24 Teva has also been asked to produce documents 25 that are similar in nature to what Impax has been ordered</p>	<p style="text-align: right;">Page 20</p> <p>1 documents that we've produced in the last few weeks and 2 redesignate them accordingly. Thus far, Abbott has told 3 us they're unwilling to allow us to do that. 4 THE COURT: Yes, you're right. We can handle 5 that pretty quick. 6 MR. HOLDING: Thanks. 7 THE COURT: I'm not undoing what has been done. 8 So if it's out there in one category, it can stay in that 9 category. But that says nothing about protection going 10 forward. We'll take that up in a moment. 11 All right. Ms. McGeever or whoever else is 12 speaking on behalf of your client, do you have a dog in this 13 fight? 14 MR. LUKENS: Your Honor, this is Joe Lukens. 15 We don't really have a dog in the fight other 16 than our concern will stem from what occurs after this 17 with subsequent production of any documents. Our position 18 relates more, Your Honor, to the schedule and our position 19 should be that if documents are produced even going forward, 20 that the schedule hold, and that means that the expert 21 reports stay when they're due both for the opening reports 22 and any responsive reports. Other than that, we don't have 23 much of a dog in the fight. 24 THE COURT: All right. Mr. Goddess or whoever 25 else is speaking on behalf of your client?</p>
<p style="text-align: right;">Page 19</p> <p>1 to produce and that bear the same sensitivity, documents 2 that include our projections for the scores and literally 3 hundreds of different documents that we make. And our 4 position that is -- 5 THE COURT: Hundreds of different drugs, you 6 mean? 7 MR. HOLDING: Different drugs, yes, Your Honor. 8 THE COURT: All right. 9 MR. HOLDING: And our position is if the Court 10 is going to allow a layer of production for Impax, the same 11 level of protection ought to be equally applicable to the 12 same sorts of documents that Teva is producing and, thus 13 far, Abbott has been unwilling to agree to that. 14 The second related point is this. Once this 15 issue arose and we recognized that the documents were going 16 to be responsive, we have in fact already produced some, and 17 we took the position we knew this was coming and we would 18 produce them, and given the state of the protective order 19 as it existed, we believed the only ethical choice we had 20 was to produce them on a highly confidential basis because 21 they don't fall within the language of restricted pricing 22 material. Now that we've gotten to the point where they 23 have it and we're deciding this issue, we believe it's 24 appropriate that in whatever designation you decide is 25 proper here, that we be entitled to go back to these</p>	<p style="text-align: right;">Page 21</p> <p>1 MR. DES ROCHE: Good afternoon, Your Honor. 2 Stuart Des Roche. I just echo the same comments that 3 Mr. Lukens made. 4 THE COURT: Okay. Now, I know I have forgotten 5 somebody here and I apologize. It's Mr. Parshall, I 6 believe, and anybody else on behalf of your client. 7 MR. PARSHALL: Your Honor, this is Jonathan 8 Parshall. I would simply join in Mr. Lukens comments. 9 THE COURT: Okay. 10 MR. CAFFERTY: Your Honor, this is Patrick 11 Cafferty for the indirect purchaser plaintiff. And we also 12 join in those comments. 13 THE COURT: All right. Thank you very much. Is 14 there anybody else that needs to speak before I turn back to 15 Mr. Pippert? 16 MR. BHANSALI: Your Honor, this is Asim 17 Bhansali. I'm not sure of the order of these things. I 18 would like to address Mr. Hendrickson's comments about the 19 scope of the outside counsel category, but I can do that 20 whenever the Court is ready. 21 THE COURT: Well, no. I'll give you a chance 22 right now. Go ahead. 23 MR. BHANSALI: Okay, Your Honor. I just want 24 to be clear in terms of the staff issue, our position was, 25 in our meet and confer, we suggested to Fournier that if the</p>

Page 22

1 number of staff people we proposed to allow disclosures,
 2 this very limited category of material, to is insufficient,
 3 that we would be happy to discuss with them a different
 4 number that they would feel would sufficiently allow them
 5 to do what they need to do and they never made any counter-
 6 proposal. Our only concern is that we want to make sure
 7 that people who are receiving just this one category of
 8 information understand its sensitivity and have signed on
 9 to the protective order if they're staff, and if they're
 10 attorneys, that they've been admitted pro hac vice and
 11 agree to be bound by the local rules and orders of the
 12 Court. I think we laid that out in the letter. And I think
 13 the statements that Abbott and Fournier made about the sort
 14 of a risk of the secrets getting out if it's disclosed to
 15 a large number of people back a year ago when they were
 16 seeking protection are applicable to that issue as well.

17 THE COURT: Well, I will give you the last word,
 18 Mr. Pippert, because you folks are the ones who are trying
 19 to shift this off the place where we were before, so go
 20 ahead.

21 MR. PIPPERT: Okay. Your Honor, I think that
 22 the existing protection cover what Impax is concerned
 23 about or that anyone else is concerned about and that the
 24 information is not materially different from what has been
 25 recognized in the legion of cases we cited. All of these

Page 24

1 lot of respect for folks who work in the in-house legal
 2 departments. But at the end of the day, Mr. Pippert, I
 3 just disagree with your position. Maybe that puts me on the
 4 other side of legions of cases, but I'm satisfied when you
 5 ask for the most sensitive documents you can possibly get
 6 from a company, you ought to expect they're not going to
 7 want anybody from inside the company, no matter what title
 8 they carry, to see it if it's not absolutely necessary.
 9 That is not an unreasonable position.

10 And, you haven't persuaded me that it's
 11 absolutely necessary for anybody inside Abbott to see this
 12 set of documents, which sounds to me like it is indeed the
 13 most sensitive documents that a pharmaceutical company has
 14 it would expose and which indeed, by the statements that
 15 Abbott and Fournier themselves made in previous conferences
 16 with the Court, are the "keys to the kingdom." I think it's
 17 ironic but those are indeed the words you guys put out there
 18 in a not terribly dissimilar situation. There is nothing
 19 magic about "the relevance threshold" when we're talking
 20 about right now how sensitive stuff is. That has to do with
 21 whether you get it at all, et cetera, but it doesn't mean
 22 anything about how sensitive something is. So you guys
 23 recognized this before as the ultimate in sensitive kind of
 24 documentation so you're poorly positioned to say, yeah, but
 25 it's not really that sensitive when it's theirs, that one

Page 23

1 parties got through the underlying patent litigations
 2 without there being an outside-counsel-eyes category. The
 3 case in front of Your Honor, the case in the Northern
 4 District of Illinois got by without there any need for this
 5 category. And what we need to do is to recognize that one
 6 in-house person can honor all of the concerns that have been
 7 raised by Impax.

8 And this is a different argument than the one
 9 Abbott and Fournier made that were successful on the
 10 relevance on what was being sought at that time by the
 11 plaintiffs. Here, we're past the relevance threshold. We
 12 want one person who is going to sign whatever the Court
 13 requires to see these documents. And if there is any
 14 tinkering that needs to be done with the existing protective
 15 order, it should be in describing what that in-house
 16 attorney can and cannot do in the present and the future.
 17 It shouldn't be to eliminate them entirely.

18 THE COURT: All right.

19 MR. HENDRICKSON: Your Honor, this is Matt
 20 Hendrickson. Would you like me to address Mr. Bhansali's
 21 comments?

22 THE COURT: Let's see. No, I think I've got
 23 everybody's positions pretty well in mind here.

24 Now, let me start by noting I spent five
 25 years as an in-house counsel myself so I have a whole

Page 25

1 of our own people can't take a look at it.
 2 I think they've made an apt analogy when they
 3 say it's a little like giving away the source code for a
 4 software company. There is not something a lot more
 5 sensitive I wouldn't think for a pharmaceutical company than
 6 a layout of their product development pipeline in detail.
 7 And you wanted it, I'm making them give it up, but I'm not
 8 making them give it to anybody inside Abbott. You are going
 9 to have apple opportunity to advise your client through the
 10 conclusions of the experts that are appropriately scrubbed,
 11 through your own commentary to your client, appropriately
 12 scrubbed. This all is rooted in your desire to say, hey,
 13 there is not manufacturing capacity so nobody in Abbott
 14 needs to know what the pipeline contains with specificity
 15 for you to comment to them about capacity.

16 So that's where we are. There will be an
 17 outside-counsel only category for this set of documents.
 18 Now, as to what that outside-counsel category ought to have
 19 in the way of additional restrictions, look, I think there
 20 is only one thing that Impax has said in this regard that
 21 has merit, and that is if there is to be outside counsel
 22 getting ahold of this, the only people that are going to get
 23 ahold of this are outside counsel who are admitted pro hac
 24 vice in this case so that they are clearly under my power to
 25 enforce the protective order against and to impose sanctions

Page 26

1 on, should I determine that somebody acted in a way that is
 2 sanctionable and people who have signed appropriate
 3 undertakings who are not already working for those counsel.

4 So you don't have to make staff people sign
 5 undertakings. I'm not agreeing that that is necessary. If
 6 they're working in your firm, then presumably you've got
 7 the control over them and you will recognize that if they
 8 do something, you're on the hook and I think that is an
 9 adequate safeguard. If they're experts, there is already a
 10 provision for them to sign an appropriate undertaking. So
 11 that is good enough for me and that is how it will stand.
 12 So the one thing Impax said in this regard that I think has
 13 merit is the fact that they're outside counsel alone isn't
 14 enough. They have to be outside counsel admitted in this
 15 case so that if there is a problem, I can reach out and
 16 touch them.

17 Okay. Now, I think that addresses everything
 18 that we needed to address today as to the folks at Teva. I
 19 agree with you if you are doing the same kind of documents,
 20 you will get the same kind of protection but there is no
 21 clawback. If you gave it before, it stays in the category
 22 you gave it up at.

23 And I, of course, will rely on Abbott and
 24 Fournier to make sure that stuff isn't being overdesignated
 25 and I'll direct Impax and Teva as expressly and implicitly

Page 27

1 and as emphatically as I can, you better make darn sure you
 2 are not putting stuff in this category that doesn't belong
 3 because I don't want to have to spend time parsing this and
 4 arguing over things like this. So unless you really have a
 5 "keys to the kingdom" kind of document you are turning over,
 6 don't designate it outside-counsel only.

7 Okay. Does everybody understand the rulings
 8 I've made with respect to this dispute? Mr. Pippert, are
 9 you on board?

10 MR. PIPPERT: Absolutely, Your Honor. And thank
 11 you for listening to our argument on the merits.

12 THE COURT: All right. Mr. Bhansali, do you
 13 understand?

14 MR. BHANSALI: Yes, Your Honor. We do.

15 THE COURT: Okay. Does anybody else have a
 16 question or concern?

17 (Pause.)

18 THE COURT: Hearing nothing, thanks for your
 19 time. We're done.

20 (The attorneys respond "Thank you, Your Honor.")

21 (Telephone conference ends at 3:41 p.m.)

22

23

24

25

<p>A</p> <p>Abbott 1:4,23 4:9 5:12 5:14,16 6:14,20 7:8 8:17 9:10 12:5,13,21 12:22,23,24,25 14:7 14:13 15:3,8,8 16:18 16:19 19:13 20:2 22:13 23:9 24:11,15 25:8,13 26:23</p> <p>Abbott's 5:25 6:13 16:12</p> <p>ability 15:25 16:7</p> <p>able 6:4,20 15:4,6,10</p> <p>absolutely 24:8,11 27:10</p> <p>access 17:21</p> <p>acted 26:1</p> <p>ACTION 1:4</p> <p>acts 6:5</p> <p>actual 16:15</p> <p>add 17:12</p> <p>additional 17:11,15 25:19</p> <p>address 6:24 15:4,16 21:18 23:20 26:18</p> <p>addressed 16:19</p> <p>addresses 13:11 26:17</p> <p>adequate 26:9</p> <p>adequately 9:3</p> <p>admitted 18:2 22:10 25:23 26:14</p> <p>advertising 11:7</p> <p>advice 6:15 10:2,2 11:4 15:9,11 16:13</p> <p>advise 11:4 16:8,12 25:9</p> <p>advised 15:19</p> <p>affect 14:22 18:17</p> <p>afternoon 4:3,8,10,12 4:16 5:3 21:1</p> <p>ago 8:10 22:15</p> <p>agree 19:13 22:11 26:19</p> <p>agreeing 26:5</p> <p>ahead 14:7 15:12 18:19 21:22 22:20</p> <p>ahold 25:22,23</p> <p>Aid 3:20</p> <p>allow 19:10 20:3 22:1,4</p> <p>allowing 5:21</p> <p>analogy 25:2</p> <p>analysis 16:2</p> <p>Ann 3:6</p> <p>Anne 2:3 4:4</p> <p>answer 15:17</p> <p>anticipated 8:19 9:4</p> <p>anybody 5:6 12:5 21:6 21:14 24:7,11 25:8 27:15</p> <p>apologize 10:14 21:5</p> <p>apology 5:22</p>	<p>APPEARANCES 1:17 2:1 3:1</p> <p>apple 25:9</p> <p>applicable 12:13 19:11 22:16</p> <p>appropriate 17:12 19:24 26:2,10</p> <p>appropriately 25:10,11</p> <p>apt 25:2</p> <p>Arbor 3:6</p> <p>arguing 27:4</p> <p>argument 13:12,16 15:20,22 18:7 23:8 27:11</p> <p>arisen 18:11</p> <p>ARONCHICK 3:18</p> <p>arose 19:15</p> <p>ARSHT 1:18</p> <p>Asim 2:19 4:18 7:20,22 21:16</p> <p>asked 8:3 18:24</p> <p>asking 17:16,16</p> <p>asserted 7:8</p> <p>assertion 12:16</p> <p>attorney 9:18 10:19,20 11:8,14 12:14 15:10 23:16</p> <p>attorneys 6:2 11:13 12:9,15 13:25 22:10 27:20</p> <p>A-S-I-M 7:24</p>	<p>B</p> <p>B 1:19</p> <p>back 8:9 10:15 14:4 19:25 21:14 22:15</p> <p>bar 13:21</p> <p>based 14:19</p> <p>basis 12:4 19:20</p> <p>bear 19:1</p> <p>beginning 3:25</p> <p>behalf 2:24 3:20 4:4,9 4:13,17 18:7 20:12 20:25 21:6</p> <p>beings 13:2</p> <p>believe 4:5 19:23 21:6</p> <p>believed 19:19</p> <p>Belknap 1:21 4:10</p> <p>belong 27:2</p> <p>benefit 11:25 12:1</p> <p>Betsy 4:20</p> <p>better 27:1</p> <p>Bhansali 2:19 4:18 7:20,20,22,22,24 8:1 8:8 9:5,20 15:12,14 18:9 21:16,17,23 27:12,14</p> <p>Bhansali's 23:20</p> <p>bit 13:10</p> <p>blizzard 4:15</p> <p>board 27:9</p>	<p>Boston 2:13</p> <p>bound 22:11</p> <p>Brian 1:24</p> <p>briefly 18:13</p> <p>bring 18:16</p> <p>burdens 17:11,15</p> <p>business 11:16,22 12:12</p> <hr/> <p>C</p> <p>C 2:5 3:23</p> <p>Cadwalader 2:5 17:7</p> <p>Cafferty 3:5,5 5:2,2 21:10,11</p> <p>California 2:19</p> <p>call 7:19 14:11 17:4</p> <p>capacity 15:23 25:13 25:15</p> <p>carry 24:8</p> <p>cascade 14:15</p> <p>cascading 7:12</p> <p>case 6:7,12 7:7 9:11 12:3,14 14:19 15:19 16:21 17:13 23:3,3 25:24 26:15</p> <p>cases 10:1 12:8 13:15 13:16 22:25 24:4</p> <p>category 7:3 8:3 9:2,7 9:18 20:8,9 21:19 22:2,7 23:2,5 25:17 25:18 26:21 27:2</p> <p>certain 4:21 16:20</p> <p>certainly 16:8</p> <p>certification 14:20</p> <p>cetera 24:21</p> <p>chambers 3:25</p> <p>chance 5:18 13:8 21:21</p> <p>Chicago 4:14</p> <p>CHIMICLES 3:2</p> <p>choice 19:19</p> <p>Chris 4:14 18:6,23</p> <p>CHRISTOPHER 2:12</p> <p>cite 14:3</p> <p>cited 6:8 12:8 13:15 22:25</p> <p>citizens 12:10,15 13:1</p> <p>CIVIL 1:4</p> <p>claim 14:18</p> <p>claims 6:17 7:13 14:25 14:25 15:1</p> <p>Bhansali 2:19 4:18 7:20,20,22,22,24 8:1 8:8 9:5,20 15:12,14 18:9 21:16,17,23 27:12,14</p> <p>Bhansali's 23:20</p> <p>bit 13:10</p> <p>blizzard 4:15</p> <p>board 27:9</p>	<p>Columbia 2:6</p> <p>come 13:4,20 17:8 18:13</p> <p>coming 19:17</p> <p>comment 15:3 25:15</p> <p>commentary 25:11</p> <p>comments 21:2,8,12,18 23:21</p> <p>communicate 9:25</p> <p>communicating 10:25</p> <p>company 11:24 13:5 24:6,7,13 25:4,5</p> <p>company's 8:12</p> <p>competing 8:18</p> <p>competitively 8:21</p> <p>completely 9:15</p> <p>CONAWAY 2:9</p> <p>concern 11:20,20 12:11 13:23 20:16 22:6 27:16</p> <p>concerned 11:13 22:22 22:23</p> <p>concerning 6:22</p> <p>concerns 23:6</p> <p>conclusions 16:9 25:10</p> <p>confer 21:25</p> <p>conference 1:13 3:25 27:21</p> <p>conferences 24:15</p> <p>confidential 9:3 19:20 9:18 20:8,9 21:19 22:2,7 23:2,5 25:17 25:18 26:21 27:2</p> <p>certain 4:21 16:20</p> <p>certainly 16:8</p> <p>certification 14:20</p> <p>cetera 24:21</p> <p>chambers 3:25</p> <p>chance 5:18 13:8 21:21</p> <p>Chicago 4:14</p> <p>CHIMICLES 3:2</p> <p>choice 19:19</p> <p>Chris 4:14 18:6,23</p> <p>CHRISTOPHER 2:12</p> <p>cite 14:3</p> <p>cited 6:8 12:8 13:15 22:25</p> <p>citizens 12:10,15 13:1</p> <p>CIVIL 1:4</p> <p>claim 14:18</p> <p>claims 6:17 7:13 14:25 14:25 15:1</p> <p>Bhansali 2:19 4:18 7:20,20,22,22,24 8:1 8:8 9:5,20 15:12,14 18:9 21:16,17,23 27:12,14</p> <p>Bhansali's 23:20</p> <p>bit 13:10</p> <p>blizzard 4:15</p> <p>board 27:9</p>
---	---	---	---	--

<p>difficulty 17:12 direct 3:14 4:21,24 6:18 14:24 26:25 disagree 24:3 disclosed 22:14 disclosing 16:15 disclosure 16:22 disclosures 22:1 discovery 14:20 discrete 18:10 discuss 22:3 dispute 5:17 17:9 27:8 disputes 5:9 dissimilar 24:18 distinction 12:19 13:3 distinctions 13:18 District 1:1,2 2:6 3:7 23:4 document 17:21 27:5 documentation 24:24 documents 6:4,11,16 6:21 7:9 8:3,10,13 16:11,15,15,22 18:24 19:1,3,12,15 20:1,17 20:19 23:13 24:5,12 24:13 25:17 26:19 dog 20:12,15,23 doing 26:19 drawn 13:18 drug 9:22,25 10:1,21 10:22 drugs 19:5,7 due 16:18 20:21 </p> <hr/> <p>E</p> <p>E 3:5,23,23 echo 21:2 effect 7:12 14:15 eliminate 15:25 23:17 eliminated 11:15 eliminating 9:15 ELIZABETH 3:16 ELLIOTT 3:16 emphasized 16:21 emphatically 27:1 ends 27:21 enforce 25:25 entirely 13:2 23:17 entitled 6:10 19:25 environments 13:19 equally 19:11 ESQ 1:19,21 2:3,5,6,10 2:12,16,19,22 3:3,5 3:10,13,16,19 essentially 6:2,9 established 14:10,11 establishes 6:8 et 1:5 2:7 24:21 ethical 13:21,25 19:19 everybody 27:7 everybody's 23:23</p>	<p>evidence 15:4,6 exist 13:19 existed 19:19 existence 15:24 existing 9:14,21 10:18 11:2,8,15 22:22 23:14 expect 24:6 expected 7:6 expert 20:20 experts 14:20 16:3,5,9 25:10 26:9 explained 7:6 expose 24:14 expressly 26:25 extraordinarily 11:22</p> <hr/> <p>F</p> <p>fact 7:2 16:3 19:16 26:13 factual 13:18 fall 19:21 false 11:6 far 19:13 20:2 Faucher 3:5 5:2 feel 22:4 fees 12:21 fenofibrate 7:11 8:12 15:25 16:7 fenofibrates 10:21 fight 20:13,15,23 Finger 2:2 4:5 finished 18:13 firm 4:18 17:21 26:6 first 5:12,14,24 7:24 13:1 five 8:16 17:23 23:24 five-year 11:23 flaw 12:6,7,18 flows 18:11 folks 15:4 17:3 22:18 24:1 26:18 following 3:24 follow-on 18:10 forgotten 21:4 form 16:9 formulating 9:23,24 10:22,24 forth 16:25 forward 5:21 20:10,19 Fournier 1:4,5 2:7,8 4:4 5:16 8:17 14:7 16:19 17:4,7,17 21:25 22:13 23:9 24:15 26:24 Francisco 2:19 4:19 fraud 11:6 French 1:5,6 Friday 1:13 front 23:3 fully 11:10</p>	<p>function 6:2 functions 6:9 11:12 Fund 3:8 further 15:17 Furthermore 16:17 future 8:19 16:24 23:16</p> <hr/> <p>G</p> <p>Gaffigan 1:24 Gaza 2:3 4:3,4 generic 14:21,23 genuinely 12:2 getting 22:14 25:22 give 5:17 10:2,2 11:3 13:8 15:7 21:21 22:17 25:7,8 given 13:9 19:18 giving 15:8,9,10,11 25:3 go 5:21 10:15 14:7 15:12 18:19 19:25 21:22 22:19 Goddess 3:10,10 4:23 4:23 20:24 goes 12:7 going 5:16 6:16 7:7,9 7:12 10:7 11:17 16:2 19:10,15 20:9,19 23:12 24:6 25:8,22 good 4:3,8,12,16,25 5:3 11:21 21:1 26:11 Goodwin 2:12 4:14 gotten 19:22 Graham 1:19 4:8,9 5:17 12:10,20 grain 12:8 guess 5:11 guys 5:14 24:17,22</p> <hr/> <p>H</p> <p>hac 18:2 22:10 25:23 hallway 13:24 handle 20:4 handset 10:12 HANGLEY 3:18 happy 15:17 18:8 22:3 Health 2:24 3:8 hear 17:3,4,17 heard 9:4 Hearing 27:18 heavily 6:14 held 3:25 13:25 Hendrickson 2:6 4:6 17:6,7,19 18:1 23:19 23:20 Hendrickson's 21:18 hey 25:12 Hi 4:1 highly 19:20</p>	<p>HITCHENS 2:16 hold 10:4 20:20 Holding 2:12 4:14 18:6 18:6,20,23,23 19:7,9 20:6 Holding's 18:16 honor 4:3,8,12,16,20 4:23,25 5:3,20,25 6:8 7:5,20 8:8,25 9:12 11:11 12:17 13:14,18 13:23 14:9 15:5,14 16:17 17:6,7 18:6,15 18:23 19:7 20:14,18 21:1,7,10,16,23 22:21 23:3,6,19 27:10,14,20</p> <hr/> <p>HONORABLE 1:15 Honor's 14:12 18:17 hook 26:8 hope 8:1,23 horizon 11:24 Houston 2:23 human 13:2 hundreds 19:3,5</p> <hr/> <p>I</p> <p>identifying 16:10 ignored 13:5 Illinois 1:4 23:4 impact 14:24 16:1 Impax 1:9 2:20 4:17 6:16,17 7:8,14,18,18 9:12 11:10,13 12:5 13:7 14:23 17:11 18:25 19:10 22:22 23:7 25:20 26:12,25</p>	<p>joined 5:1 Jonathan 2:22 5:4 21:7 JONES 3:16 Jordan 1:15 4:1 Joseph 3:19 4:21 Josy 2:10 4:13 Judge 4:1</p> <hr/> <p>K</p> <p>KAJ 1:10 Keker 2:18 4:18 KENT 1:15 key 13:7 keys 24:16 27:5 kind 24:23 26:19,20 27:5 kingdom 13:8 24:16 27:5 knew 19:17 know 15:8 21:4 25:14 knowing 9:10 known 5:25</p> <hr/> <p>L</p> <p>Laboratories 1:4,5,9 1:23 2:8,20 laid 22:12 Landon 2:22 5:4 language 14:4 19:21 large 22:15 law 6:7,12 12:14 17:20 lawyer 18:1 lawyers 16:12 layer 18:8 19:10 layout 25:6 lays 9:18</p>
---	--	---	--	--

<p>Layout 2:2 4:4 learn 7:9 learned 6:14 legal 10:2 11:3 24:1 legion 22:25 legions 24:4 letter 5:10,13 6:8 8:23 11:11 13:7,15 14:5,6 22:12 letters 5:24 Let's 23:22 level 7:11 19:11 likelihood 16:2 limit 17:20 limitations 13:9 limited 11:9 22:2 line 4:2,9,13,17 13:11 lines 11:23 list 10:18 listening 27:11 literally 19:2 litigation 6:6,10,11,15 6:21 13:23 litigations 23:1 little 13:10 25:3 live 17:17 livelihood 12:21 LLP 1:21 2:5,12,16,18 3:12 local 22:11 logical 12:6,7 look 25:1,19 looking 14:5 lot 24:1 25:4 Louisiana 3:13 Lukens 3:19 4:22 20:14 20:14 21:3,8</p> <hr/> <p>M</p> <p>M 3:16 magic 24:19 making 10:10,16 15:2 25:7,8 manufacture 11:15 15:25 16:7 manufacturing 8:11,15 8:16 15:23 25:13 market 7:10,11,14 marketing 9:23,23 10:22,23 11:5,6,7 marketplace 14:22,24 Mary 1:19 2:16 4:9,17 Massachusetts 2:13 material 9:2,17 10:20 11:18 19:22 22:2 materially 22:24 materials 9:8 Matt 4:5 17:6 23:19 matter 11:20 24:7 Matterer 2:16 4:16,17 5:11 8:24 14:6</p>	<p>MATTHEW 2:6 McGEEVER 3:16 4:20 4:21 20:11 mean 8:13 16:19,24 19:6 24:21 meaningful 12:20 17:14 means 20:20 meant 9:8 meet 21:25 members 13:21 merit 1:25 25:21 26:13 merits 27:11 Michigan 3:6 Miller 3:5 5:2 mind 23:23 mistake 5:23 model 16:1 models 14:18 moment 20:10 MONHAIT 3:10 morning 4:25 MORRIS 1:18 2:16 Murphy 2:22 5:4</p> <hr/> <p style="text-align: center;">N</p> <p>N 3:23 name 7:24,25 8:2 nature 11:22 15:6 18:25 Naylor 3:3 4:25 5:1 necessary 24:8,11 26:5 need 6:24 9:5 10:9 15:22 16:5 17:9,20 22:5 23:4,5 needed 6:20 9:17 26:18 needs 9:13 21:14 23:14 25:14 Nest 2:18 4:18 never 11:17 22:5 New 1:22,22 3:13 4:10 NICHOLS 1:18 night 17:22 Northern 23:3 NOTE 3:24 noting 23:24 November 6:8 8:23 13:15 14:5,6 number 17:20 22:1,4 22:15</p> <hr/> <p style="text-align: center;">O</p> <p>O 3:23 obligations 13:21 14:1 obviously 7:13 8:9 13:16 occasionally 10:10 occurs 20:16 ODOM 3:12 offer 16:6 office 12:22</p>	<p>Officers 13:20 Oh 17:24 Okay 4:7 5:8 8:1 10:17 15:14 17:24 18:22 21:4,9,23 22:21 26:17 27:1,7,15 25:1 25:22 26:2,4 Once 19:14 ones 8:17 22:18 oOo 3:22 opening 20:21 opinion 16:6 opinions 16:8 opponents 8:3 opportunity 25:9 oppose 6:3 order 5:10 8:15 9:14,21 10:2,18 11:3,4,8,16 19:18 21:17 22:9 23:15 25:25 ordered 18:25 orders 13:22 14:2 22:11 Orleans 3:13 ought 11:24,25 19:11 24:6 25:18 outside 6:2,6,10,11 8:4 16:12,23 17:16 21:19 25:21,23 26:13,14 outside-counsel 25:17 25:18 27:6 outside-counsel's-eyes 13:17 outside-counsel-eyes 23:2 outside-counsel-only 6:3 17:10 overall 14:22 overcome 13:24 overdesignated 26:24 oversight 5:25 o'clock 1:13</p> <hr/> <p style="text-align: center;">P</p> <p>P 1:24 3:23 PacificCare 2:24 5:5 page 7:17 9:1,21 10:17 pages 11:3 Painters 3:7 Parshall 2:22 5:3,4 21:5,7,8 parsing 27:3 participate 6:21 parties 6:12 13:17 23:1 party 6:4,7 passing 13:24 Pat 5:2 patent 23:1 Patrick 3:5 21:10 Patterson 1:21 4:10 Pause 5:7 27:17 offer 16:6 office 12:22</p>	<p>pending 13:23 Pennsylvania 3:19 people 11:16,21 12:12 13:20,24 15:7 17:22 17:23 22:1,7,15 25:1 25:22 26:2,4 person 6:6 14:13 15:8 23:6,12 personal 5:23 persuaded 24:10 Peterman 18:12 pharmaceutical 24:13 25:5 Pharmaceuticals 2:14 Philadelphia 3:19 phone 16:4 pick 10:11,11 picked 10:13 pieces 16:1 pipeline 25:6,14 pipelines 16:24 Pippert 1:21 4:10 5:17 5:20,20 6:23,25 7:5 8:22,25 9:12 10:4,6 10:13,17 12:7,17 13:14 14:9 15:5 18:15,15,22 21:15 22:18,21 24:2 27:8 27:10 place 22:19 plaintiff 5:1 21:11 plaintiffs 1:7 3:7 6:19 7:13 14:19 23:11 plans 8:11,15,16 11:22 please 7:21 10:11 point 6:24 10:9,16 15:2 15:15,18 16:5,21 19:14,22 points 15:16 policies 6:1 poorly 24:24 position 5:16,19 17:1,8 19:4,9,17 20:17,18 21:24 24:3,9 positioned 24:24 positions 23:23 possibly 24:5 power 25:24 precision 8:6 preparing 8:14 present 23:16 presumably 26:6 pretty 20:5 23:23 previous 9:7 24:15 price 10:20 14:22 prices 11:1 pricing 9:2,8,17,24,24 10:23,24 11:17 19:21 PRICKETT 3:16 Pause 5:7 27:17 offer 16:6 office 12:22</p>	<p>probably 15:15 problem 26:15 processing 17:22 Procter 4:14 PROCTOR 2:12 produce 8:14 18:24 19:1,18,20 produced 9:4 16:20 19:16 20:1,19 produces 7:9 producing 6:16 19:12 product 10:21,22 11:14 11:23 14:23 25:6 production 8:11,11 19:10 20:17 products 8:12,17,18,19 14:21 15:23,24 16:10 16:24 projections 19:2 proper 19:25 proposal 22:6 proposed 17:23 18:1 22:1 protect 9:3 protected 11:10 protection 17:9,14 19:11 20:9 22:16,22 26:20 protective 5:10 9:14,21 10:18 11:3,16 14:1 19:18 22:9 23:14 25:25 provide 16:13 provided 17:10 providing 17:13 provision 26:10 purchaser 3:7,14 4:24 5:1 21:11 purchasers 4:21 6:18 14:25 put 14:4 16:1 24:17 puts 24:3 putting 9:14 27:2 P.A 3:10 p.m 1:13 3:25 27:21</p> <hr/> <p style="text-align: center;">Q</p> <p>question 12:25 13:1 14:12 27:16 questions 15:17 quick 18:10 20:5 quickly 18:13</p> <hr/> <p style="text-align: center;">R</p> <p>R 3:23 raised 5:23 13:24 23:7 raw 12:4 reach 26:15 ready 21:20 really 17:13 20:15 24:25 27:4</p>
---	--	--	---	--

reasons 10:8 receiving 22:7 recognize 23:5 26:7 recognized 19:15 22:25 24:23 record 18:2 redesignate 20:2 referred 11:11 refers 8:8 regard 17:5 25:20 26:12 regardless 17:8 regards 10:25 Registered 1:25 regulatory 10:3 11:4 Reinhart 16:4 related 19:14 relates 16:14 20:18 relevance 7:7 15:21 16:14 23:10,11 24:19 relevant 6:17 12:2 14:10,13 reliable 12:10 relied 6:14 relief 16:20 rely 26:23 remember 15:20 reporter 1:25 10:11 REPORTER'S 3:24 reports 20:21,21,22 representative 6:7 represents 4:22 require 16:2 required 13:22 requires 23:13 reserved 8:4 respect 13:25 15:18 16:18 18:7 24:1 27:8 respectfully 6:5 18:17 respond 27:20 response 5:13 8:14 responsive 19:16 20:22 rest 18:8 restricted 9:2,8,17 10:20 11:17 19:21 restrictions 9:15 25:19 result 8:20 review 17:17 Richard 3:8 Richards 2:2 4:4 right 5:19 6:6,25 7:16 8:2,14,22 9:12 15:12 17:3 18:3,4 19:8 20:4 20:11,24 21:13,22 23:18 24:20 27:12 risk 16:22 22:14 Rite 3:20 Rite-Aid 4:22 15:1 Roche 4:24 21:1,2 ROCHES 3:12,13 rooted 25:12	ROSENTHAL 3:10 round 5:24 rules 22:11 rulings 27:7 run 12:23 S S 3:10,23 safeguard 26:9 sales 7:15 10:1 11:1 San 2:19 4:18 sanctionable 26:2 sanctions 25:25 Sante 1:5 2:8 satisfied 24:4 saying 8:2 17:17 says 11:8,13 12:14 20:9 schedule 20:18,20 scope 21:19 scores 19:2 scrubbed 25:10,12 second 9:1 12:9,14 13:1 14:23 19:14 secretary 17:22,22 secrets 22:14 see 6:4,11 9:21 10:19 11:17 14:8,13 15:7 17:16 23:13,22 24:8 24:11 seeing 11:25 12:1 seeking 13:17 15:9 22:16 sees 15:3 sense 15:15 sensitive 8:4,7,21 11:22 13:4 24:5,13,20,22 24:23,25 25:5 sensitivity 19:1 22:8 sent 8:24 seriously 14:1 set 8:10 24:12 25:17 setting 13:5 settings 13:2,3,3 SHEA 2:3 shift 22:19 shop 11:25 shorten 13:10 showing 12:4 shows 14:18 side 15:13 17:1 24:4 sign 14:1 23:12 26:4,10 signed 13:22 22:8 26:2 significant 7:7 similar 16:23 18:25 simply 16:13 21:8 sir 7:24 8:2 10:6 situation 6:13 24:18 slice 8:5 slightly 5:15 software 25:4 somebody 9:10 15:3	21:5 26:1 sort 22:13 sorts 9:19 11:16 19:12 sought 16:20 23:10 sounds 24:12 source 25:3 Spadaro 2:22 5:4 speak 10:7 13:8 21:14 speaker 10:5 speakerphone 10:9 14:14 speaking 5:21 6:13 7:18 9:20 13:6 14:15 18:5 20:12,25 specific 16:10 specifically 6:13 specificity 25:14 Spell 7:23 spelled 11:2 spend 27:3 spent 23:24 staff 17:20 21:24 22:1 22:9 26:4 stand 26:11 STARGATT 2:9 start 5:22 10:14,16 15:15 23:24 state 19:18 statements 16:18 22:13 24:14 STATES 1:1 statutory 11:6 stay 20:8,21 stays 26:21 stem 20:16 Steve 4:5 STEVEN 2:5 Stewart 4:24 stick 17:1 stop 6:23 7:16 straighten 5:14 strategies 9:23,24 10:23,24 strategy 6:15,22 15:11 strongly 16:21 structure 14:22 Stuart 3:13 21:2 stuff 9:10 24:20 26:24 27:2 submission 5:18 submit 6:5 9:16 12:17 18:17 submitted 6:12 subsequent 20:17 successful 23:9 sufficiently 22:4 suggest 16:11 suggested 17:11 21:25 suggesting 17:19 Sunshine 2:5 4:5 supplied 7:10,11,14	suppliers 10:1,25 sure 7:17 8:8 21:17 22:6 26:24 27:1 Systems 2:24 S.A 1:5 2:8 T T 3:19 tact 13:12 TAFT 2:5 take 5:18 11:19,20 13:25 15:13 20:10 25:1 talk 9:5 talking 7:4 8:5 11:10 13:4 14:8 16:14 24:19 talks 9:1 TAYLOR 2:9 telephone 1:13 3:24 14:11 27:21 tell 5:19 7:2 8:2,6 14:7 telling 9:7 terms 13:7 16:17 21:24 terribly 24:18 Teva 2:14 4:13 8:17 18:5,7,24 19:12 26:18,25 Texas 2:23 thank 5:21 21:13 27:10 27:20 thanks 17:25 20:6 27:18 theirs 24:25 thing 25:20 26:12 things 9:6 10:19 11:9 11:12 14:3 21:17 27:4 think 5:19 7:3 9:6 13:18 14:12 15:14,18 15:20 16:4,18,25 17:9,11 18:16 22:12 22:12,21 23:22 24:16 25:2,5,19 26:8,12,17 thinking 12:6 13:12 THOMAS 1:21 threshold 23:11 24:19 tier 6:3 TIKELLIS 3:2 time 5:9 7:21 11:23 13:9,10 23:10 27:3 27:19 tinkered 9:13 tinkering 9:16 23:14 title 24:7 today 16:4 26:18 told 20:2 Tom 4:10 5:20 18:15 18:20 touch 26:16 treat 12:9	trying 5:9 13:10 16:11 22:18 TUNNELL 1:18 turn 21:14 turning 5:14 27:5 two 9:6,9 10:8 14:21 18:12 TYLER 1:21 type 7:3 9:3 types 6:10 U ultimate 24:23 underlying 23:1 understand 5:15 6:21 13:6,12 15:10,23 17:25 18:3 22:8 27:7 27:13 undertaking 26:10 undertakings 26:3,5 undoing 20:7 UNITED 1:1 unnecessary 17:12 unreasonable 24:9 unwilling 19:13 20:3 USA 2:14 U.S.D.C.J 1:15 V v 1:8 Van 2:18 4:18 vice 22:10 25:24 violations 10:3 11:5,6 volume 7:15 W W 1:21 2:10 walk 9:20 12:24 want 5:13 7:17 17:5 21:23 22:6 23:12 24:7 27:3 wanted 25:7 Washington 2:6 way 13:6 16:13 25:19 26:1 WEBB 1:21 weeks 8:9 20:1 Welfare 3:8 went 16:22 We'll 20:10 we're 5:9 7:4,17 8:5,14 15:7,8,9,11 16:14 19:23 23:11 24:19 27:19 we've 5:15 12:8 14:10 19:22 20:1 WICKERSHAM 2:5 Wild 3:8 WILLIAMS 2:16 Wilmington 1:12 word 17:22 22:17
---	---	---	---	---

words 24:17
work 24:1
working 26:3,6
world 8:5
worried 17:18
wouldn't 7:15 25:5
wrong 5:15 9:6,13 12:5

Y

yeah 24:24
year 8:15,16 22:15
years 23:25
yesterday 5:11
York 1:22,22 4:11
YOUNG 2:9

Z

ZACHARY 3:3
Zack 4:25

0

03-120 1:10

1

1 1:13
10 9:21 10:18 11:3
11 11:3
14th 8:15

2

2006 1:13
21 14:5
24th 6:8 13:15

3

3:06 1:13 3:25
3:41 27:21
30 3:8 8:23 14:6

EXHIBIT F

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

PITNEY BOWES INC., a Delaware	:	
Corporation,	:	
Plaintiff,	:	
v.	:	Civil Action No. 99-381-JJF
STAMPS.COM INC., a Delaware	:	
Corporation,	:	
Defendant.	:	

THE SOUTHERN SLAVE.

MEMORANDUM ORDER

Plaintiff, Pitney Bowes, has filed a Motion to Compel Defendant to Produce Source Code in Machine Readable Form (D.I. 86). In support of its motion, Plaintiff cites decisions by Judges Robinson and McKelvie of this Court asserting that these decisions set forth Plaintiff's entitlement to an appropriate method of production of Defendant's source code in machine readable form.

Defendant, Stamps.com, agrees that its source code as requested in machine readable form by Plaintiff is discoverable but argues that greater protection than that available under the protective order entered in this case should be required for technology information as valuable as a litigant's source code. To resolve the issue, Defendant proposes the use of a software escrow agent which Plaintiff objects to for various reasons. Plaintiff argues that the sanctions available under the protective order upon any violation are more than sufficient to address the concerns of the Defendant.

I agree with the decisions of Judges Robinson and McKelvie with some modification to comport with the facts presented here.

In resolving this dispute, I make the following findings:

1. Plaintiff needs Defendant's source code to prove its claim of infringement.
2. Defendant, like any litigant, should be afforded the utmost protection, within reason, when required to disclose proprietary material.
3. Each such dispute is fact sensitive. In this case, because computer technology is involved I believe, as the Defendant has argued, that there is a high risk of inadvertent acquisition or disclosure by and to third parties.
4. Plaintiff's needs can be met by employing a software escrow agent with no undue hardship to Plaintiff, although perhaps some inconvenience. In reaching this finding, I have considered the access to the source code required by Plaintiff's expert and find that the expert's work will not be impeded by the employment of an escrow agent.

In sum, I conclude that litigants are entitled to reasonable protection when required to produce proprietary material to an adversary in litigation. The inquiry as to what is reasonable is fact sensitive and case specific requiring a court to protect the disclosure without undue hardship to the requestor. In my view, these considerations will be balanced in this case by the production of the source code in machine readable form through an escrow agent.

NOW THEREFORE, FOR THE REASONS DISCUSSED, IT IS HEREBY ORDERED that Plaintiff's Motion to Compel Defendant to Produce Source Code in Machine Readable Form (D.I. 86) is GRANTED. IT IS FURTHER ORDERED that the production by Defendant shall be through a software escrow agent.

12 | 13 | 01
DATE


UNITED STATES DISTRICT JUDGE

EXHIBIT G

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ADVANCED MICRO DEVICES, INC.,)	
a Delaware corporation, and AMD)	
INTERNATIONAL SALES & SERVICE,)	
LTD., a Delaware corporation,)	
))	
Plaintiffs,))	
))	
v.))	C.A. No. 05-441-JJF
))	
INTEL CORPORATION, a Delaware)	
corporation, and INTEL KABUSHIKA)	
KAISHA, a Japanese corporation,)	
))	
Defendants.))	
))	
))	
IN RE INTEL CORPORATION)	
MICROPROCESSOR ANTITRUST)	MDL No. 1717-JJF
LITIGATION)	
))	
Phil Paul, on behalf of himself and all other)	
similarly situated,)	
))	
Plaintiff,))	
))	
v.))	C.A. No. 05-485-JJF
))	
INTEL CORPORATION,)	
))	
Defendant.))	

NOTICE OF HEARING RE: D.I. 109

PLEASE TAKE NOTICE that the Special Master will conduct a hearing on Monday, June 12, 2006 beginning at 10:00 a.m. to consider the Proposed Protective Order (D.I. 109) to be entered in the above-captioned cases and the objections thereto of any party or third party wishing to be heard. The hearing will be conducted in Courtroom 2B of the J. Caleb Boggs

Courthouse, United States District Court for the District of Delaware, 844 N. King Street, Wilmington, Delaware 19801. The objections of any party or third party unable to attend the hearing will be considered on their previously docketed submissions.

SO ORDERED this 2nd day of June, 2006.



Vincent J. Poppiti (DSBA No. 100614)
Special Master

EXHIBIT H

Subject: Advanced Micro Devices, Inc. et al., v. Intel Corporation, et al., C.A. No. 05-441-JJF, In re Intel Corporation, C.A. No.
05-MD-1717-JJF, and Phil Paul, et al. v. Intel Corporation, C.A.
05-485-JJF
From: "Stuhlman, Gregory E." <Stuhlman@RLF.com>
Date: Fri, June 9, 2006 1:31 pm
To: peter@mcmahonserepca.com
danielkim@appro.com
jgreen@fclaw.com
epower@zuckerman.com
jjjoyce@JonesDay.com
jneiman@mofo.com
pstern@mofo.com
greg.call@gateway.com
ggerst@kirkland.com
wstreff@kirkland.com
jhersey@sheppardmullin.com
bpower@zuckerman.com
mpaskin@cravath.com
skesh@cravath.com
mrhodes@cooley.com
Clayton.James@Sun.com
msundermeyer@wc.com
pcollins@morrisjames.com
aturan@furth.com
john.schultz@morganlewis.com
thoward@morganlewis.com
robert.skitol@dbr.com
"Alison S. Hightower" <ahightower@nossaman.com>
"Michael P. Kelly" <mkelly@mccarter.com>
"Karen H. Bromberg" <kbromberg@cohengresser.com>
"Kelly K. Pierce" <kkpierce@rkmc.com>
"Maria L. Koss" <maria.koss@bestbuy.com>
"Brian J. Chapman" <bchapman@kentmcbride.com>
"Howard Feller" <hfeller@mcguirewoods.com>
"Ted Daniel" <tdaniel@jenkens.com>
"Kathryn K. Conde" <kconde@nutter.com>
"Brian Henri" <bdh@i.frys.com>
"David Primack" <david.primack@dbr.com>
"Michael J. Holston" <mholston@morganlewis.com>
"Hayden J. Silver, III" <jaysilver@kilpatrickstockton.com>
"J. Christopher Jackson" <jcjackson@kilpatrickstockton.com>
"Dale A. Rice" <Dale.rice@hellerehrman.com>
"R. Montgomery Donaldson" <rdonaldson@mmwr.com>
"Brian T. Hansen" <bthansen@mpccorp.com>
"Erika C. Birg" <ebirg@paulweiss.com>
"Robert Parker" <Rparker@paulweiss.com>
"Dean A. Morehous" <dam@thelenreid.com>
"Heather Stern" <hstern@officedepot.com>

"P. Benjamin Zuckerman" <zuckermanb@gtlaw.com>
"Bill Garvey" <bgarvey@rackable.com>
"Bruce C. Piontkowski" <bpiontkowski@ropers.com>
"Craig Benson" <cbenson@paulweiss.com>
"Jon Abramczyk" <jabramczyk@mnat.com>
"Eric S. Adams" <eadams@shutts-law.com>
"Kevin Teismann" <kevin.teismann@techdata.com>
"George Paul" <gpaul@whitecase.com>
"John D. Donaldson" <jdonaldson@whitecase.com>
"Vernon Proctor" <vproctor@proctorheyman.com>

Cc: jlholzman@prickett.com
rhorwitz@potteranderson.com

<<Ltr with attachs.pdf>>

To Counsel for All Interested Third Parties:

Re: Advanced Micro Devices, Inc. et al., v. Intel Corporation, et al., C.A. No. 05-441-JJF, In re Intel Corporation, C.A.
No. 05-MD-1717-JJF, and Phil Paul, et al. v. Intel Corporation, C.A.
05-485-JJF

In connection with Monday's hearing before Judge Poppiti, enclosed is a letter sent on behalf of counsel for the parties summarizing the procedures that Judge Poppiti wishes to be followed. Also, please note that the hearing location has been changed to Courtroom 4B (Judge Farnan's courtroom).

Gregory E. Stuhlman
Richards, Layton & Finger
One Rodney Square
Wilmington, Delaware 19801
Tel: 302.651.7578
Fax: 302.498.7578

Richards, Layton and Finger, P.A. is not providing any advice with respect to any federal tax issue in connection with this matter.

The information contained in this e-mail message is intended only for the use of the individual or entity named above and may be privileged and/or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any unauthorized dissemination, distribution or copying of this communication is strictly prohibited by law. If you have received this communication in error, please immediately notify us by return e-mail or telephone (302-651-7700) and destroy the original message. Thank you.

CHAD M. SHANDLER
DIRECTOR

RICHARDS, LAYTON & FINGER
A PROFESSIONAL ASSOCIATION
ONE RODNEY SQUARE
920 NORTH KING STREET
WILMINGTON, DELAWARE 19801
(302) 651-7700
FAX: (302) 651-7701
WWW.RLF.COM

DIRECT DIAL
(302) 651-7836
SHANDLER@RLF.COM

June 9, 2006

VIA ELECTRONIC MAIL

Re: *Advanced Micro Devices, Inc., et al. v. Intel Corporation, et al. C.A. No. 05-441-JJJ, In re Intel Corporation, C.A. No. 05-MD-1717-JJJ, and Phil Paul, et al. v. Intel Corporation, C.A. 05-485-JJJ*

To Counsel For All Interested Third Parties:

Special Master Vincent J. Poppiti has asked that we send this letter to you concerning the hearing on the Proposed Protective Order that will commence at 10:00AM on Monday, June 12, 2006. While the hearing will still be held in the J. Caleb Boggs Federal Building, the room for the hearing has been changed to Courtroom 4B (Judge Farnan's Courtroom) to better accommodate those counsel who will be attending. In addition, this is to inform you that participation by telephone will not be available.

In an effort to ensure that the hearing proceeds as efficiently as possible, the following procedure will be followed. After all counsel have signed in and indicated which third party or parties they are representing, the Special Master has asked that counsel for the parties confer with third party counsel and prepare a chart indicating which provision(s) of the Proposed Protective Order each third party counsel wishes to address. For your convenience, a list of provisions of the Proposed Protective Order triggering third-party objections is enclosed as Attachment A.

After the submission of third party objections, on May 31, AMD, Interim Class Counsel and Intel agreed upon and submitted a revised Proposed Protective Order that attempts to address certain of the objections received. For your convenience, a redlined version of the revised Proposed Protective Order (that you were previously served with) is attached as Attachment B. To the extent that these revisions satisfy objections raised by third parties, this will also be indicated on the chart. It would greatly facilitate matters if, when you arrive on Monday, you are prepared to indicate which specific provisions on Attachment A you wish to address.

Using the chart, the Special Master then proposes to proceed through each provision of

June 9, 2006

Page 2

the Proposed Protective Order in the order listed on Attachment A and give each third party counsel who wishes to address that provision an opportunity to be heard. After all third parties have been heard on a given provision, the Special Master will then hear any responses from AMD, Interim Class Counsel and Intel.

It is hoped that this process will provide some structure for the hearing and allow it to proceed efficiently, while, at the same time, giving each third party counsel an opportunity to be heard on any provisions of the revised Proposed Protective Order to which they object.

Very truly yours,

/s/Chad M. Shandler

Chad M. Shandler

CS/afg
Attachments (2)

cc: Richard L. Horwitz, Esquire (via e-mail)
James L. Holzman, Esquire (via e-mail)

ATTACHMENT A

POTENTIAL ISSUES FOR PROTECTIVE ORDER HEARING

1. Restrictions on In-House Counsel - Definition J
 - a. Adequacy of Parties' Proposed Expanded Definition
2. Enumerated Categories of Confidential Material - Definition R
 - a. Consumer information carve-out of S and addition of Para. 6(i)
3. Definition R.7 - Non-public Negotiations
 - a. Adequacy of Parties' Proposed Expanded Definition
4. Definition R.10 - Trade Secrets
5. Definition R.11 - Non-public information re: manufacturing, design or development
 - a. Adequacy of Parties' Proposed Expanded Definition
6. Definition R.14 - Internet sites, databases and networks
 - a. Adequacy of Parties' Proposed Expanded Definition
7. Catch-All Category/"Serious and Specific Harm" Standard - Definition R.16
8. Sunset Provision - Definition S
9. "Non-Public" - Definition U
 - a. Adequacy of Parties' Proposed Expanded Definition
10. Addition of Definition V
11. Use of Discovery Material - Paragraph 1
 - a. Use of Confidential Discovery Material in Japan Litigation
 - b. Use of Confidential Discovery Material in Federal Class and California Class Litigation
 - c. Use of Non-Confidential Discovery Material for Any Purpose
12. Affixing Case Number to Confidential Designation - Paragraph 4
13. Designation of Deposition Testimony - Paragraph 5
 - a. Adequacy of Parties' Proposed Revision
14. Separate Agreements - Paragraph 6 (and 15)
15. Disclosure to Experts and Consultants - Paragraph 6(b)
16. Disclosure to In-House Counsel - Paragraph 6(c)
 - a. Adequacy of Parties' Proposed Revision
17. Disclosure to Former Employees in Deposition - Paragraph 6(f)
18. Disclosure to Other Persons (based on reasonable and good faith belief) - Paragraph 6(g)
19. Production of Acknowledgement Forms to Third Parties - Paragraph 7
20. Restrictions on Attorneys (In-House and Outside Counsel) - Paragraph 8

- a. Adequacy of Parties' Proposed Revision
- 21. Storage of Confidential Discovery Material - Paragraph 9
- 22. Procedure for Disclosure pursuant to Paragraph 6(f) and (g) - Paragraph 10
 - a. Adequacy of Parties' Proposed Revision
- 23. Disclosure to Experts and Consultants - Paragraph 11
 - a. Adequacy of Parties' Proposed Revision
- 24. Trial Exhibits - Paragraph 14
 - a. Adequacy of Parties' Proposed Revision
- 25. Separate Agreements - Paragraph 15
- 26. Designation Request Procedure - Paragraph 16(a)
 - a. Adequacy of Parties' Proposed Revision
- 27. Application to the Court - Paragraph 16(b)
 - a. Adequacy of Parties' Proposed Revision
- 28. Redaction Procedure - Paragraph 16(e)
- 29. Designation of Other Parties' Confidential Material - Paragraph 17
 - a. Adequacy of Parties' Proposed Revision
- 30. Production of Other Parties' Confidential Information - Paragraphs 18 and 19
 - a. Adequacy of Parties' Proposed Revision
- 31. Notification of Producing Party when its Information is Requested - Paragraph 20
 - a. Adequacy of Parties' Proposed Revision
- 32. Procedure for Use of Discovery Material in Japan Litigation - Paragraph 22
 - a. Adequacy of Parties' Proposed Revision
- 33. Filing Confidential Discovery Material Under Seal - Paragraph 24
 - a. Adequacy of Parties' Proposed Revision (to Para. 14)
- 34. Destruction Obligations upon Conclusion of Litigation - Paragraph 27
- 35. Additional Protective Orders - Paragraph 31
 - a. Adequacy of Parties' Proposed Revision
- 36. Inadvertent Production - Paragraphs 32 and 33
 - a. Adequacy of Parties' Proposed Revision
- 37. Miscellaneous
 - a. Definition of "Disclose" - Definition T
 - b. Protection afforded Initial Designation - Paragraph 3

- c. Copying for “permitted uses” - Paragraph 12
- d. Reservation of Right to Object to Discovery
- e. Court’s Retention of Jurisdiction
- f. Other

ATTACHMENT B

**UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE**

ADVANCED MICRO DEVICES, INC., a
Delaware corporation, and AMD
INTERNATIONAL SALES & SERVICE, LTD., a
Delaware corporation,

Plaintiffs,

vs.

INTEL CORPORATION, a Delaware
corporation, and INTEL KABUSHIKI KAISHA, a
Japanese corporation,

Defendants.

Civil Action No. 05-441-JJF

IN RE INTEL CORPORATION
MICROPROCESSOR ANTITRUST
LITIGATION

MDL No.1717-JJF

PHIL PAUL, on behalf of himself and all other
similarly situated,

Plaintiffs,

vs.

INTEL CORPORATION,

Defendant.

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
COUNTY OF SANTA CLARA**

COORDINATION PROCEEDING SPECIAL
TITLE (Rule 1550(b))

J.C.C.P. No. 4443

INTEL X86 MICROPROCESSOR CASES

**STIPULATED CONFIDENTIALITY AGREEMENT AND [PROPOSED] PROTECTIVE
ORDER**

RLF1-3007754-1

RLF1-3019965-1

WHEREAS, plaintiffs Advanced Micro Devices, Inc., and AMD International Sales & Service, Ltd. and their subsidiaries, on the one hand, and defendants Intel Corporation and Intel Kabushiki Kaisha and their subsidiaries, on the other, compete in the development, manufacture and sale of microprocessors; and

WHEREAS, a number of third parties, many of whom are competitors in, *inter alia*, the manufacture and sale of computer systems, will be the subject of document and deposition discovery in these actions; and

WHEREAS, the preparation for trial of these actions may require the discovery and use of documents and other information which constitute or contain commercial or technical trade secrets, or other confidential information the disclosure of which would be competitively harmful to the producing party; and

WHEREAS, both party and third-party discovery will also be made available to various state and federal consumer plaintiffs who have filed putative class actions against the defendants and who have agreed to subscribe to this stipulation and order; and

WHEREAS, the parties anticipate that this case will involve the production of hundreds of millions of pages of documents among and between actual and potential competitors and their customers; and

WHEREAS, the parties agree that their interests, the interests of the customers of the corporate parties and of other non-parties that may be requested to provide discovery, and the public interest can be accommodated by a stipulation and order facilitating a timely production and appropriately limiting the use and dissemination of proprietary and competitively sensitive non-public discovery information entitled to confidential treatment;

NOW THEREFORE, the parties in the above-captioned cases, by and through their respective counsel, hereby stipulate, pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, subject to approval and entry by the Court, that the following Stipulated Confidentiality Agreement and Protective Order ("Protective Order") shall govern the handling of all Discovery Material during the pendency of these litigations, as hereafter defined.

DEFINITIONS

A. The "AMD Litigation" means the litigation captioned *Advanced Micro Devices, Inc. et al. v. Intel Corporation et al.*, Civil Action No. 05-441-JLF, filed in the United States District Court for the District of Delaware, and all subsequent appellate or other review proceedings related thereto.

B. The "Japan Litigation" means the litigations captioned *AMD Japan K.K. v. Intel K.K.*, Case No. Heisei 17 (Wa) No. 13151 (Tokyo Dist. Ct., 6/30/05), and *AMD Japan K.K. v. Intel K.K.*, Case No. Heisei 17 (Wa) No. 4 (Tokyo High Court, 6/30/05), and all subsequent appellate or other review proceedings related thereto.

C. The "Class Litigation" means the various actions filed by or on behalf of putative classes of indirect purchasers of Intel microprocessors, including certain actions which have been or will be transferred to this Court by the Judicial Panel on Multidistrict Litigation under Docket No. 1717, together with all such actions originally filed in this Court. When used to refer to proceedings in which Confidential Discovery Material subject to this order may be used, "Class Litigation" shall also include certain follow-on matters filed in various state courts asserting claims substantially the same as those asserted in the class actions comprising the MDL.

D. The "California Class Litigation" means the actions filed by or on behalf of a putative California class of indirect purchasers of Intel microprocessors, including certain actions

which have been or will be transferred to the Honorable Jack Komar of the Santa Clara County Superior Court by the Judicial Council for the State of California under JCCP 4443, together with such actions originally filed in that Court. These actions include: *Melkonians v. Intel Corp.*, Santa Clara County Superior Court Case No. 1-05-CV-045077; *Macias v. Intel Corp.*, formerly in the Los Angeles County Superior Court Case No. BC336897; *Toronto v. Intel Corp.*, formerly in the San Diego County Superior Court Case No. GIC850053; *Gross v. Intel Corp.*, Santa Clara County Superior Court Case No. 1-05-CV-053490; *Wangler v. Intel Corp.*, formerly in the Los Angeles County Superior Court Case No. BC340460; *Pishvaei v. Intel Corp.*, Santa Clara Superior Court Case No. 1-05-CV-053300; and any action that subsequently is made part of JCCP 4443.

E. "Competition Investigation" means any investigation commenced by a duly authorized federal, state or foreign governmental competition or antitrust agency into the conduct of a Party prior to, or during the pendency of the AMD Litigation.

F. "Intel" means defendants Intel Corporation and Intel Kabushiki Kaisha, together with their respective direct and indirect subsidiaries.

G. "AMD" means plaintiffs Advanced Micro Devices, Inc., and AMD International Sales & Service, Ltd., together with their respective direct and indirect subsidiaries.

H. "Party" means Intel or AMD. "Class Party" means any named plaintiff in the Class Litigation. "Parties" means Intel, AMD and all Class Parties.

I. "Outside Counsel" means the law firm(s) that are counsel of record for the Parties in the AMD Litigation, the Japan Litigation, the Class Litigation, and the California Class Litigation, and counsel for a Party in connection with any Competition Investigation, including their associated attorneys, and other persons regularly employed by such law firm(s), and temporary personnel retained by such law firm(s) to perform legal or clerical duties, or to provide

logistical litigation support; provided that no person who is or becomes a director, officer or employee of a Party shall be considered Outside Counsel.

J. "In-House Litigation Counsel" means any attorney who is an employee in the legal department of a Party whose responsibilities consist of overseeing the AMD Litigation, the Class Litigation, the Japan Litigation, the California Class Litigation or any Competition Investigation and who shall not from the date of entry of this Protective Order through a period of one (1) year following the conclusion of the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, whichever occurs later, be engaged in: (a) the review and approval of competitive pricing or marketing programs; (b) the review of any aspect of microprocessor, or chipset manufacturing, (c) the filing or prosecution of patent applications, (d) the review or negotiation of any contract with a Producing Party related to the sale or marketing of microprocessors, (e) counseling in connection with PC or server manufacturing or operating system or software design or development, and (f) the licensing of Microsoft software or technology.

Deleted: any of the aforementioned

Deleted: or
Deleted: or

K. "Japan Counsel" means the outside law firm(s) that are counsel of record for AMD or Intel in the Japan Litigation, including their associated attorneys and other persons regularly employed by such law firm(s), and temporary personnel retained by such law firm(s) to perform legal or clerical duties or to provide logistical litigation support; provided that no person who is or becomes a director, officer or employee of a Party shall be considered Japan Counsel.

L. "Producing Party" means a Party, Class Party or Third Party that produced or intends to produce Discovery Material in the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation. "Receiving Party" means any Party or Class Party furnished Discovery Material in the AMD Litigation, the Japan Litigation, the Class Litigation or the California Class Litigation.

Deleted: or

M. "Third Party" means any natural person, partnership, corporation, association, or other legal entity not named as a party to the AMD Litigation, the Japan Litigation, the Class Litigation or the California Class Litigation.

N. "Expert/Consultant" means experts or other consultants (and their assistants and staff) who are retained to assist Outside Counsel.

O. "Japan Expert/Consultant" means experts or other consultants (and their assistants and staff) who are retained to assist Japan Counsel in the Japan Litigation.

P. "Document" shall have the meaning ascribed to it in Federal Rule of Civil Procedure 34(a) and shall include all "writings," "recordings" and "photographs" as those terms are defined in Rule 1001 of the Federal Rules of Evidence. Without limiting the generality of the foregoing, "document" includes the complete original or a true, correct and complete copy and any non-identical copies of any written or graphic matter, no matter how produced, recorded, stored or reproduced, including, but not limited to, any writing, letter, envelope, telegram, meeting minute, memorandum, statement, affidavit, declaration, book, record, survey, map, study, handwritten note, working paper, chart, index, tabulation, graph, tape, data sheet, data processing card, printout, microfilm, index, computer readable media or other electronically stored data, appointment book, diary, diary entry, calendar, desk pad, telephone message slip, note of interview or communication or any other data compilation, including all drafts of all such documents. "Document" also includes every writing, drawing, graph, chart, photograph, phono record, tape and other data compilations from which information can be obtained, and includes all drafts and all copies of every such writing or record that contain any commentary, note, or marking whatsoever not appearing on the original.

Q. "Discovery Material" includes without limitation deposition testimony, deposition exhibits, interrogatory responses, admissions, affidavits, declarations, and Documents (whether

paper or electronic and whether generated or received by the party possessing them), including those produced pursuant to compulsory process or voluntarily in lieu thereof.

R. "Confidential Discovery Material" means any Discovery Material consisting of or containing information falling into any of the following categories:

1. Non-public pricing information;
2. Non-public sales and marketing strategies, business plans and tactics, including product roadmaps and planned product introductions;
3. Non-public data concerning sales, revenues, profits, margin and variances;
4. Non-public contracts which by their terms are required to be maintained in confidence;
5. Non-public sales budgets, forecasts, and projections;
6. Non-public customer lists;
7. Non-public negotiations relating to the purchase or sale of microprocessors, chipsets, PCs, servers, operating systems, software licensing agreements or any other product manufactured or sold by a Producing Party; Deleted: with customers
8. Non-public strategic plans;
9. Non-public data concerning costs, capacity and ROI or other similar benchmarks;
10. Any invention, formula, pattern, compilation, program device, product design, method, technique, or process, and information relating to the same, that: (i) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its

disclosure or use, and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy;

11. Non-public information that concerns microprocessor, chipset, PC or server manufacturing, or operating system and software design and development, including capital expenditure plans, yields, capacity, costs, utilization, process and scale;
12. Non-public business or market research, whether acquired or generated internally;
13. Confidential personnel information whether contained in HR records or otherwise;
14. Information the disclosure of which could jeopardize the security of public or private Internet sites, confidential databases, networks or other sources of non-public information;
15. Non-public financial information the public disclosure of which is prohibited by law or regulation or which could jeopardize the integrity of public trading of the Producing Party's securities;
16. Other information or documents the disclosure of which the Producing Party can demonstrate would cause it serious and specific harm.

Deleted: or

Deleted: ¶

S. In order to address potential issues relating to the passage of time on the continued confidentiality of documents, the parties agree that, except with respect to materials the disclosure of which would raise consumer privacy issues, for documents in categories R(1) through R(8) dated or prepared more than 24 months prior to a Designation Request under paragraph 16, the Producing Party must also satisfy the standard contained in paragraph R(16) for the documents to be maintained as confidential. For purposes of this paragraph, undated materials or materials or deposition testimony relating to an indeterminate time period shall be deemed dated as of the date of their production or the date of the deposition.

T. "Disclose" means producing any "Discovery Material" directly and providing any description of its contents or in any way revealing the contents of any "Discovery Material."

U. "Non-public" documents and information are those (a) that the Producing Party maintains internally as confidential, (b) that are not disclosed to third-parties except under written agreements requiring that they be maintained in confidence, pursuant to a course of dealing whereby such communications are maintained in confidence, or under compulsory process or involuntary seizure, and (c) that the disclosure of which could damage the Producing Party competitively.

V. Time periods prescribed by this order shall be computed in accord with Federal Rule of Civil Procedure 6(a).

TERMS AND CONDITIONS OF PROTECTIVE ORDER

1. Except as set forth in this Protective Order, Confidential Discovery Material, or information derived therefrom, shall be used solely by the Parties for purposes of the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, and shall not be used for any other purpose, including, without limitation, any business or commercial purpose, or dissemination to the media. Confidential Discovery Material that loses that designation, either by agreement of the Parties or the challenge process set out in Paragraph 16, may be used for any lawful purpose, unless such use is restricted by agreement or by the Court.

2. Nothing in this Protective Order shall be deemed to grant or create discovery rights to any Party, Class Party or Third Party in the AMD Litigation, the Japan Litigation, the Class Litigation or the California Class Litigation in any other proceeding relating to or arising out of the subject-matter thereof, nor shall the Parties' agreement to this Protective Order

constitute a waiver of any rights to resist any discovery efforts that may be initiated in any other proceeding whether or not relating to or arising out of the same subject-matter.

Confidential Discovery Material

3. Solely for the purposes of the efficient and timely production of documents, and to avoid the need for a detailed and expensive confidentiality examination of millions of Documents the disclosure of which is not likely to become an issue, a Producing Party may initially designate as "Confidential Discovery Material" any Non-public Discovery Material. This designation shall control unless and until a Designation Request is made by a Receiving Party under Paragraph 16.

4. Such a designation shall be made at the time of production by marking documents or other tangible Discovery Material by placing on or affixing, physically or electronically, in such manner as will not interfere with the legibility thereof, the notation "CONFIDENTIAL - MDL 1717/JCCP 4443." Electronic or native documents or data shall be similarly marked where practicable, and where not practicable, written notification by a Producing Party that it is producing Discovery Material as Confidential Discovery Material shall suffice to require Confidential treatment.

5. To facilitate discovery, all deposition testimony will be presumed to constitute, and all transcripts shall be treated as, Confidential Discovery Material, unless and until a Designation Request is made by a Receiving Party under Paragraph 16. Accordingly, no deponent may refuse to answer a deposition question on the ground that the answer would disclose confidential information or information subject to a non-disclosure agreement. Should a Receiving Party wish to disclose any deposition testimony to a person other than as permitted by Paragraph 6, it shall first make a Designation Request under the provisions of Paragraph 16.

Deleted: <#>Deposition testimony may be designated as Confidential Discovery Material by instructing the Court Reporter recording the testimony to designate portions of the transcript as "CONFIDENTIAL" during the deposition or within thirty (30) days after the deposition transcript is sent to the witness or his or her attorney. Unless those attending a deposition agree at its conclusion that it may be treated as non-confidential, until the expiration of the thirty-day period, the transcript shall be treated as "CONFIDENTIAL" in its entirety under the terms of this Order unless specific designations are made earlier. If a party claiming confidentiality makes no specific designations during the thirty-day period, no part of the deposition transcript will be considered to be subject to this Order. ¶

Such a request shall be made to the Party and/or Non-Party it reasonably concludes has the right to protect the information. The provisions of Paragraph 16 shall thereafter apply.

Access to Confidential Discovery Material

6. Confidential Discovery Material shall not, directly or indirectly, be disclosed or

otherwise provided to anyone except to:

- (a) Outside Counsel;
- (b) Experts/Consultants, subject to the provisions and limitations set forth in Paragraph 11 herein;
- (c) Two In-House Litigation Counsel identified to the Producing Party;
- (d) The Court and other court personnel of any court having jurisdiction over any proceedings involving the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation. However, with regard to documents used in the proceedings in Japan, Confidential Discovery Materials produced in the AMD Litigation, the Class Litigation, or the California Class Litigation may only be used if the Japan court institutes procedures to protect the confidentiality of the information at a level of protection comparable to that provided in this Order. The Parties shall cooperate reasonably in seeking such protection. The procedures to effectuate this provision shall be those the Japan Court deems appropriate;
- (e) Court reporters, their staffs, and professional vendors to whom disclosure is reasonably necessary for this litigation and who have signed the "Acknowledgement of Protective Order" attached hereto;
- (f) During the deposition of any current employee, director, agent or Rule 30(b)(6) designee of the Producing Party, a Receiving Party may show the Producing Party's witness any document produced by the Producing Party; and it may show to any former employee of the Producing Party any document the Receiving Party's Outside Counsel reasonably and in good faith believes to have received the information or document, or to have become familiar with its contents, in the ordinary course of his or her business duties, consistent, however, with the provisions of paragraph 10;
- (g) The author of a document containing Confidential Discovery Material or the original source of the information, as well as addressees, copyees or other persons whom the Receiving Party's Outside Counsel reasonably and in good faith believes to have received the information or document, or to have become familiar with its contents, in the ordinary course of his

← Formatted: Indent: Left: 0", First line: 0.75", Tabs: 0.75", Left

Deleted: 10
Deleted: opposing

Deleted: an Opposing

or her business duties, consistent, however, with the provisions of paragraph 10:

Deleted: and

- (h) Japan Counsel and Japan Experts/Consultants, subject to the provisions and limitations set forth herein: and

Deleted: .

- (i) Any individual specifically retained for the preparation and dissemination of class notices and/or the administration and/or settlement of class plaintiffs' claims.

7. Any person under the Control of a Party Disclosing Confidential Discovery

Material who is shown or given access to Confidential Discovery Material will execute or agree to the terms of the "Acknowledgement of Protective Order" set forth and attached hereto. The Acknowledgements will not be exchanged, but will be maintained and made available to the Court upon the Court's request.

8. Any attorney (including In-House Litigation Counsel) for any Party or Class Party who receives any technical document designated Confidential Discovery Material by a Producing Party other than his or her client shall not participate in the preparation or prosecution of any patent application or patent license relating to any aspect of microprocessors, chipsets, PCs, operating systems, software or servers discussed in any such technical document, from the time of receipt of such information through and including one (1) year following the conclusion of the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, whichever occurs later.

Deleted: produced

Deleted: or

9. Confidential Discovery Material must be stored and maintained by a Receiving Party at a location and in a secure manner that ensures that access is limited to the persons authorized under this Order. In no event shall Confidential Discovery Material be stored at any business premises of the Receiving Party, or be made accessible electronically to employees of the Receiving Party, except that In-House Litigation Counsel may view, but not store, Confidential Discovery Material at his or her normal workplace by electronically and remotely accessing a Receiving Party's electronic document repository. In-House Litigation Counsel

must implement and document reasonable precautions to prevent unauthorized persons from accessing or otherwise viewing Confidential Discovery Material.

10. Upon disclosing Confidential Discovery Material pursuant to paragraphs 6(f) or 6(g), other than to a current employee, director, agent or Rule 30(b)(6) designee of the Producing Party, counsel shall inform the witness of the existence of this Order, the confidential status of the information disclosed, and the restriction that the information not be further disseminated or used for any purpose other than the litigation; and counsel shall request the witness to execute and agree to the terms of the Acknowledgment of Protective Order set forth and attached hereto. A Party or Class Party shall not disclose Confidential Discovery Material to a witness over whom the Party or Class Party has control until the witness has executed and agreed to the terms of the Acknowledgement of Protective Order. No copies of Confidential Discovery Material shall be provided to the witness other than for purposes of the deposition examination without the written consent of the Producing Party. No Confidential Discovery Material shall be shown to a former employee of a Party employed by the opposing Party, except pursuant to separate written agreement.

Deleted: such

Deleted: party

Deleted: party

11. Before any Confidential Discovery Material may be disclosed or otherwise provided, directly or indirectly, to an Expert/Consultant (or Japan Expert/Consultant), such person must execute and agree to the terms of the Acknowledgment of Protective Order set forth and attached hereto, and shall:

- (a) maintain such Confidential Discovery Material in a manner calculated to prevent its public disclosure;
- (b) return such Confidential Discovery Material to counsel for the Party or Class Party that retained such Expert/Consultant within ninety (90) days of the conclusion of the Expert/Consultant's assignment or retention, but in no event shall the expert retain documents beyond the period set out in paragraph 26 herein;
- (c) not disclose such Confidential Discovery Material to anyone, or use such Confidential Discovery Material, except as permitted by the Protective Order;

- (d) submit to the jurisdiction of this Court for purposes of enforcing the Protective Order; and
- (e) use such Confidential Discovery Material and the information contained therein solely for the purpose of rendering consulting services to a Party or Class Party to the AMD Litigation, the Japan Litigation or the Class Litigation, including providing testimony in any such proceeding.

Except with the consent of the Producing Party, however, Confidential Discovery Material shall not be disclosed to an expert or consultant who at the time of the intended disclosure is an officer or employee of a Party.

12. Confidential Discovery Material shall not be copied or otherwise reproduced except to the extent such copying or reproduction is reasonably necessary for permitted uses, and all such copies or reproductions shall be subject to the terms of this Protective Order. If the duplication process by which copies or reproductions of Confidential Discovery Material are made does not itself preserve the confidentiality designations that appear on the original documents, all such copies or reproductions shall be appropriately marked with those confidentiality designations.

13. This Protective Order shall not apply to the disclosure or use by a Producing Party or its counsel of such Producing Party's Confidential Discovery Material.

14. The Parties agree to meet and confer prior to the filing of final exhibit lists to evaluate, on a document by document basis, which of the proposed exhibits require confidential treatment for purposes of trial. The confidentiality legend may be redacted by the Producing Party prior to trial for any use of the material at trial by any Party or Class Party. The Parties further agree to meet and confer with any Third Party whose documents will or may be used at trial concerning their appropriate treatment and to afford such Third Parties sufficient advance notice of any such use such that they can move to have the materials received under seal. Should any material furnished by a Third Party and received under seal be the subject of a

Deleted: parties

Deleted: party.

motion to unseal, the Parties shall give sufficient notice to the Third Party so that it may oppose the motion.

Third Parties

15. Any Third Party that produces documents or provides testimony in the AMD Litigation, the Class Litigation or the California Class Litigation, either voluntarily or by compulsory process, shall have the full benefits and protections of this Protective Order and may designate documents or deposition testimony as Confidential Discovery Material in the manner, and subject to the same protections, set forth above. Nothing in this Order shall be construed to allow any Third Party to obtain access to any Confidential Discovery Material produced by any Party, Class Party, or other Third Party.

Designation Requests and Resolving Disputed Designations

16. The parties anticipate designating all Non-public Discovery Material as Confidential Discovery Material under Paragraph 3. Should a Receiving Party wish to disclose any such material to a person other than as permitted by Paragraph 6, it shall make a written Designation Request to the Producing Party, as set forth below:

- (a) Designation Request: The Receiving Party shall identify with specificity (*i.e.*, by document control numbers, deposition transcript page and line reference, or other means sufficient to easily locate such materials) the Discovery Material it intends to disclose and a representation that the material is probative of one or more material facts in this litigation. A Designation Request will trigger an obligation on the part of the Producing Party to make a good faith determination of whether the Discovery Material is entitled to be treated as Confidential Discovery Materials under Paragraph R. Except in the case of a Designation Request for more than 250 documents or more

Deleted: massive
Deleted: as to which a prompt reply would be impractical

than 250 pages of deposition testimony, within ten (10) days the Producing

Deleted: court

Party shall respond in writing to the Designation Request either agreeing to the disclosure or designating the material as Confidential Discovery Material.

If a Designation Request entails more than 250 documents or more than 250 pages of deposition testimony, the Requesting Party and the Producing Party shall meet and confer, in good faith, to establish a reasonable timeframe for designation and response.

- (b) Court Determination: If the Receiving Party disagrees with a Producing Party's designation of material as Confidential Discovery Material, it shall provide to the Producing Party a written objection. Thereafter, the Producing Party may make written application to the Court for protective treatment. Except in the case of disputes involving massive numbers of documents, the application will be made within twenty (20) days of receiving the Receiving Party's written objection to the designation. If the Producing Party fails to make such timely application, the Producing Party's designation will be void.
- (c) In any proceeding on such an application, the Producing Party will bear the burden to demonstrate that the designated Discovery Material qualifies as Confidential Discovery Material under Paragraph R. No presumption or weight will attach to the initial designation of Discovery Material as Confidential Discovery Material.
- (d) Pending a ruling, the Discovery Material shall continue to be treated as Confidential Discovery Material under the terms of this Protective Order.
- (e) With respect to Discovery Material the Parties agree does not constitute Confidential Discovery Material, or as to which the Producing Party does not

file a timely application, or which the Court orders not to be treated as Confidential Discovery Material, within ten (10) days of such agreement or order, the Producing Party shall produce a new version with the confidentiality legend redacted.

- (f) Nothing in this Protective Order shall be deemed to prevent a Producing Party from arguing during the determination process for limits on the use or manner of dissemination of Discovery Material that is found to no longer constitute Confidential Discovery Material.

Disclosure Requested or Provided in Other Proceedings

17. In the event that any Party or Class Party gains access to Discovery Material of

the other Party or a Third Party from another Producing Party or a U.S., state, or foreign governmental agency or court, that has not been designated as Confidential Discovery Material, the Receiving Party shall promptly notify, in writing, the party whose documents are implicated.

The party whose documents are implicated shall be entitled, and shall be given a reasonable opportunity (not to exceed thirty (30) days following notice) prior to any non-confidential disclosure or use of such materials, to designate, as appropriate, such materials as Confidential

Discovery Material pursuant to the terms of this Protective Order. Such designation shall be subject to the terms set forth in Paragraph 16. If any such Discovery Material has already been produced and designated as Confidential Discovery Material pursuant to the terms of this Order, then such material shall at all times be governed by the terms of this Protective Order even

though also received from a Third Party or a U.S., state or foreign governmental agency or court. Designation Requests regarding the Discovery Material described in this paragraph shall be made directly to the party whose documents are implicated, rather than the Third Party or U.S., state, or foreign governmental agency or court from whom the Receiving Party received the Discovery Material. This paragraph shall not govern the use in connection with the

Deleted: an
Deleted: from

Deleted: the Producing Party
Deleted: Producing Party

Deleted: This paragraph shall not apply to materials freely furnished by the Producing Party to a Third Party or a U.S., state, or foreign governmental agency or court without any requested restriction on the recipient's use or disclosure of the materials or without otherwise identifying the confidential nature of the materials. Nor shall it

Formatted: Font: (Default) Arial,
Font color: Auto

Japanese Litigation of materials produced in that Litigation, which instead will be controlled by the Japanese court.

18. Except as provided in this paragraph, a Party, Class Party or Third Party who is otherwise required in the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation to disclose or produce documents shall not delay or refuse to do so on grounds that such documents contain information of another party (other than AMD and Intel) which is subject to obligations of confidentiality in favor of that party ("Originating Party"). Instead, the Party, Class Party or Third Party from whom discovery is sought shall promptly notify the "Originating Party" in writing of the required disclosure. The Originating Party shall be given a reasonable opportunity (not to exceed thirty (30) days from the date of notice), prior to any production or disclosure of any such Discovery Material, to object to the production and until those objections are resolved, the Discovery Material will not be produced. In the event that such Discovery Material is produced, the Discovery Material produced shall be deemed Confidential Discovery Material pursuant to Paragraph 3 and shall be marked by the Producing Party in accordance with the requirements of Paragraph 4.

19. The production of documents designated as Confidential Discovery Material pursuant to this Protective Order by a Third Party in the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation shall not constitute a violation of the confidentiality provisions of any nondisclosure agreement ("NDA") between any party and AMD or Intel. However such Third Party may consult, in a timely fashion, with AMD and/or Intel about the nature of the materials to be produced in advance of their production for the purpose of ensuring that the confidential materials are adequately protected from public disclosure.

20. If another court or any U.S., state or foreign governmental agency should request, subpoena, or order the production of Confidential Discovery Materials from any Party that have been produced by any other Party or Third Party, the Party receiving such a request

Deleted: or other Discovery Material that may
Deleted: the Confidential Discovery Material
Deleted: Party, Class Party or Third Party ("Originating Party") shall not delay or refuse to do so on grounds that such documents or
Deleted: Discovery Material are held by the Party, Class Party or Third Party
Deleted: toward the

Formatted: Bullets and Numbering

shall promptly notify the Producing Party in writing. Should the Producing Party object to the production, it may seek appropriate relief from the appropriate court or agency, and pending such a request and, if necessary, the entry of an appropriate stay order, the Party receiving the request shall not produce the material in dispute so long as it may lawfully refuse.

Deleted: party

Provisions Related to the Japan Litigation

Formatted: Bullets and Numbering

21. To the extent that discovery properly conducted and permitted in the AMD Litigation, the Class Litigation, or the California Class Litigation is relevant to the issues pending in the Japan Litigation, the Receiving Party may, subject to the terms and limitations of this Protective Order, disclose the Confidential Discovery Material to its Japan Counsel and Japan Experts/Consultants. Nothing herein shall be deemed to create an independent discovery right for purposes of the Japan Litigation, nor limit the rights of a Party or Class Party to object to discovery propounded in the AMD Litigation, the Class Litigation, the Japan Litigation, or the California Class Litigation.

22. In the event that any Confidential Discovery Material is also made available for use in the Japan Litigation (as contemplated by this Order), the material shall remain subject to all terms of this Protective Order and the Party desiring to use or file papers containing such information shall identify it to the appropriate Japanese Court as Confidential so that the provisions of Paragraph 6(d) can be appropriately implemented.

Deleted: , inform the Japanese Court

Deleted: information is subject to the terms

Deleted: this Protective Order entered by this Court, furnish a copy of the Protective Order to the Japanese Court, and request that the Japanese Court or other authority respect the terms of this Protective Order and maintain the confidentiality of the material so produced.

23. Prior to accessing Confidential Discovery Material (other than Discovery Material produced in the Japanese Litigation), Japan Counsel and Japan Experts/Consultants shall separately execute a copy of the Acknowledgment of Protective Order attached hereto, binding each of them to the terms set forth therein and in this Protective Order. Such Japan Counsel and Japan Experts/Consultants agree to submit to the jurisdiction of the United States District

Court for the District of Delaware for the purpose of having the terms of the Protective Order enforced.

Filing Confidential Discovery Material with the Court

← Formatted: Bullets and Numbering

24. In the event that any Confidential Discovery Material is contained in any pleading, motion, exhibit, or other paper (collectively "papers") filed or to be filed with the Clerk of the Court, the Clerk shall be so informed by the Party or Class Party filing such papers, and the Clerk shall keep such papers under seal until further order of the Court; provided, however, that such papers shall be furnished to the Court and Outside Counsel of the Parties. A Party or Class Party submitting Confidential Discovery Material to the Santa Clara Superior Court in the California Class Litigation under seal shall comply with the requirements of California Rule of Court 243.2.

25. Information filed under seal shall be placed in sealed envelopes on which shall be written the title to this action, the words "FILED UNDER SEAL," and a statement substantially in the following form:

"This envelope is sealed pursuant to order of this Court and contains confidential information filed in this case by [name of party] and is not to be opened or the contents thereof to be displayed or revealed except by order of the Court."

← Formatted: Bullets and Numbering

26. Parties shall produce and file redacted versions of any papers in the District Court actions in accordance with the "Administrative Procedures Governing Filing and Service by Electronic Means" as issued by the United States District Court for the District of Delaware, such that there is no disclosure of any Confidential Discovery Material, or in accord with the rules of the Santa Clara Superior Court in the case of Confidential Discovery Material filed with that Court.

Duties Upon Conclusion of Litigation

27. Within one hundred twenty (120) days of the conclusion of the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, whichever occurs later, counsel for any Party or Class Party that has received Discovery Material shall return to the Producing Party, or destroy, all originals and copies of all documents and all notes, memoranda, or other papers containing Confidential Discovery Material, including any and all Confidential Discovery Material disseminated pursuant to the terms of this Protective Order. Notwithstanding this provision, Outside Counsel are entitled to retain an archival copy of all pleadings, motion papers, transcripts, legal memoranda, correspondence or attorney work product prepared or received in connection with the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, even if such materials contain protected material. Any such archival copies that contain or constitute protected material shall remain subject to this Order.

← Formatted: Bullets and Numbering

28. Counsel of record shall certify their compliance with the terms of this paragraph and, not more than one hundred and twenty (120) days after the conclusion of the AMD Litigation, the Japan Litigation, the Class Litigation, or the California Class Litigation, whichever comes later, shall deliver the same to counsel for the Producing Party.

29. The provisions of this Protective Order, insofar as they restrict the communication and use of Confidential Discovery Material by any Party, Class Party, counsel, or expert witness shall, without written permission of the Producing Party or further order of the Court, continue to be binding after the conclusion of the AMD Litigation, the Japan Litigation, the Class Litigation, and the California Class Litigation.

Remedies for Non-Compliance

← Formatted: Bullets and Numbering

30. The Parties agree that any disclosure of Confidential Discovery Material contrary to the terms of this Order by a Party or Class Party or anyone acting on its, his or her behalf

constitutes a violation of the Order remediable by the Court, regardless of where the disclosure occurs. However, the Santa Clara, California Superior Court shall have enforcement responsibility for any impermissible disclosure by plaintiffs, plaintiffs' witnesses, plaintiffs' counsel and employees, or any other person given access to Confidential Discovery Material by the plaintiffs in the California Class Litigation.

31. Nothing contained in this Protective Order shall diminish any attorney-client privilege or attorney work product claim, or obligate any person to provide any discovery to which it asserts objections. Entry of the foregoing Protective Order is without prejudice to the right of the Parties or any Third Party, for good cause shown, to move for modification of this Protective Order, or to apply for other protective orders unrelated to the confidentiality of Discovery Material.

Deleted: to apply for further protective orders regarding certain categories of information,
Deleted: for modification of
Deleted: provision of

Inadvertent Production.

32. In the event that a Producing Party discovers that it has failed to mark Confidential Discovery Material as required by Paragraphs 4 and 5, it may notify in writing the Receiving Party within a reasonable time of such discovery. So long as the unmarked Discovery Material has not already been disclosed to persons other than as permitted by Paragraph 6 such that it has entered the public domain, the failure to mark such Confidential Discovery Materials shall not be deemed to be a waiver of the confidential status of the materials, and the Receiving Party shall return all copies of such material to the Producing Party to allow the materials to be appropriately marked.

Formatted: Bullets and Numbering

33. The production or disclosure of any Discovery Material made after the entry of this Protective Order, which disclosure a Producing Party claims was inadvertent and should not have been produced or disclosed because of a privilege, will not be deemed to be a

wavier of any privilege to which the Producing Party would have been entitled had the privileged Discovery Material not inadvertently been produced or disclosed.

Dated: _____

POTTER ANDERSON & CORROON LLP

By: _____

Richard L. Horwitz (#2246)
rhorwitz@potteranderson.com
W. Harding Drane, Jr. (#1023)
wdrane@potteranderson.com
1313 North Market Street
P.O. Box 951
Wilmington, DE 198999-0951
(302) 984-6027
Attorneys for Intel Corporation and Intel
Kabushiki Kaisha

Dated: _____

GIBSON, DUNN & CRUTCHER LLP

By: _____

Daniel S. Floyd
DFloyd@gibsondunn.com
333 South Grand Avenue
Los Angeles, CA 90071-3197
(213) 229-7000
Attorneys for Intel Corporation and Intel
Kabushiki Kaisha

Dated: _____

HOWREY LLP

By: _____

Darren B. Bernhard
BernhardD@howrey.com
1299 Pennsylvania Avenue, N.W.
Washington, DC 20004-2402
(202) 383-6774
Attorneys for Intel Corporation and Intel
Kabushiki Kaisha

Dated: _____

RICHARDS, LAYTON & FINGER, P.A.

By:

Frederick L. Cottrell (#2555)
cottrell@rlf.com
Richards, Layton & Finger
One Rodney Square
920 North King Street
P.O. Box 551
Wilmington, DE 19899
(302) 651-7700
Attorneys For Advanced Micro Devices,
Inc. And AMD International Sales &
Service, Ltd.

Dated: _____

O'MELVENY & MYERS LLP

By:

Charles B. Diamond
cdiamond@omm.com
1999 Avenue of the Stars
7th Floor
Los Angeles, CA 90067-6035
(310) 553-6700
Attorneys for Advanced Micro Devices, Inc.
And AMD International Sales & Service,
Ltd.

Formatted: French (France)

Dated: _____

INTERIM CLASS COUNSEL

PRICKETT JONES & ELLIOTT, P.A.

By: _____

James L. Holzman (#663)

jholzman@prickett.com

J. Clayton Athey (#4378)

jcathey@prickett.com

Eric M. Andersen (#4376)

emanderson@prickett.com

1310 King Street

P.O.Box 1328

Wilmington, DE 19899

(302) 888-6509

Attorneys for Co-Lead and Interim Counsel
for Plaintiffs

Formatted: German (Germany)

**COHEN, MILSTEIN, HAUSFELD & TOLL
PLLC**

By: _____

Michael D. Hausfeld

mhausfeld@cmht.com

Daniel A. Small

dsmall@cmht.com

Brent W. Landau

blandau@cmht.com

Allyson B. Baker

abaker@cmht.com

1100 New York Avenue, NW

Suite 500, West Tower

Washington, DC 20005

Attorneys for Co-Lead and Interim Counsel
for Plaintiffs

Formatted: French (France)

Field Code Changed

Formatted: French (France)

Formatted: French (France)

Formatted: German (Germany)

Formatted: German (Germany)

Formatted: German (Germany)

Field Code Changed

Formatted: French (France)

Field Code Changed

Formatted: French (France)

Formatted: French (France)

THE FURTH FIRM, LLP

By:

Michael P. Lehmann
mplehmann@furth.com

Thomas P. Dove
tdove@furth.com

Alex C. Turan
aturan@furth.com

225 Bush Street, 15th Floor
 San Francisco, CA 94104
 Attorneys for Co-Lead and Interim Counsel
 for Plaintiffs

Formatted: French (France)
 Formatted: French (France)
 Field Code Changed
 Formatted: French (France)

HAGENS BERMAN SOBOL SHAPIRO, LLP

By:

Steve W. Berman
steve@hbsslaw.com

Anthony Shapiro
tony@hbsslaw.com

Craig R. Spiegel
craig@hbsslaw.com
 1301 Fifth Avenue
 Suite 2900
 Seattle, WA 98101
 Attorneys for Co-Lead and Interim Counsel
 for Plaintiffs

Formatted: Portuguese (Brazil)
 Field Code Changed
 Formatted: Portuguese (Brazil)
 Formatted: Portuguese (Brazil)
 Formatted: German (Germany)
 Field Code Changed
 Formatted: German (Germany)
 Formatted: German (Germany)
 Formatted: French (France)

SAVERI & SAVERI, INC.

By:

Guido Saveri
guido@saveri.com

R.Alexander Saveri
rick@saveri.com

111 Pine Street, Suite 1700
 San Francisco, CA 94111
 Attorneys for Co-Lead and Interim Counsel
 for Plaintiffs

Dated: _____

ALEXANDER HAWES & AUDET, LLP

By: _____

Michael McShane
152 North 3rd Street
Suite 600
San Jose, CA 95112
(408) 289-1776

IT IS SO ORDERED THIS _____ day of _____, 2006.

United States District Judge

UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

ADVANCED MICRO DEVICES, INC., a
Delaware corporation, and AMD
INTERNATIONAL SALES & SERVICE, LTD., a
Delaware corporation,

Plaintiffs,

vs.

INTEL CORPORATION, a Delaware
corporation, and INTEL KABUSHIKI KAISHA, a
Japanese corporation,

Defendants.

IN RE INTEL CORPORATION
MICROPROCESSOR ANTITRUST
LITIGATION

Civil Action No. 05-441-JJF

MDL No.1717-JJF

PHIL PAUL, on behalf of himself and all other
similarly situated,

Plaintiffs,

vs.

INTEL CORPORATION,

Defendant.

SUPERIOR COURT OF THE STATE OF CALIFORNIA
COUNTY OF SANTA CLARA

COORDINATION PROCEEDING SPECIAL
TITLE (Rule 1550(b))

INTEL X86 MICROPROCESSOR CASES

J.C.C.P. No. 4443

ACKNOWLEDGMENT OF PROTECTIVE ORDER

I, _____, am a _____ (employee, partner, associate, etc.) of _____, and I hereby acknowledge that:

1. I have read the Protective Order entered in the action captioned above, understand the terms thereof, and agree to be bound by such terms;
2. I will make only such copies or notes as are required to enable me to render assistance in connection with the matters for which I am engaged;
3. I will not disclose Confidential Discovery Materials to any person not expressly entitled to receive it under the terms of the Protective Order;
4. I will not use Confidential Discovery Materials for any purpose other than that authorized by the Protective Order; and
5. I agree to submit to the jurisdiction of the United States District Court for the District of Delaware/Superior Court of the State of California, County of Santa Clara, for the sole purpose of having the terms of the Protective Order enforced.

Dated: _____

Signature:_____

UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

ADVANCED MICRO DEVICES, INC., a
Delaware corporation, and AMD
INTERNATIONAL SALES & SERVICE, LTD., a
Delaware corporation,

Civil Action No. 05-441-JJF

Plaintiffs,

vs.

INTEL CORPORATION, a Delaware
corporation, and INTEL KABUSHIKI KAISHA, a
Japanese corporation,

Defendants.

IN RE INTEL CORPORATION
MICROPROCESSOR ANTITRUST
LITIGATION

MDL No.1717-JJF

**JAPAN COUNSEL AND JAPAN EXPERT/CONSULTANT
ACKNOWLEDGMENT OF PROTECTIVE ORDER**

I, _____, am a _____ (employee, partner, associate, etc.)
of _____, and I hereby acknowledge that:

1. I have read the Protective Order entered in the action captioned above by the
United States District Court for the District of Delaware, understand the terms thereof, and
agree to be bound by such terms;

2. I will make only such copies or notes as are required to enable me to render
assistance in connection with the matters for which I am engaged;

3. I will not disclose Confidential Discovery Material to any person not expressly
entitled to receive it under the terms of the Protective Order;

4. I will not use Confidential Discovery Material for any purpose other than that
authorized by the Protective Order; and

5. I agree to submit to the jurisdiction of the United States District Court for the
District of Delaware for the sole purpose of having the terms of the Protective Order enforced.

Dated: _____

Signature:_____